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1 Introduction 
 
1.1 The murine immune 
system 
 
The first chapter serves as a general introduction 
into the constituents of the immune system of the 
mouse, whose physiological function is the defense 
against pathogens (antigens) invading the body. It 
bears high resemblance to other mammalian immune 
systems, such as its human equivalent. All cell types 
making up the immune system are continuously 
regenerated from multipotential precursor cells, the 
hematopoietic stem cells (HSCs) that reside mainly 
in the bone marrow of adult mammals. Commitment 
to the different hematopoietic lineages and 
differentiation of HSCs into the different effector 
types of cells of the immune response proceeds in a 
cascade of irreversible steps, as depicted in Figure 1. 
The HSCs differentiate in the hematopoietic organs, 
including bone marrow, spleen, thymus and lymph 
nodes, and migrate and patrol through the body in 
the bloodstream and in the lymphatic system.  
One can distinguish two types of immune 
responses: innate and adaptive immune responses. 
The adaptive immune response is a specific reaction 
of an individual to infection with a pathogen, while 
the innate immune response does not rely on 
previous exposure to the pathogen and acts in the 
same way in different individuals. Both responses 
are, however, intricately linked: the specific immune 
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responses often rely on components of the innate 
immune system. We will focus here on the 
mechanisms and effector cells of adaptive immunity. 
The major cellular components of the adaptive 
immune responses are the B and T lymphocytes that 
arise from a common lymphoid progenitor (CLP) 
detectable early in embryonic development in the 
fetal liver and, during adulthood, in the bone 
marrow. Both B and T cells bear highly diverse 
receptors on their cell surface that are able to 
recognize a vast diversity of antigens. Both share an 
ordered rearrangement of their antigen receptor 
genes, obligatory expression of a surrogate, invariant 
component of their pre-receptors, and ligand-
dependent positive and negative selection of their 
mature antigen receptor repertoires. Each cell is 
genetically programmed to encode unique cell 
surface receptors specific for a particular antigen. 
The B cell antigen receptor (BCR) is the membrane-
bound form of an antibody (immunoglobulin) that 
would be secreted upon activation of the cell. Each 
B cell presents only one type of BCR on its surface. 
The T cell antigen receptor (TCR) is a membrane-
bound molecule related to immunoglobulin, and 
recognizes a complex of a peptide fragment bound 
to a molecule specialized in antigen presentation, an 
MHC molecule (Janeway et al., 1999).  
 
We will focus first on the development of T cells 
and then dedicate a chapter to B cell development in 
the mouse. 
 
Figure 1  Differentiation of hematopoietic stem cells (HSCs) to the different lymphoid and myeloid lineages. The 
different progenitor cells can be distinguished by the expression of different cell surface molecules (as indicated). 
(Figure modified from (Kondo et al., 2003).) 
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1.1.1 Murine T cell development 
 
1.1.1.1 Main stages of T cell development 
in the thymus 
 
As mentioned before, T cells originate from 
pluripotent hematopoietic stem cells (HSCs) present 
in the fetal liver and, during life, in the bone marrow 
of mammals. These HSCs can give rise to proT cells 
that are the earliest committed T cell progenitors that 
migrate to the thymus, the main site of T cell 
development. Here, the immature T cells undergo 
distinct stages of proliferation and differentiation, 
which can be identified by discrete cell surface 
expression of a number of protein markers. T cell 
development is accompanied by gene 
rearrangements that produce the T cell receptor and 
is guided by positive and negative selection 
processes that determine the mature TCR repertoire 
and that are the cause of extensive cell death in the 
thymus. The main stages of thymic T cell 
development are depicted in Figure 2 and reviewed 
extensively in (Gill et al., 2003). The thymus itself is 
structured in several lobules, each containing 
discrete cortical (outer) and medullary (central) 
regions. As shown in Figure 3, the cortex consists 
mainly of immature thymocytes embedded in a 
network of branched cortical epithelial cells and 
intermittent macrophages. The outer cortical area 
contains mostly proliferating immature cells, while 
the deeper layers of cortical thymocytes are mostly 
in the process of undergoing thymic selection. The 
medulla consists of mature thymocytes, surrounded 
by medullary epithelial cells, macrophages and 
dendritic cells.  
 
1.1.1.1.1 The classical pathway of αβ T cell 
development 
The majority of lymphoid progenitor cells 
present in the thymus follow the main pathway of T 
cell development (Figure 2), resulting in the 
generation of a repertoire of T cells that carry a 
unique T cell receptor (TCR), consisting of an alpha 
and a beta chain, on their surface, and a co-receptor 
molecule that can be either CD4 or CD8. The 
functional consequences of this will be discussed 
later.  
However, there are several branch points during 
early thymocyte development that can divert the 
cells into other lineages.  
 
 
 
Figure 3  Thymic architecture. (Taken from (Janeway et 
al., 1999).) The thymus lies above the heart and is 
composed of several lobules with cortical (outer) and 
medullary (inner) regions. The architecture and the cells 
making up the thymus are indicated. 
 
 
 
 
Figure 2  T cell development. The developmental stages can be distinguished by the expression of cell surface molecules
and the TCR rearrangement status. Sub-lineage branch points and selection checkpoints are indicated. (Figure taken 
from ? .)
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1.1.1.1.2 γδ T cells 
A second T cell lineage, the γδ T cells, express γδ 
T cell receptors instead of αβ TCRs, and make up 1-
5% of the T cells in the thymus. γδ T cells are also 
the first T cells that appear during embryonic mouse 
development as bursts of cells that populate distinct 
sites in the adult animal, starting with the epidermis, 
leading to the establishment of so-called dendritic 
epidermal T cells (DETCs), and proceeding with the 
epithelial layers of the reproductive tract (Havran 
and Allison, 1988; Hayday, 2000). αβ T cells appear 
only a few days after the earliest γδ T cells and 
rapidly become the predominant thymocyte 
population. There is still some controversy about 
how the decision between αβ and γδ T cell fate is 
made. What is clear is that following the definitive 
commitment to the T cell lineage in the thymus, T 
cell precursors express the IL-2 receptor α chain 
(CD25) and begin to rearrange and express their 
TCR β, γ and δ genes. Cells that successfully 
rearrange TCR γ and TCR δ express a γδ TCR and 
can proceed along the γδ lineage pathway. Similarly, 
cells that successfully rearrange their TCR β gene 
express a pre-TCR (formed by association of TCR β 
with the invariant pTα chain) and are able to 
differentiate along the αβ lineage. However, to 
which extent the γδ TCR and pre-TCR play an 
instructive - rather than a selective - role in the 
αβ/γδ lineage decision remains controversial 
(Fehling et al., 1999; Kang and Raulet, 1997; 
MacDonald and Wilson, 1998; Robey and Fowlkes, 
1998). The instructive model postulates that 
expression of a γδ TCR or pre-TCR per se is 
sufficient to direct a bipotential precursor cell to 
adopt a γδ or αβ T cell fate. In contrast, the selective 
model assumes that the αβ/γδ cell fate is determined 
independently of the TCR, but that appropriate TCR 
(or pre-TCR) signaling is required for survival and 
subsequent differentiation along the predetermined 
lineage pathway (MacDonald et al., 2001). 
The biological function of this T cell subset is 
still poorly understood. γδ T cells are often 
considered to be a more primitive cell type, since 
they are emerging earlier than αβ T cells in 
phylogeny and in ontogeny, and might be defining 
an interface between the adaptive and innate 
immune systems (reviewed in (Hayday and Tigelaar, 
2003)). In addition, γδ T cell deficits are more often 
associated with defective immunoregulation than 
with a failure of immunity (Girardi et al., 2002; 
Roberts et al., 1996). These immunoregulatory γδ T 
cell subsets have several effector potentials, 
including the potential for cytolysis and chemokine 
secretion.  
 
1.1.1.1.3 NK cells 
Second, natural killer (NK) cells can develop 
from a common T/NK cell precursor. While NK 
cells arise mostly from a bone marrow precursor, a 
minor subset (approximately 0.1%) of cells with NK 
phenotype can be detected in the adult thymus, 
arising from bipotential T/NK precursors. A working 
model for the NK cell development is presented in a 
recent review (Colucci et al., 2003) 
NK cells are lymphocytes which are able to 
recognize and kill a limited range of abnormal cells 
by a cytotoxic attack highly similar to that of 
cytotoxic T cells, even though they do not bear any 
known antigen-specific receptors on their cell 
surface. This cytotoxic attack is triggered when an 
antibody of the IgG1 or IgG3 subclass bound to a 
cell makes contact with the FcγRIII receptor (CD16) 
on the NK cell surface.  
 
1.1.1.1.4 NKT cells 
Yet another cell type, the NKT cells, constitute a 
lymphocyte subpopulation that is abundant in the 
thymus, spleen, liver and bone marrow and is also 
present in the lung. NKT cells express surface 
markers that are characteristic of both natural killer 
cells (such as NK1.1 and CD122) and conventional 
T cells (such as TCRs). They have been implicated 
in the regulation of immune and autoimmune 
responses, particularly in the development of type 1 
diabetes. The majority of NKT cells utilizes a 
restricted TCR repertoire that recognizes glycolipids 
in association with the non-polymorphic MHC-like 
molecule CD1d. These cells preferentially use a 
single invariant V alpha 14 antigen receptor 
(Taniguchi et al., 2003). A natural ligand for V14 
NKT cells has been identified, namely α-
galactosylceramide (α-GalCer), a glycolipid which 
is presented by CD1d (Kawano et al., 1997). It is 
generally assumed that a very small population of 
conventional CD4+CD8+ cells randomly express the 
NKT semi-invariant TCR, and these are selected by 
CD1d to develop into NKT cells (MacDonald, 
2002). NKT cells are extensively reviewed in (Sharif 
et al., 2002).  
 
1.1.1.2 T cell function 
 
T cells are able to distinguish cells that are 
harboring pathogens by recognizing peptide 
fragments of pathogen-derived proteins displayed by 
the cell in a complex with the Major 
Histocompatibility Complex molecule (MHC). 
There are two different classes of MHC, class I and 
class II, that are specialized in the presentation of 
peptides derived from different cellular 
compartments. MHC class I molecules present 
peptides from the cytosol and are recognized by 
CD8+ killer T cells, while MHC class II molecules 
display peptides generated in vesicles and are 
recognized by CD4+ helper T cells. Thus, the two 
different functional subsets of T cells can become 
activated and contribute to the host defense against 
different types of pathogens. Proteins from viruses 
or other intracellular parasites are displayed on 
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MHC class I molecules and the infected cell can be 
killed by a killer T cell (CD8+ T cell) that recognizes 
the antigen as non-self. On the other hand, 
extracellular pathogens and toxins taken up in 
vesicles, usually by phagocytic cells such as 
macrophages, are presented in MHC class II 
complexes to helper T cells (CD4+ T cells) that 
activate B cells to secrete specific antibodies that 
help to eliminate the pathogens (Janeway et al., 
1999). The MHC class I and class II molecules are 
depicted in Figure 4. 
Each individual TCR is specific for a particular 
MHC-peptide complex or, in other words, MHC-
restricted for antigen recognition. Thymocytes with 
TCRs that are able to recognize self-MHC molecules 
and function in self-MHC-restricted responses to 
foreign antigens are positively selected for survival 
in the thymus. The positive selection relies critically 
on thymic cortical epithelial cells that make close 
contacts with the T cells which express CD4 and 
CD8 co-receptors on their cell surface during the 
process. The positive selection depends on the 
engagement of both the antigen receptor and co-
receptor with an MHC molecule, and determines the 
survival of single-positive cells that express only the 
appropriate co-receptor. Having accomplished 
positive selection, these single-positive thymocytes 
are ready for export to the periphery. The function of 
the CD4 or CD8 co-receptors of the mature T cells 
lies in their distinct abilities to bind invariant sites on 
MHC class II or class I molecules, respectively.  
Negative selection in the thymus occurs to cells 
that encounter their corresponding antigen (a self-
peptide) on a self-MHC of an antigen presenting cell 
(APC). The most important types of APCs are the  
 
bone marrow-derived dendritic cells and 
macrophages. These are professional antigen-
presenting cell types that also activate mature T cells 
in peripheral lymphoid tissues. Negative selection is 
controlled by the transcription factor AIRE 
(autoimmune regulator), which promotes ectopic 
expression of peripheral tissue-restricted antigens in 
thymic medullary epithelial cells. This 
“immunological self shadow” is an important 
mechanism in central tolerance to autoantigens and 
thus a key factor in controlling autoimmunity 
(Anderson et al., 2002; Liston et al., 2003). 
Once they have completed their development in 
the thymus, T cells enter the bloodstream and are 
carried by the circulation. On reaching a peripheral 
lymphoid organ they leave the blood again to 
migrate through the lymphoid tissue, returning to the 
bloodstream to recirculate between blood and 
peripheral lymphoid tissue until they encounter their 
specific antigen. 
The activation of naive T cells in response to 
antigen, and their subsequent proliferation and 
differentiation, constitutes a primary immune 
response. At the same time as providing armed 
effector T cells, this response generates 
immunological memory, which gives protection 
from subsequent challenge by the same pathogen. 
The generation of memory T cells, long-lived cells 
that give an accelerated response to antigen, is much 
less well understood than the generation of effector 
T cells. Memory T cells differ in several ways from 
naive T cells, but like naive T cells they are 
quiescent and require activation by antigen-
presenting cells with co-stimulatory activity in order 
to regenerate effector T cells. This cell type is 
reviewed in (Sad and Krishnan, 2003). 
 
 
Figure 4  Molecular structure of MHC class I (left panels (a) to (d)) and MHC class II molecules (right panels (a) to 
(d)) (from (Janeway et al., 1999)). 
    MHC class I  MHC class II  
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1.1.2 Murine B cell development 
 
1.1.2.1 Development of immature B cells 
 
Just like the aforementioned T lymphocytes, B 
cells arise from pluripotent progenitors in the fetal 
liver or in the bone marrow of adult mice. They start 
their maturation in these tissues and complete it in 
the secondary lymphoid organs, such as the spleen 
and the lymph nodes. Commitment to the B cell 
lineage is followed by rearrangement and expression 
of the B cell receptor genes, the immunoglobulin 
heavy and light chain genes. First, rearrangement of 
the immunoglobulin heavy chain gene is observed, 
followed by expression of the pre-B cell receptor 
(pre-BCR), composed of the heavy chain and the 
surrogate light chains λ5 and V-preB. Signaling 
through this pre-BCR leads to a transient phase of 
cellular proliferation, and triggers the transition from 
early pre-B cells to late small pre-B cells. 
Recombination of the κ and λ light chains loci is 
initiated at the pre-B cell stage. Successful pairing of 
one of the light chains with the heavy chain results 
in surface expression of Immunoglobulin M (IgM), 
the hallmark of immature B cells. Upon encounter 
with autoantigens that are recognized by this sIgM, 
the cells can downregulate the IgM surface 
expression and induce a further rearrangement of the 
Ig light chain gene by a process termed receptor 
editing. Cells that remain autoreactive undergo 
programmed cell death (apoptosis), but those that 
lose the autoreactivity through receptor editing can 
proceed normally in their development. IgM-
expressing cells that were not negatively selected for 
recognition of self molecules can subsequently exit 
the bone marrow and complete their maturation in 
the spleen. Discrete stages of B cell development 
have been defined based on (i) cell cycle status and 
cell size, (ii) the status of Ig heavy (H) and light (L) 
chain rearrangement and, (iii) the expression of 
several genes on the cell membrane or in the 
cytoplasm (especially those of the rearrangement 
machinery (Rag-1, Rag-2, TdT) and the pre-BCR 
and BCR complex (IgH chain, (surrogate) IgL chain, 
Igα and Igβ chains). Figure 5, in combination with 
Table I, depicts these successive stages of antigen 
independent B cell development. In addition, it 
indicates the stages at which various transcription 
factors have been found to be important, usually on 
the basis of knockout studies. 
 
Figure 5  Murine B cell development. Discrete stages of B cell development, based on cell size, the rearrangement status of 
the immunoglobulin genes and the expression of genes on the cell membrane or in the cytoplasm, are shown. Some of the 
markers are only indicated where their expression/inexpression is required to identify a specific B cell subset. Immature B 
cells are depicted overlapping the bone marrow and the spleen because these cells are present in both organs. 
 
Table I  Genes controlling murine early B cell development 
Developmental 
transitions 
pro-B to preB-I preB-I to large 
preB-II 
large preB-II to 
small preB-II 
small preB-II 
to immature B 
immature to 
mature B 
centrocyte to 
plasma cell 
Hallmark 
events 
DH- to JH-  
rearrangement 
VH- to DJH-
rearrangement 
VL- to JL-
rearrangement 
IgM surface 
expression  
IgD surface 
expression 
 
Important 
transcription 
factors 
Sox-4 
E2A 
EBF 
Pax-5 
Pax5 IRF-4 / IRF-8  OBF-1 / 
Aiolos 
OBF-1 
Oct-2 
NF-κB 
Blimp-1 
XBP-1 
Aiolos (?) 
Important other 
genes 
RAG-1, -2 
SCID 
BLNK 
JH  
µmb;  
Igβ 
IL-7; IL-2Rβ 
Syk 
PI3K 
λ5 
VpreB1 / 
VpreB2 
DNA 
Polymerase Mu 
Btk / Tec  
κ / λ L chain Btk  
1.1.2  Murine B cell development 
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1.1.2.2 T cell dependent immune 
responses 
 
Immature B cells enter the spleen from the blood 
at the level of the marginal zone (MZ) where they 
can be selected for self-reactivity in the periphery 
and consequently enter an anergic state, or they can 
mature further. B cells that have freshly entered the 
spleen can be identified by their cell surface reaction 
with the monoclonal antibody 493 (Rolink et al., 
1998), which presumably recognizes the cell surface 
marker AA4.1, which is the complement component 
C1q like receptor C1qRp (Rolink et al., 2002). 
Subsequently, the (naïve) B cells cross the marginal 
sinus and migrate via the periarteriolar lymphoid 
sheath (PALS) to the lymphoid follicles, which are 
areas specialized in antigen retention and 
presentation. Upon encounter with T cell dependent 
(TD) antigen such mature IgM+ IgD+ B cells become 
activated and proliferate with T cell help. The T 
helper cells (Th) required for this activation are 
CD4+ CD8- cells that can be divided into two 
subpopulations according to their cytokine profile: 
Activated Th1 cells secrete mainly IL-2 and IFN-γ, 
while activated Th2 cells secrete IL-4 and IL-5. Th 
cell get activated by binding of antigen processed 
and displayed by antigen presenting cells (APCs). 
Upon activation, Th cells upregulate the expression 
of a number of accessory receptors and ligands (e.g. 
CD40L and CD28) that are essential for B cell 
activation in TD immune responses. The activated  
 
mature B cells then differentiate predominantly into 
low affinity antibody-forming cells (AFCs), which 
are short-lived plasmacytes that initially secrete 
IgM, but subsequently switch to secondary isotypes 
and die by apoptosis within two weeks of 
immunization. Some cells from the expanded B cell 
pool do not become AFCs but migrate into the 
adjacent follicles, which are subsequently 
transformed into germinal centers (GCs). GC B cells 
undergo iterative cycles of proliferation, somatic 
hypermutation and apoptosis in cooperation with 
antigen-primed T cells and follicular dendritic cells 
(FDCs), a process resulting in the selection of B cell 
clones that make an antibody with high affinity for a 
cognate antigen. Additionally, Ig class switching 
occurs during the GC reaction. These steps expand, 
refine and diversify the repertoire of the early 
immune response to assure the long-term 
maintenance of protective immunity. Two types of 
terminally differentiated B cells eventually emerge 
from the GC reaction: nonsecreting, Ig surface-
positive memory B cells and high affinity antibody-
secreting plasmablasts that carry no 
immunoglobulins at their surface and that are the 
final mediators of the humoral immune response. 
Figure 6 gives an overview over the B cell fate in the 
spleen.  
 
Figure 6  B cell maturation in the spleen. Immature B cells enter the spleen in the marginal zone (MZ) where they are selected 
for self-reactivity. Positively selected (naïve) B cells migrate via the periarteriolar lymphoid sheath (PALS) to the lymphoid
follicles, where they can encounter TD antigens, become activated, proliferate and differentiate into short-lived low affinity 
antibody-forming cells (AFCs). Some cells do not become AFCs but migrate into the adjacent follicles, which are then
transformed into germinal centers (GCs). GC B cells undergo iterative cycles of proliferation, somatic hypermutation and
apoptosis in cooperation with antigen-primed T cells and follicular dendritic cells (FDCs), a process resulting in the selection 
of B cell clones that make a high affinity antibody for the specific antigen. Two types of terminally differentiated B cells
eventually emerge from the GC reaction: non-secreting memory B cells and high affinity antibody-secreting plasmablasts. 
TH, T helper; IDC, interdigitating cell. 
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1.1.2.3 T cell independent immune 
responses 
 
As we have seen in the previous section, antigens 
recognized by the BCR usually require 
costimulatory signals from helper T cells to elicit a 
specific (TD) immune response. Some antigens 
however, including mostly bacterial cell wall 
components, such as LPS and certain sugars (e.g. 
Ficoll), can stimulate the B cells by themselves to 
proliferate and to secrete antibodies independently 
of T cell help. These T cell independent (TI) 
antigens do not lead to the formation of 
immunological memory, and the antibodies that arise 
from a TI immune response usually do not undergo 
affinity maturation or class switching. The B cell 
subsets that are required for TI immune responses 
are preactivated splenic marginal zone (MZ) B cells, 
as well as B1 B cells which provide a bridge 
between the very early innate and the later appearing 
adaptive immune response by generating an initial 
wave of IgM producing plasmablasts during the first 
three days of a primary response to particulate 
bacterial antigens (Martin and Kearney, 2000a; 
Martin et al., 2001). 
 
1.1.2.3.1 B-1 B cells 
B-1 cells constitute a subset of B cells that are 
localized predominantly in the peritoneal and pleural 
cavities and can be distinguished from the 
conventional (B-2) B cells by their self-renewal 
capacity and unique cell surface proteins. In contrast 
to other B cell populations, they are CD45 (B220lo), 
IgMhi, CD23-, CD43+, and IgDlo. While the origins 
of B-1 cells remain controversial, it is well 
established that they secrete natural antibodies 
important for innate immunity – preferentially low-
affinity, poly-reactive, mostly self-reactive 
antibodies (Forster and Rajewsky, 1987; Hayakawa 
et al., 1990; Hayakawa et al., 1984; Mayer and 
Zaghouani, 1991; Shirai et al., 1991). B-1 cells make 
antibody responses mainly to polysaccharide 
antigens in a T cell independent manner. It appears 
that they arise either as a distinct lineage from 
committed fetal/neonatal precursors (Hayakawa et 
al., 1985; Lam and Stall, 1994), or from follicular B-
2 cells in response to BCR ligation (Clarke and 
Arnold, 1998; Haughton et al., 1993). For a detailed 
review of B1 cells see (Berland and Wortis, 2002). 
In either case it appears that BCR specificity and 
surface density together are also decisive factors in 
the development of B-1 versus B-2 cells (Lam and 
Rajewsky, 1999). 
The B-1a cells subset expresses CD5, but is 
otherwise almost indistinguishable from the B-1b 
cells (Kantor et al., 1992; Stall et al., 1992).  
 
1.1.2.3.2 Marginal zone (MZ) B cells 
MZ B cells consist mainly of a large, mostly 
non-circulating subset of mature B cells that are 
localized in the marginal zone of the spleen. As 
mentioned before, they have an important function 
at the early stages of the immune response. This 
could be attributed to their observed lower activation 
threshold that triggers them more easily into 
proliferation or differentiation than immature or 
recirculating mature B cells. Several recent reviews 
discuss these properties in more detail (Bendelac et 
al., 2001; Martin and Kearney, 1999; Martin and 
Kearney, 2000a; Martin and Kearney, 2002).  
A number of genes that are crucial for the 
generation or maintenance of the MZ B cell 
compartment have been identified by targeted 
disruption or overexpression studies.  
A first group of mutations that specifically affect 
MZ B cells is modulating the BCR signal strength. 
For example, mice with a targeted disruption of the 
Aiolos transcription factor have a strongly reduced 
number of MZ B cells, most likely due to an 
increase in BCR signal strength in the absence of 
Aiolos (Cariappa et al., 2001). In Lyn-/- mice and in 
mice with a mutated Igα ITAM motif, MZ B cell 
numbers are also strongly decreased, and both Lyn 
and Igα are known to negatively regulate BCR 
signaling. Conversely, MZ B cell numbers are 
enhanced in mice lacking the coreceptor CD21, and 
this enhancement correlates with an expected 
decrease in BCR signal strength (Cariappa et al., 
2001). In the absence of the BCR costimulatory 
molecule CD19, MZ B cells are lacking completely 
(Hiemstra et al., 1999; Martin and Kearney, 2000b).  
A second group of genes is presumably required 
for the migration of precursors to the MZ, such as 
NFκB p50, Pyk2 and Lsc, or for the development 
and maintenance of the microarchitecture and 
microenvironment of the spleen (such as Ltα, Ltβ, 
LtβR, NFκB p52, RelB, and Dock2) (reviewed in 
(Cariappa and Pillai, 2002)). Recently, the 
transcriptional coactivator OBF-1 has also been 
suggested to be important for MZ B cell 
development, probably due to altered homing 
properties of OBF-1 deficient cells (Samardzic et al., 
2002b).  
Another recent report investigating the effect of 
conditional mutagenesis of the transcription factor 
RBP-J (recombination signal binding protein-J) in B 
cells demonstrates that Notch-RBP-J signaling is 
involved in cell fate determination of marginal zone 
B cells (Tanigaki et al., 2002). It has been suggested 
that Notch-RBP-J signaling regulates the lineage 
commitment of mature B cells into follicular versus 
MZ B cells. 
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1.1.3 B cell function / 
Immunoglobulins 
 
The expression of immunoglobulins, either as 
cell surface receptors, or in secreted form as 
antibody molecules, is a unique feature of B cells. 
An immunoglobulin (Ig) molecule consists of two 
identical heavy (H) and two identical light (L) 
polypeptide chains held together by a combination 
of noncovalent bonds and covalent disulfide bonds 
(Figure 7). Each polypeptide chain features one 
variable (V) and one constant (C) domain. The 
antigen is bound by both the VH and VL domains. 
The variable region can be further divided into 
hypervariable regions, also called complementarity 
determining regions (CDRs), and more conserved 
framework regions (FR). The C region is 
characteristic for each distinct isotype and is non-
variable within the same isotype group. There are 
five main heavy-chain classes (isotypes), some of 
which have several subtypes: IgM, IgD, IgG, IgA, 
and IgE. Antibodies of different isotypes operate in 
distinct places in the body and have distinct 
functional activities. The different functions for 
human isotypes are listed in Table II. The 
corresponding heavy-chains are denoted µ, δ, ε, γ 
and ε, respectively. Initially, all immature B cells 
express the IgM isotype and may switch to a 
different isotype at later stages of B cell maturation. 
 
 
 
 
Figure 7  Structure of a prototypic immunogobulin 
molecule. The constant regions of the heavy and light 
chains are depicted in blue, the variable regions are 
shown in red. (Figure modified after (Janeway et al., 
1999), Fig. 3.1 to 3.3) 
 
Table II  Effector functions and distribution of human 
immunoglobulin isotypes (from (Janeway et al., 1999),Fig. 
8.16) 
Functional 
activity 
IgM IgD IgG1  IgG2 IgG3 IgG4 IgA IgE 
Neutralization + - ++ ++ ++ ++ ++ - 
Opsonization - - +++ - ++ + + - 
Sensitization 
for killing by 
NK cells 
- - ++ - ++ - - - 
Sensitization 
of mast cells 
- - + - + - - +++ 
Activation of 
complement 
system 
+++ - ++ + +++ - + - 
         
Distribution IgM IgD IgG1  IgG2 IgG3 IgG4 IgA IgE 
Transport 
across 
epithelium 
+ - - - - - +++ 
(dimer) 
- 
Transport 
across 
placenta 
- - +++ + ++ +/- - - 
Diffusion into 
extravascular 
sites 
+/- - +++ +++ +++ +++ ++ 
(monomer)
+ 
Mean serum 
level (mg/ml) 
1.5 0.04 9 3 1 0.5 2.1 3x10-5
 
 
1.1.3.1 Organization and transcription of 
the Ig loci 
 
The functional gene segments that make up the 
Ig L and H chains are organized into three clusters, 
located on different chromosomes: the κ and λ light-
chain genes, and the heavy-chain genes. Multiple 
copies of all of these gene segments exist in 
germline DNA (see Figure 8). The two loci of light-
chain genes, κ and λ, are alternatively used, with 
species-specific preferences (κ to λ ratios of 2:1 in 
man and 20:1 in mouse), but apparently without 
functional differences.  
In order to form the functional Ig molecules, the 
gene segments have to be assembled by somatic 
recombination. Two types of recombinatorial events 
take place at the Ig locus during B cell development: 
V(D)J recombination at both H and L loci, and 
class switch recombination (CSR) at the H locus.  
 
1.1.3.1.1 V(D)J recombination 
During the process of V(D)J recombination, the 
H chain rearrangement occurs first, starting with a 
rearrangement joining one of the DH gene segments 
with one of the JH genes. Subsequently, one VH gene 
segments is joined to shape a VDJ-CH gene. 
Rearrangement of the L chain follows, where one of 
the VL gene segments is directly joined to a JL gene 
segment, leading to a VJ-CL κ or λ gene. In both 
cases, RNA splicing after transcription joins the 
V(D)J segments to the closest downstream C region 
coding sequence. In immature B cells, that is Cµ or, 
if alternative splicing occurs during late phases of B 
cell development, Cδ. The C genes are organized in 
the following order in the mouse genome: 5’-V(D)J-
Cµ-Cδ-Cγ3-Cγ1-Cγ2b-Cγ2a-Cε-Cα-3’(D'Eustachio 
et al., 1980). 
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Figure 8  Organization and control elements of the murine immunoglobulin heavy (IgH) and light chain (Igκ, Igλ) gene loci. 
The variable (V), joining (J) and constant (C) gene segments are represented as boxes. The enhancers are shown as grey 
boxes, and the detailed view of the IgH enhancer shows important regulatory elements and transcription factor binding sites. 
The intronic enhancer of the IgH locus is flanked by matrix attachment regions (MARs). The IgH 3’ enhancer contains four 
DNAse hypersensitive sites (HS1 to HS4) essential for its activity; the arrows below indicate three inverted repeats that 
illustrate the palindromic structure of the 3’ enhancer.  
 
 
1.1.3.1.2 Class switch recombination 
The second type of rearrangement occurring at 
the Ig locus during B cell development is class 
switch recombination (CSR) at the IgH locus. CSR 
is a deletional process that places a constant region 
(C) gene other than Cµ or Cδ directly downstream of 
the rearranged VDJ segments, leading to the 
expression of other, secondary Ig isotypes encoded 
by downstream C genes, such as IgG, IgE and IgA 
(Stavnezer, 1996). CSR occurs between highly 
repetitive G-rich switch (S) sequences with abundant 
palindromes that precede every C region, except for 
Cδ. This process is controlled by a series of signals 
involving BCR and cytokine signaling, and in which 
B cell - T cell interactions play a critical role 
(Stavnezer, 1996). The activation and targeting of 
CSR correlates with the capability of certain 
mitogens and cytokines to either induce or suppress 
germline transcription of specific C genes (Manis et 
al., 2002; Snapper et al., 1997). Both 
recombinatorial events are thus intimately linked to 
transcription of the locus. 
 
1.1.3.1.3 The recombination machinery 
In both V(D)J rearrangement and CSR, double-
strand breaks in the DNA are generated and 
differentially re-ligated, thereby deleting the 
interjacent genomic sequence. In the case of V(D)J 
rearrangement, this relies on highly conserved 
recombination signal sequences (RSS), short 
stretches of DNA present 3’ of each V region, 5’ and 
3’ of D regions and 5’ of each J region. RSS always 
consist of a conserved heptamer and nonamer 
separated by 12 or 23 base pairs. V(D)J 
rearrangement occurs only between gene segments 
located on the same chromosome and follows the 
12/23 rule: Recombination can link only a gene 
segment flanked by a 12mer-spaced RSS to one with 
a 23mer-spaced RSS. This has the effect that DH to 
JH segment joining and VH to DH segment joining is 
possible, but VH to JH segment joining is not 
possible, as both VH and JH segments are flanked by 
23bp spacers and the DH segments are flanked by 
12bp spacers (Eastman et al., 1996; Tonegawa, 
1983; van Gent et al., 1996).  
The recombination activating enzymes RAG-1 
and RAG-2 catalyze the double strand break and re-
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ligation reactions, assisted by components of the 
DNA double-strand break repair machinery, 
including Ku proteins and the DNA-dependent 
protein kinase (DNA-PK).  
Isotype switch recombination also requires 
DNA-PK and Ku proteins (Ku70 and Ku80), but can 
occur in the absence of RAG-1 and RAG-2 gene 
expression; the enzymes that perform the 
recombination reactions are yet unknown.  
 
1.1.3.1.4 Sterile and productive transcripts 
Two types of Ig transcripts are expressed during 
B cell development: sterile germline transcripts and 
productive transcripts. Sterile transcripts result from 
Ig gene transcription preceding gene rearrangement 
and class switching and are not transcribed. It is 
generally believed that sterile transcripts alter the 
accessibility of the Ig loci and thereby influence the 
regulation of gene rearrangements. Sterile transcripts 
have been characterized from most of the CH genes, 
as well as for Cκ and Cλ light chain genes.  
Productive transcripts originate from the 
transcription of rearranged Ig genes and are 
translated into functional proteins.  
 
1.1.3.1.5 Affinity maturation 
The efficiency of antigen elimination is also 
enhanced by affinity maturation, which is 
accomplished by excessive point mutations in the V-
region gene, coupled with selection of high-affinity 
antibody-producing cells by limited amounts of 
antigen. Point mutations are introduced by two types 
of molecular mechanisms: non-templated somatic 
hypermutation (SHM), and gene conversion, 
which takes place in chickens and rabbits, with 
pseudogenes serving as template (Reynaud et al., 
2003). 
The process of somatic hypermutation can be 
divided into three phases: targeting, DNA 
recognition and cleavage, and repair. The first phase 
of targeting a nuclease to the Ig locus necessitates 
transcription (reviewed in (Jacobs and Bross, 2001)). 
While some sequence specificity was reported, it 
remains unclear what is recognized by this nuclease 
(Michael et al., 2002). The cleavage mediated by the 
nuclease leads to a DNA double strand break (DSB) 
(Bross et al., 2000; Papavasiliou and Schatz, 2000), 
which might be preceded by a single strand lesion 
(Kong and Maizels, 2001). In the final phase, the 
DSB is probably repaired into a mutation by a subset 
of error-prone polymerases ((Gearhart and Wood, 
2001), reviewed in (Papavasiliou and Schatz, 2002)). 
 
 
 
1.1.3.1.6 AID 
The activation-induced deaminase (AID) is an 
enzyme specifically expressed in germinal center B 
cells (Muramatsu et al., 1999) which is required for 
CSR, and also for the processes of somatic 
hypermutation (SHM) (Muramatsu et al., 2000; 
Nagaoka et al., 2002) and gene conversion (Arakawa 
et al., 2002; Harris et al., 2002). The analyses of 
several AID mutants indicate a requirement for 
class-switch-specific cofactors (Ta et al., 2003). Still, 
the mechanism of action of AID remains uncertain. 
Since AID displays a sequence similarity with the 
RNA-editing enzyme APOBEC-1, it is believed by 
some that AID may also act as an RNA-editing 
enzyme. Alternatively, it has been shown in E. coli 
and in in vitro assays to directly edit DNA (Petersen-
Mahrt et al., 2002) by catalyzing deamination of 
deoxycytidine (dC) on single-strand DNA in a 
transcription-dependent manner, but not on double-
strand DNA, RNA-DNA hybrids or RNA 
(Bransteitter et al., 2003; Chaudhuri et al., 2003). 
According to the DNA deamination model 
(Neuberger et al., 2003), AID deaminates dC on one 
strand of DNA to generate dU residues. Following 
the deglycosylation and removal of the 
misintegrated dU residues by UNG, the apyrimidic 
endonuclease (APE) could then generate DNA 
breaks, a necessary step common to both CSR and 
SHM. In agreement with this model, a partial CSR 
defect and a skewed pattern of SHM in uracil N-
glycosylase (UNG)-deficient mice was described 
recently (Rada et al., 2002), providing further 
evidence that AID acts directly on DNA. A model 
integrating AID in CSR, SHM and gene conversion 
pathways is shown below (Figure 9). 
 
 
Figure 9  DNA deamination model for antibody 
diversification according to the Neuberger group, taken 
from (Neuberger et al., 2003). This model shows how 
different mechanisms resolving the initiating dU-dG lesion 
could lead to various patterns of antibody diversification. 
Phase 1A: somatic hypermutation (SHM) with activation-
induced deaminase (AID) triggers dC → dU deamination. 
DNA synthesis occurring opposite this dU residue leads to 
dC → dT (and dG → dA) transitions. Phase 1B: the action 
of a uracil-DNA glycosylase (UNG) that excises a base 
before DNA synthesis can occur leads to both transitions 
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and transversions subsequent to DNA synthesis opposite 
the apyrimidinic site. Phase 2: Alternatively, recognition 
of the dU–dG mismatch by components of the mismatch 
repair pathway could trigger a mutagenic DNA repair 
synthesis leading to mutations at dA and dT that also 
occur during SHM. Alternatively, the lesion could be 
repaired by the mismatch repair system. In the case of 
chicken or rabbit, IgV gene conversion results when the 
initiating dU–dG lesion (or an intermediate in its repair) 
is resolved by a recombinational process templated on one 
of the proximal IgV pseudogenes. Switch recombination is 
thought to be triggered when AID-mediated deamination 
is targeted to dC residues in the vicinity of the m switch 
region with the resolution involving a partner switch-
region from the downstream immunoglobulin (Ig) isotype. 
The major pathway of switch recombination might occur 
by a form of non-homologous end-joining involving Ku70 
or Ku80 (Casellas et al., 1998; Manis et al., 1998). 
Abbreviations: AP-endonuclease, apyrimidinic 
endonuclease; dRPase, 5’-deoxyribophosphodiesterase. 
 
 
 
1.1.3.1.7 Allelic exclusion, receptor editing 
For each Ig locus, there are two alleles that can 
undergo gene rearrangement, and this increases the 
chance of a successful rearrangement. After 
successful rearrangement of the first allele, the 
recombination machinery is quickly downregulated, 
so that generally only one successfully rearranged 
IgH and IgL locus is found in any one B cell. This 
phenomenon is called allelic exclusion. The other 
allele remains in germline configuration, is partially 
rearranged or has completed an unproductive 
rearrangement.  
Another rescue mechanism that prevents 
excessive unproductive rearrangements is the 
process of receptor editing. Unlike the heavy-chain 
genes, repeated light-chain gene rearrangements of 
unused V and J gene segments can occur, thereby 
increasing the chance of the B cell precursors to 
generate progeny that bears intact IgM molecules: 
the immature B cells. 
 
 
 
Note: Diversity of the antibody repertoire is achieved by a number of mechanisms:  
• many V-region gene segments exist in the genome of an individual, providing a hereditable source of 
diversity, 
• random recombination of separate V, D, and J gene segments during V(D)J recombination provide 
additional diversity, 
• variability of the junctions between the gene segments is increased by the random insertion of P- and N-
nucleotides and by deletion of nucleotides at the ends of some coding sequences,  
• the association of different light- and heavy-chain V regions adds diversity, 
• the modification of V regions of expressed immunoglobulins in the process of somatic hypermutation
upon antigen stimulation of mature B cells further increases diversity of the antigen-binding site 
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1.2 Transcription 
 
At this point, it is useful to give a brief overview 
over the general mechanisms of eukaryotic gene 
transcription, which constitute the basis of the most 
common and most immediate point of regulation of 
gene expression in a cell.  
Transcription of the eukaryotic genes is 
performed by three RNA polymerases: RNA 
polymerase I (Pol I) synthesizes the large ribosomal 
RNA (rRNA), Pol II synthesizes mRNA and Pol III 
synthesizes tRNA and 5S rRNA. We will focus here 
on Pol II transcription; a review on Pol I and Pol III 
transcription can be found in (Paule and White, 
2000). 
 
 
1.2.1 Pol II transcription  
 
1.2.1.1 The basal transcription machinery 
 
Synthesis of mRNA by RNA polymerase II (Pol 
II) is governed by two distinct DNA elements: a 
core promoter and upstream – or downstream – 
enhancer sequences. The core promoter determines 
the transcription start site and directs the assembly 
of the pre-initiation complex (PIC), which consists 
of Pol II and general transcription factors (GTFs), 
namely TFIIA, TFIIB, TFIID, TFIIE, TFIIF and 
TFIIH. TFIID itself is a multi-protein complex 
containing the TATA-binding protein (TBP) and a 
set of TBP-associated factors (TAFIIs), which have 
sequence-specific DNA-binding activity and are 
involved in promoter selectivity (Burley and Roeder, 
1996).  
The core promoter often contains a TATA box, an 
AT-rich motif located 25-30 bp upstream of the 
transcription start site which is bound by TBP. 
Another common element is the initiator (Inr), 
which encompasses the transcription start site and 
which serves as a binding site for additional 
regulatory factors. The sequence elements of a 
typical core promoter and a model of the Pol II 
transcription initiation machinery are depicted in 
Figure 10.  
 
The largest subunit of Pol II contains a highly 
conserved C-terminal domain (CTD) consisting of 
tandem repeats of the heptapeptide YSPTSPS, which 
can be differentially phosphorylated during the 
different stages of transcription. During the initiation 
of transcription, the CTD is unphosphorylated and 
binds to the large SRB/Mediator complex. At the 
transition to transcription elongation, the CTD 
becomes phosphorylated and Pol II dissociates from 
the SRB/Mediator complex and recruits the 
elongator complex as well as several pre-mRNA 
processing factors. The cell cycle-specific regulation 
of Pol II activity also depends on the 
phosphorylation of its CTD.  
 
1.2.1.2 Transcription factors 
 
To achieve a specific and controlled regulation of 
gene transcription, the basal transcription machinery 
interacts with additional proteins that bind to the 
promoter or enhancer region, so-called 
transcription factors. Transcription factors contain 
at least two essential features: a sequence-specific 
DNA-binding domain and an independent 
regulatory domain that can be either transactivating 
or inhibitory. Factors that do not feature a DNA-
binding domain but are recruited by transcription 
factors to the active site of transcription and thereby 
modulate transcriptional activity are termed 
transcriptional coactivators or corepressors.  
There are various ways in which transcription 
factors regulate transcription. First, they can interact 
with components of the basal transcription 
machinery and thereby modulate the assembly of the 
preinitiation complex (Ptashne and Gann, 1997). 
Other processes that can be targeted by transcription 
factors are transcription elongation and re-initiation 
of transcription. Transcription factors can also 
recruit chromatin modifying activities that modulate 
the acetylation state of the local chromatin and 
thereby can facilitate or inhibit transcription. For 
example, the coactivators p300 and CBP contain 
histone acetyltransferase activity that activates 
transcription by altering or disrupting the repressive 
chromatin structure (Ogryzko et al., 1996). 
 
Figure 10  Components of the
DNA polymerase II transcription
initiation machinery.  
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Moreover, transcription factors could be involved in 
targeting promoters to regions in the nucleus with 
high transcriptional activities (Brown et al., 1997). 
 
 
1.2.2 Transcriptional regulation of B 
cell development 
 
The development, maturation and selection of 
mammalian B cells is a complex and strictly 
regulated process. As we have seen previously, the 
successive stages of B cell differentiation can be 
characterized by sequential rearrangement of the 
immunoglobulin (Ig) genes, and by the ordered 
appearance or disappearance of proteins at the cell 
surface, or within the cell (Rolink and Melchers, 
1993). This entire program of differentiation 
involves the selective expression of genes that are 
characteristic of the B cell lineage. The correct 
temporal expression of these cell type-specific genes 
is determined by the action of lineage-restricted 
transcriptional regulators. Experiments using 
targeted gene disruptions have shown that the loss of 
some transcription factors, such as PU.1, affects 
multiple hematopoietic lineages, whereas the loss of 
other transcriptional regulators specifically affects 
early B cell development (Scott et al., 1994). These 
transcription factors include, for example, EBF 
(early B cell factor), E2A, and Pax5 (Bain et al., 
1994). Since I have published an extensive review 
on the transcriptional control of B cell development, 
which can be found in Section 2.5 of this thesis, I 
will focus at this point specifically on the 
transcription of the immunoglobulin genes.  
 
 
1.2.3 Immunoglobulin gene 
transcription 
 
The Ig genes were among the first genes studied 
in depth in mammalian cells. For that reason, they 
are some of the best-studied transcriptional units in 
mammalian cells today, and thus constitute a very 
useful model to analyze the regulation of gene 
transcription in general. Ig gene transcription is a 
highly regulated process driven by a number of 
ubiquitous and tissue-specific transcription factors 
that bind to regulatory regions in the Ig locus. These 
control regions include the V gene proximal 
promoters and promoters used for sterile 
transcription of the H and L chain loci, the intronic 
enhancers in the J-C region of the H and κ chain loci 
(Eµ, iEκ), the silencers located near the intronic 
enhancers, and the 3’ enhancers of the κ, λ and Cα C 
region genes (3’Eκ, Eλ, and 3’EH). Additional 
regulatory elements are the matrix attachment 
regions (MARs), flanking the Eµ and iEκ intronic 
enhancers. The various control elements are depicted 
in Figure 8. 
 
1.2.3.1 V region promoters 
 
The V region promoters contain several control 
elements, the most highly conserved elements being 
a TATA box about 25 bp upstream of the initiation 
site and an octamer element (ATGCAAAT) or its 
reverse complement. This element is also conserved 
in some Ig enhancers and in the promoters of other 
B cell specific genes, including Igβ, CD20 and 
CD21, and will be discussed more in detail later. In 
the VH promoters, but not in the VL promoters, the 
octamer site is often found in conjunction with a 
heptamer sequence (CTCATGA) 2 to 22 bp 
upstream. Other conserved elements in many V 
promoters and enhancers include C/EBP (CAAT 
enhancer binding protein) binding sites and µE3 
elements, which are binding sites for E box proteins, 
such as TFEB, TFE3 and USF (Beckmann et al., 
1990).  
 
1.2.3.2 IgH intronic enhancer (Eµ 
Enhancer) 
 
The intronic enhancer is located between the J 
regions and Cµ and spans approximately 220 bp 
sequence featuring a number of E box motifs 
(CANNTG), such as µE1, µE2, µE3, µE4, µE5, µA, 
as well as C/EBP and octamer binding sites 
(Arulampalam et al., 1997; Engel and Murre, 2001; 
Ernst and Smale, 1995). The E box binding proteins 
(E-proteins) E2A, E2-2 and HEB belong to a 
subclass of bHLH factors that act as transcriptional 
activators and can homo- or heterodimerize on the E 
box motifs E2, E4 and E5 (Hu et al., 1992; Murre et 
al., 1989). Another subclass of bHLH factors 
possesses an additional leucine zipper motif, 
allowing them to form higher order multimers. 
Members of this subclass, including USF, TFE3 and 
TFEB, bind to the E3 box (Beckmann et al., 1990). 
Additional motifs termed µA and µB were also 
implicated in the activation of IgH gene expression. 
These binding sites are recognized by the 
transcription factors of the Ets family, including Ets-
1, Ets-2, Elf-1, Erp, and NERF, which can bind to 
the µA motif, and PU.1, which binds to the µB site 
(Nelsen et al., 1993; Rivera et al., 1993). The Ets 
transcription factors are characterized by a 
conserved DNA-binding domain (the ETS domain) 
that forms a helix-loop-helix structure that binds 
specific purine-rich DNA sequences with a GGA 
core (Crepieux et al., 1994; Sharrocks, 2001). They 
are generally weak activators of transcription by 
themselves and act mainly through cooperative 
binding with other transcription factors.  
 
Matrix attachment regions 
The intronic enhancer is flanked by two matrix 
attachment regions (MARs), consisting of A/T-rich 
sequences that associate with the nuclear matrix 
(Cockerill et al., 1987). They have been associated 
with the control of chromatin structure of entire gene 
loci and thus overlap functionally with locus control 
1.2  Transcription 
 
14 
regions (LCRs). The MARs can contribute 
positively to Eµ function by enhancing transcription 
from a transgene promoter (Forrester et al., 1994; 
Jenuwein et al., 1997). In addition, MARs have been 
implicated in constituting physical boundaries 
between genes by forming chromosome loops 
(Cockerill and Garrard, 1986; Cockerill et al., 1987). 
 
 
1.2.3.3 The 3’ IgH enhancer 
 
The 3’ IgH enhancer is located downstream of 
the IgH locus, 3’ of the Cα region. It spans over 30 
kb and encompasses four DNaseI hypersensitive 
sites with enhancer activity, termed HS1 to HS4. The 
initially identified major enhancer contains HS1 and 
HS2. This enhancer region is not active in resting B 
cells, but its activity is inducible by mitogens and by 
BCR and CD40 crosslinking in activated B cells and 
plasma cells. It was discovered early that an octamer 
site present in several of the 3’ enhancer elements is 
crucial for its activity during B cell activation (Yuan 
et al., 1995) and that interaction of Oct-2 and its 
coactivator OBF-1 with the 3’ IgH during B cell 
activation are essential (Tang and Sharp, 1999). 
HS3a and HS3b respond less strongly to mitogenic 
signals and appear to be influenced, among others, 
by Bach2 binding, together with one of the small 
Maf proteins, to Maf recognition elements (MAREs) 
in HS3a and HS3b (Muto et al., 1998). Binding of 
Pax-5 and NF-κB to their cognate DNA recognition 
sequences seems to be important as well. 
It is generally believed that the 3’ IgH enhancer 
plays an important role in the high expression of 
switched Ig loci in plasma cells compared to 
unswitched loci, presumably because it is then 
brought into the vicinity of the VH promoter and 
interacts with it (Arulampalam et al., 1997). 
 
 
 
1.2.4 Specific transcription factors 
regulating Ig gene transcription 
 
1.2.4.1 Oct factors 
 
As we have seen in the previous section, the V 
region promoters appear to be quite simple and 
contain a highly conserved octamer element (5’–
ATGCAAAT–3’, or its reverse complement), located 
upstream of a TATA box. This octamer element is 
found in the promoters of a variety of eukaryotic 
genes, including ubiquitously active genes, such as 
H2B (LaBella et al., 1988) and most U snRNA genes 
(Herr, 1992; Janson and Pettersson, 1991; Mittal et 
al., 1996; Murphy et al., 1992), but also genes that 
are restricted to distinct cell types or tissues 
(Christensen et al., 1992; Hermanson et al., 1989; 
Thevenin et al., 1993). Importantly, the octamer 
element is present in all immunoglobulin heavy and 
light chain gene promoters as well as in the heavy 
chain intronic enhancer (Staudt and Lenardo, 1991) 
and appears to be critical for Ig gene transcription, 
as shown by a variety of in vitro and in vivo 
experiments (Bergman et al., 1984; Dreyfus et al., 
1987; Jenuwein and Grosschedl, 1991; Mason et al., 
1985; Matthias, 1998; Wirth et al., 1987). The best 
studied transcription factors that interact specifically 
with the octamer motif in B cells are the POU 
homeodomain proteins Oct-1 and Oct-2. While Oct-
1 is ubiquitous, Oct-2 is predominantly expressed in 
B cells, as well as in activated T cells and in the 
nervous system. Oct-1 and Oct-2 are members of the 
POU family of transcription factors (POU stands for 
Pit-1, Oct-1 and nematode Unc-86; for review see 
(Herr and Cleary, 1995; Latchman, 1999; Phillips 
and Luisi, 2000)). The common characteristic of the 
POU family is the 150-160 amino acid bipartite 
DNA-binding domain (POU domain), consisting of 
two structurally independent subdomains: the 
homeodomain POUH (which is related to the DNA 
binding domain of homeobox proteins), and the 
specific domain POUS (which is unique to the POU 
factors). These two subdomains are connected 
through a short flexible linker, conferring 
conformational flexibility and thereby functional 
diversity to this class of transcription factors. The 
linker spans 14-26 amino acids and allows the 
protein to contact the DNA on both sides of the 
double helix ((Phillips and Luisi, 2000); Figure 11).  
 
 
Figure 11  Three-dimensional structure of the Oct-1 POU 
domain bound to an octamer site. The POU homeodomain 
(POUH) and POU specific domain (POUS) bind on 
opposite sites of the DNA. Figure adapted from (Andersen 
and Rosenfeld, 2001). 
 
Oct-1 and Oct-2 show identical DNA binding 
activities and share 90% sequence identity in their 
DNA binding POU domain, but differ in other 
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protein regions, mostly in the C-terminal activation 
domain (Tanaka et al., 1992).  
Due to its B cell-restricted expression pattern, 
Oct-2 was considered as one prime candidate for the 
activation of immunoglobulin transcription in B 
cells. Yet, targeted disruption of the Oct-2 gene in 
mice failed to demonstrate an essential role of Oct-2 
in Ig gene transcription (Corcoran et al., 1993; 
Schubart et al., 2001). The analysis of Oct-2 
deficient mice showed that this factor is required for 
B cell maturation and also, surprisingly, for postnatal 
survival (Corcoran and Karvelas, 1994; Corcoran et 
al., 1993). In addition, Oct-2 was found to be 
essential for cell proliferation following LPS 
stimulation and also for development of B1 B cells 
(Humbert and Corcoran, 1997). 
Oct-1 appears to rely on cooperative binding 
with other factors to achieve its full activation 
potential. It was shown that Oct-1 activates snRNA 
promoters by binding to octamer sites in the core 
promoter in cooperation with SNAPc. Ternary 
complex formation with tissue-restricted co-
activators, such as OBF-1 and SNAPc (Ford et al., 
1998), can increase the specificity of the 
transcriptional activation mediated by Oct factors.  
While it was known early that Oct-1 and Oct-2 
can bind to DNA elements as monomers (Staudt et 
al., 1986), it was discovered only recently that they 
can also form homo- and heterodimers on specific 
octamer-related DNA motifs: the PORE 
(Palindromic Oct-factor Recognition Element: 
ATTTGAAATGCAAAT) and the MORE (More 
PORE: ATGCATATGCAT) (Remenyi et al., 2001; 
Tomilin et al., 2000). This can confer additional 
selectivity, as discussed below.  
 
1.2.4.2 OBF-1 
 
OBF-1 (OCA-B, Bob-1), is a proline-rich 
lymphoid-specific transcriptional coactivator protein 
that interacts with the POU domains of Oct-1 or Oct-
2 and with the conserved octamer element on the 
DNA (Gstaiger et al., 1996; Luo and Roeder, 1995; 
Strubin et al., 1995) to form a ternary complex on a 
subset of octamer sites. The structure of this 
complex was solved by co-crystallization, showing 
that OBF-1 makes contacts to both the POUH and 
POUS domains, as well as to the major groove of the 
DNA (Chang et al., 1999; Chasman et al., 1999; 
Sauter and Matthias, 1998) (Figure 12).  
OBF-1 strongly potentiates transcription from 
octamer-containing promoters such as the 
immunoglobulin κ light chain promoter in 
transfection assays and in vitro (Luo and Roeder, 
1995; Schubart et al., 1996b; Strubin et al., 1995). In 
B cells derived from OBF-1 knockout mice 
containing an inducible OBF-1 allele it was found 
that activity of strictly octamer-dependent reporters 
was also dependent on OBF-1 (Laumen et al., 2000). 
However, in vivo data from OBF-1 deficient 
mice indicated that OBF-1 is dispensable for early 
antigen-independent B cell development and that the 
level of unswitched Ig gene transcription is 
unaffected in the absence of the co-activator (Kim et 
al., 1996; Nielsen et al., 1996; Schubart et al., 1996a; 
Schubart et al., 2001). 
 
Figure 12  Ternary complex of OBF-1 (purple) and Oct-1 
POUH (red) and POUS (yellow) domains on an octamer 
site in the DNA. OBF-1 traverses the major groove at the 
A:T base pair at position 5 of the octamer motif. Figure 
taken from (Chasman et al., 1999). 
 
However OBF-1 seems to play a role for cell 
survival at earlier B cell stages, since a significant 
reduction of transitional (immature 493+) B cells in 
the spleen was observed by FACS analyses, 
indicating a malfunction in the B cell homing from 
bone marrow to the spleen in the absence of OBF-1 
(Schubart et al., 2000) or an impaired production of 
transitional B cells in the bone marrow of OBF-1 
deficient mice (Hess et al., 2001). 
Importantly, histochemical studies have shown 
that OBF-1 function is crucial for the formation of 
germinal centers in secondary lymphoid organs, 
which are absent in OBF-1 deficient mice. As a 
consequence, OBF-1 deficient mice have defects in 
the Ag-dependent B cell development and show a 
strongly impaired immune response to T cell-
dependent antigens (Kim et al., 1996; Schubart et 
al., 1996a). 
OBF-1 expression is largely restricted to B cells 
(Schubart et al., 1996b), but it can also be induced in 
T lymphocytes by in vitro costimulation (Sauter and 
Matthias, 1997; Zwilling et al., 1997). The 
phenotype observed in OBF-1 deficient mice clearly 
coincides with the expression pattern of the OBF-1 
gene in B cells, which peaks at two distinct time 
points in B cell development: at the immature B cell 
stage in the bone marrow, and with highest 
expression levels in germinal centers and germinal 
center-derived B cell lymphomas (Greiner et al., 
2000; Qin et al., 1998). The increased expression 
levels in germinal center B cells are partly due to 
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increased transcription (Qin et al., 1998) and partly 
due to increased protein stability (Boehm et al., 
2001; Tiedt et al., 2001).  
In addition, OBF-1 expression is strongly 
upregulated in murine activated splenic B cells after 
immunization (Qin et al., 1998). Following 
stimulation of the BCR, CD40 or IL-4 signaling 
pathways OBF-1 is upregulated specifically in GC B 
cells where it acts as an integrator essential for full 
differentiation and function of these cells (Qin et al., 
1998). 
OBF-1 expression can also be specifically 
upregulated in vitro at the level of mRNA and 
protein in resting B cells by stimulation with a 
combination of IL-4 and CD40 ligand or LPS alone 
(Greiner et al., 2000; Qin et al., 1998).   
Interestingly, recent structural and functional 
data have demonstrated that, at least on some of the 
Ig heavy chain promoters, Oct-1 binds to the 
octamer site in a dimeric conformation (MORE) that 
precludes recruitment of OBF-1 to the DNA 
(Tomilin et al., 2000). Conversely, the osteopontin 
gene contains a permissive dimeric binding site 
(PORE) for Oct factors that specifically recruits 
OBF-1; on this site the binding of the Oct dimer is 
dramatically stabilized by OBF-1 (Lins et al., 2003). 
These different dimer configurations are depicted in 
Figure 13. 
 
OBF-1 and POU1 on Ig OBF-1 and POU1 dimer:
PORE-like configuration
OBF-1 and POU1 dimer:
Novel configuration
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Figure 13  Models of Oct-1 binding to specific octamer 
sites on the DNA. A. “Archetypical” binding of an Oct-1 
momomer, together with OBF-1 on a canonical octamer 
element (as described in (Chasman et al., 1999)). B. 
Proposed POU1 dimer configuration (Botquin et al., 
1998) with OBF1 binding to the POU1 molecule at the 
octamer half-site (Remenyi et al., 2001) on a PORE-type 
of octamer site. C. POU1 dimer as in (B), but with a 
different linker connectivity causing OBF-1 to bind to the 
POUS and POUH domains of two different POU1 
molecules on the octamer half-site. Configuration based 
on the crystal structure described previously (Remenyi et 
al., 2001), proposed in (Lins et al., 2003). D. POU1 dimer 
precluding OBF-1 binding (as described in (Tomilin et al., 
2000)), binding on a MORE-type of octamer site, probably 
in conjunction with an unknown cofactor X. The 3D 
crystal structure clearly differs from (C). Both the POU 
homeodomain (H) and POU specific domain (S) of 
individual Oct-1 molecules are represented in blue and 
green; OBF-1 (O) is represented in red. 
To date, known direct target genes depending on 
OBF-1 include the BLR1 gene (which is 
cooperatively regulated by NF-κB, OBF-1 and Oct-2 
in B cells (Wolf et al., 1998)), the CCR-5 gene 
(regulated by OBF-1 and Oct-1) in T cells (Moriuchi 
and Moriuchi, 2001), as well as the B cell specific 
B29 and mb1 promoters (Malone and Wall, 2002). 
Recently, the Kcnn4 promoter, the Lck distal 
promoter (Kim et al., 2003b) and the Adh2-like 
promoter (Brunner et al., 2003b) have been 
identified to be directly bound and activated by 
OBF-1. However, the physiological relevance of 
these target genes for GC formation and TD immune 
responses remains unclear. I have recently identified 
the Ets factor Spi-B as another, crucial target of 
OBF-1 coactivation during the germinal center 
reaction (see Section 2.1). 
In addition, a myristoylated isoform of OBF-1 
has been identified that is membrane-bound and 
could play a role as a signal transducer itself (Yu et 
al., 2001).  
OBF-1 deficient mice also show a severe 
reduction of the number of immature B cells in the 
spleen; this reduction is even more dramatic in OBF-
1/Oct-2 (Schubart et al., 2001) and OBF-1/btk 
(Bruton’s tyrosine kinase) (Schubart et al., 2000) 
compound mutant mice. The molecular mechanisms 
underlying these defects are still unclear. However, a 
bcl-2 transgene expressed in the B lineage rescues, 
to a large extent, the defect in OBF/btk double-
mutant mice, suggesting that lifespans of immature 
B cells may play a role in this transition (Rolink et 
al., unpublished data), an effect that might again be 
related to BCR signaling strength. In line with this, it 
was very recently reported that Bcl-2 is 
downregulated in the bone marrow of OBF-1 
deficient mice (Brunner et al., 2003b). Finally, mice 
lacking simultaneously OBF-1 and the chromatin 
regulator Aiolos show a severe developmental block 
in the bone marrow, at the transition between pre-B 
and immature B cells (Sugai et al., 2003; Sun et al., 
2003). This phenotype is all the more surprising 
given the fact that the individual knockouts of these 
two factors show defects only in late stages of B cell 
development, as mentioned above. This observation 
underscores the concept that the same factors may 
perform different functions (and therefore may have 
different targets) at different developmental stages. 
In addition, recent studies have shown that even 
in the absence of both Oct-2 and OBF-1, B cells 
were able to develop normally to the IgM+ stage and 
immunoglobulin gene transcription was still largely 
unaffected (Schubart et al., 2001). These unexpected 
observations imply that the ubiquitous factor Oct-1 
may play a previously unrecognized role in the 
control of immunoglobulin gene transcription and 
suggest the possible existence of another, as yet 
unidentified, cofactor. In line with this is the binding 
of Oct dimers on several IgH promoters in the 
MORE configuration which precludes OBF-1 
recruitment (Tomilin et al., 2000). On the other 
hand, it was very recently found that OBF-1 is 
critical for the activity of a subset of IgL promoters 
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(Casellas et al., 2002) and also strongly enhances the 
expression of the osteopontin gene in B cells (Lins et 
al., 2003).  
 
1.2.4.3 Spi-B 
 
Spi-B is a member of the Ets family of 
transcription factors that encompasses over 30 
members characterized by the presence of a 
conserved DNA-binding domain (the ETS domain, 
Figure 14), a 85 amino acid motif which forms a 
unique helix-loop-helix structure that binds purine-
specific DNA sequences (Crepieux et al., 1994; 
Sharrocks, 2001). Spi-B is closely related to another 
Ets factor crucial for hematopoiesis, PU.1/Spi-1, 
through high structural homology and by its ability 
to transactivate identical target genes as PU.1 in 
vitro (Ray et al., 1992; Ray-Gallet et al., 1995). Spi-
B is also able to interact with the coactivator PU.1 
interacting protein (Pip/IRF-4) (Eisenbeis et al., 
1995). In vivo data shows however, that the target 
genes for PU.1 and Spi-B overlap only partially 
(Rao et al., 1999). Both PU.1 and Spi-B are required 
for normal BCR signaling (Garrett-Sinha et al., 
1999), but while Spi-B can functionally replace 
PU.1 in myeloid development, it cannot replace 
PU.1 in lymphoid development (Dahl et al., 2002). 
Spi-B deficient mice exhibit severe abnormalities in 
B cell function and selective T cell-dependent 
humoral immune responses accompanied by a 
dramatic defect in germinal center formation and 
maintenance (Su et al., 1997).  
Spi-B-/- mice have a BCR signaling defect and 
appear to initiate the production of germinal centers 
within splenic primary B cell follicles, but these 
structures decay prematurely due to BCR-mediated 
apoptosis. The Peyer's patches in Spi-B knock-out 
mice, just as in OBF-1 deficient mice, are normal in 
appearance and cell numbers. However, the Peyer's 
patch is under constant stimulation by antigens from 
the intestine, while the splenic germinal centers arise 
after immunization and vanish after a few weeks.  
The effect of Spi-B deficiency in gene targeted 
mice manifests itself in later stages of B cell 
development and involves mainly B cell activation 
through T cell dependent antigen stimulation, 
including germinal center formation (Su et al., 
1997). Since T cell dependent antigenic stimulation 
and germinal centers in the secondary lymphoid 
organs are important factors in the activation of Ig 
somatic hypermutation (Kelsoe, 1996) and since 
Spi-B can bind to several of the Ig enhancers, it was 
postulated that Spi-B deficiency may lead to 
diminished activation of Ig somatic mutation. In a 
recent study, however, somatic hypermutation was 
not diminished in Peyer's patches of Spi-B deficient 
mice. In contrast, the B cell clonal selection and 
affinity maturation processes seemed to be affected 
in Spi-B deficient animals (Kim et al., 2003a).  
Recently, Spi-B was implicated in the regulation 
of Igλ transcription, but not of Igκ or IgH 
transcription at the pro-B to pre-B cell transition in 
IL-7 dependent PU.1-/- Spi-B-/- pro-B cells 
(Schweitzer and DeKoter, 2004).  
 
 
1.2.4.4 Other key transcription factors in 
B cell development 
 
Many other transcription factors that are essential 
for B cell development, including other Ets factors, 
GATA factors, Ikaros family members, E2A, EBF, 
Pax-5, Sox-4, Lef-1, BCL-6, STATs, IRFs, the NF-
κB family, Blimp-1 and XBP-1, are discussed in 
detail in the recently published review (Bartholdy 
and Matthias, 2004) in Section 2.5. To avoid 
redundancy, they are not discussed again in the 
present context. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14  Alignment of the protein sequence of different Spi-B isoforms of murine and human origin. The figure shows 
differential splicing and different N-termini caused by the use of two different promoters. It also illustrates the high 
conservation among the two species and the protein domains that have been identified in (Rao et al., 1999). 
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1.3 Objective of research 
projects 
 
Gene targeting of OBF-1 revealed that this 
transcriptional coactivator is not required for B cell 
genesis or for the initial immunoglobulin gene 
transcription, despite the well documented 
importance of the conserved octamer motif in many 
B cell-specific promoters and enhancers. OBF-1 can 
be transiently induced in T cells, but does not seem 
to be required there, as OBF-1 deficient T cells 
appeared to be functionally normal. Thus, the 
possible function of OBF-1 in T cells has remained 
unclear. In contrast, OBF-1 is absolutely necessary 
for later stages of B cell development, most 
obviously for the formation of germinal centers and 
the subsequent production of secondary 
immunoglobulin isotypes following a T cell 
dependent antigen challenge. However, the target 
genes or mechanisms that could explain this 
phenotype on a molecular basis were still missing.  
We approached this problem by following two 
complementary strategies: First, we generated 
transgenic mice overexpressing OBF-1 in a 
constitutive manner in T cells to analyze its function 
in this cell type. This type of analysis proved to be a 
valid approach for the identification of novel OBF-1 
target genes, and we identified one important OBF-1 
target, Spi-B. These findings will be discussed in 
greater detail the first part of the following section.  
Secondly, we generated and analyzed transgenic 
mice overexpressing OBF-1 in a B cell-specific 
manner throughout B cell development, thereby 
overriding the tight transcriptional control imposed 
on the endogenous OBF-1 gene. For this, OBF-1 
was driven by a µ enhancer-V region promoter 
construct that allowed us to study the effect of OBF-
1 expression starting at early stages of B cell 
development where it is normally not yet expressed. 
The data obtained from this – still ongoing – 
analysis underlines the importance of the tight 
control of OBF-1 expression at these early stages, as 
B cell-specific overexpression was shown to lead to 
a partial block of B cell development. This work is 
presented in Section 2.1. 
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2 Results 
2.1 Research Publication (in press) 
The Ets factor Spi-B is a direct critical target of the 
coactivator OBF-1 
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OBF-1 (Bob.1, OCA-B) is a lymphoid-specific transcriptional coactivator that associates with the 
transcription factors Oct-1 or Oct-2 on the conserved octamer element present in the promoters 
of immunoglobulin genes and other lymphoid-specific or ubiquitous genes. OBF-1 deficient mice 
have B cell-intrinsic defects, completely lack germinal centers and have severely impaired 
immune responses to T cell dependent antigens. Although several genes have been shown to be 
regulated by OBF-1, crucial genes that might explain the observed phenotype of OBF-1 
deficiency have remained elusive to date. Here we have generated transgenic mice expressing 
OBF-1 specifically in T cells and examined these together with mice lacking OBF-1 to discover 
novel transcriptional targets of this coactivator. Using microarray analysis, we have identified the 
Ets transcription factor Spi-B as a direct target gene critically regulated by OBF-1, that can help 
explain the phenotype of OBF-1 deficient mice. Spi-B has been implicated in signaling pathways 
downstream of the BCR and is essential for germinal center formation and maintenance. The 
present findings establish a hierarchy between these two factors and provide a molecular link 
between OBF-1 and BCR signaling. 
 
 
Running title: Spi-B is a direct critical OBF-1 target gene 
Supplemental material will be available at the journal’s website 
[Keywords: Spi-B; OBF-1; germinal center; transcription; BCR signaling] 
 
 
Introduction 
 
The proline-rich lymphoid specific protein 
OBF-1 (Bob.1, OCA-B (Luo and Roeder 1995; 
Strubin et al. 1995)) forms a ternary complex 
with the POU proteins Oct-1 or Oct-2 and DNA 
on the conserved octamer element (5’-
ATGCAAAT-3’). This motif is present in the 
promoters of a number of eukaryotic genes, 
including ubiquitously active genes, such 
asH2B and U snRNA genes, but also genes that 
are restricted to distinct cell types or tissues 
(reviewed in (Matthias 1998)). Notably, the 
octamer element is present in all immunoglobu-
lin (Ig) heavy and light chain gene variable (V) 
region promoters as well as in the heavy chain 
intronic enhancer (Staudt and Lenardo 1991) 
and is critical for Ig gene transcription 
(Bergman et al. 1984; Mason et al. 1985; Drey-
fus et al. 1987; Wirth et al. 1987; Jenuwein and 
Grosschedl 1991; Matthias 1998). OBF-1 
strongly potentiates transcription from octamer-  
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containing promoters such as the 
immunoglobulin κ light chain promoter in 
transfection assays and in vitro (Luo and 
Roeder 1995; Strubin et al. 1995; Schubart et al. 
1996a). In B cells containing an inducible OBF-
1 allele it was found that the activity of oc-
tamer-dependent reporters was dependent on 
OBF-1 (Laumen et al. 2000). Yet, in vivo data 
from OBF-1 deficient mice indicated that OBF-
1 is dispensable for early antigen-independent B 
cell development and that the level of 
unswitched Ig mu gene transcription in mature 
B cells is unaffected in the absence of this co-
activator (Kim et al. 1996; Nielsen et al. 1996; 
Schubart et al. 1996a; Schubart et al. 2001). 
OBF-1 appears to play a role for cell survival at 
earlier B cell stages, and in absence of OBF-1 a 
significant reduction of transitional B cells in 
the spleen was observed by FACS analysis. 
This suggests that OBF-1 is important for 
production of transitional B cells in the bone 
marrow (Hess et al. 2001) or B cell homing 
from the bone marrow to the spleen (Schubart 
et al. 2000). 
Importantly, histochemical studies have shown 
that OBF-1 function is essential for the forma-
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tion of germinal centers (GC) in secondary lym-
phoid organs. As a consequence, OBF-1 defi-
cient mice have defects in the antigen-depend-
ent B cell development and show a dramatically 
impaired immune response to T cell-dependent 
(TD) antigens (Kim et al. 1996; Schubart et al. 
1996a). 
OBF-1 expression is largely restricted to B cells 
(Schubart et al. 1996a), but it can also be in-
duced in T lymphocytes by costimulation in 
vitro (Sauter and Matthias 1997; Zwilling et al. 
1997). The phenotype observed in OBF-1 defi-
cient mice clearly coincides with the expression 
pattern of the OBF-1 gene in B cells, which 
peaks at two distinct time points in B cell devel-
opment: at the immature B cell stage in the 
bone marrow, and with highest expression lev-
els in germinal centers and germinal center-
derived B cell lymphomas (Qin et al. 1998; 
Greiner et al. 2000). The increased expression 
levels in germinal center B cells are partly due 
to increased transcription (Qin et al. 1998) and 
partly due to increased protein stability (Boehm 
et al. 2001; Tiedt et al. 2001).  
Interestingly, recent structural and functional 
data have demonstrated that, at least on some of 
the Ig heavy chain promoters, Oct-1 binds to 
the octamer site in a dimeric conformation 
(MORE) that precludes recruitment of OBF-1 
to the DNA (Tomilin et al. 2000). Conversely, 
the osteopontin gene contains a permissive 
dimeric binding site (PORE) for Oct factors that 
specifically recruits OBF-1; on this site the 
binding of the Oct dimer is dramatically stabi-
lized by OBF-1 (Lins et al. 2003). 
To date, known direct target genes 
depending on OBF-1 are the BLR1 gene (which 
is cooperatively regulated by NF-κB, OBF-1 
and Oct-2 in B cells (Wolf et al. 1998)), the 
CCR-5 gene (regulated by OBF-1 and Oct-1) in 
T cells (Moriuchi and Moriuchi 2001), as well 
as the B cell specific B29 and mb1 promoters 
(Malone and Wall 2002). Recently, the Kcnn4 
promoter, the Lck distal promoter (Kim et al. 
2003) and the Adh2-like promoter (Brunner et 
al. 2003) have been identified to be directly 
bound and activated by OBF-1. However, the 
physiological relevance of these target genes for 
GC formation and TD immune responses 
remains unclear. Here we present evidence that 
the Ets factor Spi-B is a novel, crucial target of 
OBF-1 coactivation during the germinal center 
reaction. 
Spi-B is a member of the Ets family of 
transcription factors that encompasses over 30 
members characterized by the presence of a 
conserved DNA-binding domain (the ETS do-
main), a motif of 85 amino acids which forms a 
unique helix-loop-helix structure binding 
purine-rich DNA sequences (Crepieux et al. 
1994; Sharrocks 2001). Spi-B is closely related 
to another Ets factor crucial for hematopoiesis, 
PU.1/Spi-1, through high structural homology 
and by its ability to transactivate identical target 
genes as PU.1 in vitro (Ray et al. 1992; Ray-
Gallet et al. 1995). Spi-B is also able to interact 
with the coactivator PU.1 interacting protein 
(Pip/IRF-4) (Eisenbeis et al. 1995). In vivo data 
show however, that the target genes for PU.1 
and Spi-B overlap only partially (Garrett-Sinha 
et al. 1999). Both PU.1 and Spi-B are required 
for normal BCR signaling (Garrett-Sinha et al. 
1999), but while Spi-B can functionally replace 
PU.1 in myeloid development, it cannot replace 
PU.1 in lymphoid development (Dahl et al. 
2002). Spi-B deficient mice exhibit severe 
abnormalities in B cell function and selective T 
cell-dependent humoral immune responses 
accompanied by a defect in germinal center 
formation and maintenance (Babb et al. 1997). 
Spi-B deficient mice have a BCR signaling de-
fect and appear to initiate the production of 
germinal centers within splenic primary B cell 
follicles, but these structures decay prematurely 
due to BCR-mediated apoptosis. The Peyer's 
patches in Spi-B deficient mice, just as in OBF-
1 deficient mice, are normal in appearance and 
cell numbers. However, the Peyer's patch is 
under constant stimulation by antigens from the 
intestine, while the splenic germinal centers 
arise after immunization and vanish after a few 
weeks.  
Here we show conclusively that OBF-1 defi-
cient mice have strongly reduced levels of Spi-
B and that OBF-1 acts directly on the Spi-B 
promoter to enhance transcription of this Ets 
factor. These results establish a molecular link 
between these two transcription factors which 
are both crucial for the TD immune response 
and GC formation.  
 
 
Results 
 
Generation and phenotype of lck-OBF-1 mice 
 
The coactivator OBF-1 was previously found to 
be expressed in a mostly B cell restricted man-
ner, but expression was also induced in T cell 
lines and primary murine thymocytes following 
in vitro stimulation with PMA and ionomycin 
(Sauter and Matthias 1997; Zwilling et al. 1997). 
However, the physiological role of OBF-1 in T 
cells has remained unclear and in OBF-1 defi-
cient mice T cell development and function 
were found to be normal (Schubart et al. 1996a; 
Qin et al. 1998). To further define the potential 
function of OBF-1 in T cells we generated 
transgenic mice expressing an HA epitope-
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tagged OBF-1 cDNA under the control of the 
murine proximal lck promoter (Fig. 1A).  
This T cell specific promoter is highly active in 
thymocytes throughout their development and 
then shows low activity in peripheral T cells 
(Shimizu et al. 2001). In agreement with the 
expected activity pattern of the lck promoter 
high levels of transgenic OBF-1 mRNA and 
protein were found in the thymus and lower 
levels were found in the spleen (see 
Supplementary material); by contrast, trans-
genic OBF-1 mRNA or protein were not detect-
able in non-lymphoid organs of these transgenic 
lines (not shown). Several independent trans-
genic mouse lines were generated, which all 
showed the same phenotype described below.  
We first examined overall T cell development 
by flow cytometry, using antibodies against 
 
 
Figure 1.  Normal T cell development in lck-OBF-1 
transgenic mice. (A) Structure of the construct used 
for generation of transgenic mice. (B) FACS analysis 
of WT or lck-OBF-1 transgenic mice. Thymocytes 
were analyzed by flow cytometry with FITC-
conjugated anti-CD4 and PE-conjugated anti-CD8 
antibodies. The dot plot shows data from one 
representative animal of each genotype. The 
histogram in the lower part shows the mean ± SD of 
data from 5 mice of each genotype. 
the T lineage surface markers CD4 and CD8. As 
shown in Figure 1b total thymocyte numbers, as 
well as the numbers of double positive, double 
negative or single positive CD4 or CD8 T cells 
were all found to be normal in these transgenic 
mice. Upon further characterization by FACS 
analysis, some specific alterations in distinct T 
cell populations were observed in the thymus or 
in the periphery. For example, a subset of 
CD4+CD8+ thymocytes also co-expressed the 
IL-2 receptor alpha chain (CD25). These 
CD4+CD8+CD25+ cells were found to express a 
higher level of OBF-1 than the CD25- cells, 
thus establishing a potential link between CD25 
expression and OBF-1 levels (see Supplemen-
tary material). These cells, however, do not 
appear to correspond to CD25+ CD4+ regulatory 
helper T cells, and no elevated number of 
CD25+ cells was observed in the spleen (data 
not shown). In addition, other specific T cell 
populations such as γδ and dendritic epidermal 
T cells were also influenced by OBF-1 expres-
sion (see Supplementary material). Together, 
these results indicate that OBF-1 overexpres-
sion in the T cell compartment leads to very 
specific effects on a number of minor T cell 
subsets, but does not overtly perturb normal T 
cell development. 
Because overall T cell development and total T 
cell numbers were largely unchanged by the 
expression of OBF-1 we decided to use thymo-
cytes RNA for microarray experiments, in order 
to identify potential OBF-1 target genes. To this 
end two independent comparisons were per-
formed: (i) transgenic vs WT total thymocytes, 
(ii) transgenic thymocytes, CD4+CD8+CD25+ 
vs CD4+CD8+CD25- (see Supplementary mate-
rial). The results of these independent microar-
ray experiments were combined and allowed to 
identify overlapping subsets of genes that are 
modulated by OBF-1 expression.  
 
The expression of Spi-B is proportional to OBF-
1 levels in mouse thymocytes and reflects the 
activity of the octamer-containing promoter 2 
 
The lymphoid-specific ETS family transcription 
factor Spi-B was identified as one interesting 
potential OBF-1 target gene in the microarray 
analysis. Its elevated expression in the trans-
genic mice was confirmed by northern blot 
analysis and was compared to the expression in 
thymocytes of OBF-1-/- mice: While the wild 
type mice express low levels of Spi-B mRNA, 
the expression of this gene is severely reduced 
in OBF-1 deficient thymocytes (Fig. 2). Thus, 
expression of Spi-B and OBF-1 mRNA are di-
rectly correlated in murine thymocytes in vivo. 
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Figure 2.  Spi-B mRNA level is proportional to the 
amount of OBF-1 expression in thymocytes. 
Thymocytes were isolated from OBF-1 deficient, 
WT or lck-OBF-1 transgenic mice and total RNA 
was analyzed by Northern blotting with a Spi-B 
specific probe (left). The same membrane was 
rehybridized with a probe for beta-actin as a control 
for loading. Quantification by Phosphorimaging and 
normalization to the expression level of beta-actin 
are shown on the right.  
 
Interestingly, the Spi-B gene is transcribed from 
two distinct promoters (Chen et al. 1998); the 
downstream promoter (P2) contains a perfect 
octamer site and could therefore represent a 
good potential target of coactivation by OBF-1. 
The Spi-B promoters and mRNA isoforms are 
depicted in Figure 3A. The use of an RNase 
protection probe that distinguishes between the 
mRNA isoforms transcribed from the two 
different promoters revealed that promoter 1 is 
equally active in cells of the different OBF-1 
genotypes, while promoter 2 activity is strongly 
modulated in thymocytes lacking or 
overexpressing OBF-1 (Fig. 3B). 
 
Transcription from Spi-B promoter 2 is con-
trolled by OBF-1 
 
To verify the importance of the octamer site in 
promoter 2, we performed transient transfection 
assays using luciferase reporter genes driven by 
the Spi-B gene P1 (P1-luc) or P2 (P2-luc); we also 
used variants of P2 with different mutations in 
the octamer site. As shown in Figure 4A, upon 
cotransfection of an OBF-1 expression vector in 
293T cells activity of P1 remained unaffected, 
but activity of P2 was strongly enhanced. In 
addition, a point mutation in the octamer site 
that specifically abolishes binding of OBF-1 to 
the Oct-1/2 - DNA complex (P2-S-luc, (Babb et al. 
1997)) strongly reduced promoter activation, to 
the same extent as a multiple mutation of the 
octamer site (P2-M-luc) which completely abro-
gates binding of Oct factors (Fig. 4A). 
Electrophoretic mobility shift assays (EMSAs, 
Fig. 4B) provided additional in vitro evidence 
for the formation of a ternary complex between 
Oct-1 - or the Oct-1 POU domain - and OBF-1 
on the octamer site of promoter 2 (lanes 9 and 
 
 
Figure 3.  Spi-B promoter 2 is under the control of 
OBF-1. (A) Schematic representation of the mouse 
Spi-B gene in the promoter region. The structure of 
the mRNAs originating from promoter 1 (upstream) 
or 2 (downstream) is indicated. Exon sequences are 
depicted as boxes. The sequence surrounding the 
octamer site in promoter 2 is shown below. (B) 
RNAse protection assay with RNA from thymocytes 
of the indicated genotypes. A probe for S16 was 
included as a control in the hybridization reaction 
and its signal was used for the normalized expression 
presented in the right part of the Figure. 
 
15), visible as a supershifted complex, com-
pared to the complex obtained with Oct-1 or 
POU-1 alone (lanes 6 and 12). These results 
demonstrate that the octamer site in the Spi-B 
promoter 2 is necessary for allowing OBF-1 
binding in a ternary complex with Oct-1 (or 
possibly Oct-2) and that it mediates coactiva-
tion by OBF-1.  
 
OBF-1 binds in vivo on Spi-B promoter 2 
 
To determine whether OBF-1 is indeed bound 
on the Spi-B promoter 2 in vivo we performed 
chromatin immunoprecipitation (ChIP) experi-
ments. For this, primary thymocytes from WT 
or transgenic mice were isolated, chromatin 
bound proteins were crosslinked with 
glutaraldehyde, and OBF-1 was 
immunoprecipitated with an anti-HA antibody. 
As shown in Figure 5, the Spi-B promoter 2 
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could be amplified by PCR in the precipitate 
from transgenic thymocytes, but not from WT 
samples. The BLR-1 promoter, which has been 
shown earlier to be regulated by OBF-1 (Wolf 
et al. 1998), was used as a positive control for 
these ChIP experiments and was also robustly 
amplified in the immunoprecipitated transgenic 
sample. Previous work had established that the 
primary function of OBF-1 is in B cells 
(Schubart et al. 1996a; Qin et al. 1998). There-
fore we attempted to establish a link between 
expression of OBF-1 and Spi-B in B cells. For 
this, ChIP experiments were first repeated with 
primary splenic B cells isolated from WT mice. 
However, because OBF-1 is expressed only at 
low levels in these cells (Qin et al. 1998) and 
the available anti OBF-1 antibodies are not  
  
 
 
Figure 4.  Critical role of the octamer motif for 
activation of the Spi-B promoter 2. (A) Luciferase 
reporter constructs under the control of the Spi-B 
promoter 1 or 2 were transfected into 293T cells 
together with an empty expression vector (black 
bars) or an OBF-1 expression vector (white bars). 
The histograms represent the mean ± SD of three 
independent experiments. (B) Electrophoretic 
mobility shift assay with a WT (P2) or mutated (P2-S, 
P2-M) octamer site DNA probe derived from the Spi-
B promoter and in vitro translated proteins. Either 
full-length Oct-1 (lanes 4 to 9) or its isolated POU 
domain (lanes 10 to 15) was used for complex 
formation. 
 
sensitive enough, no conclusive results were 
obtained (data not shown). We next used Abel-
son virus transformed proB cell lines estab-
lished from WT or OBF-1-/- mice. Unlike pri-
mary mouse splenic B cells, v-Abl transformed 
proB cells are homogeneous and express high 
levels of OBF-1 mRNA and protein (our unpub-
lished data). In this case, ChIP analysis 
with an anti-OBF-1 antibody showed that the 
Spi-B promoter 2 could be amplified in 
immunoprecipitates from WT, but not from 
OBF-1-/- cells. In contrast, control primers in 
the coding region of the Spi-B gene failed to 
amplify a fragment (data not shown). These 
results thus demonstrate unambiguously the 
presence of OBF-1 on the Spi-B promoter 2 in 
vivo. 
 
 
 
Figure 5.  In vivo OBF-1 is bound on the Spi-B 
promoter 2. (A) Crosslinked chromatin was isolated 
from WT or lck-OBF-1 thymocytes and 
immunoprecipitated with an anti-HA antibody. The 
precipitated material was used as template for a PCR 
reaction with primers derived from Spi-B P2, or from 
the BLR1 promoter. The lower panel (input) shows 
PCR amplification with the chromatin before 
immunoprecipitation. (B) Crosslinked chromatin was 
isolated from WT or OBF-1-/- Abelson virus 
transformed proB cells and immunoprecipitated with 
antibodies against OBF-1. A PCR reaction with 
primers derived from Spi-B P2 is shown for the 
precipitate (upper panel) and for the input (lower 
panel).  
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OBF-1 is essential for Spi-B transcription in v-
Abl transformed proB cell lines 
 
It was shown recently that transcription of Spi-
B (and of its coactivator IRF-4) is induced upon 
treatment of v-Abl transformed proB cells with 
the Abelson kinase inhibitor STI571 (Gleevec); 
this treatment elicits further differentiation of 
the cells, as characterized by increased 
transcription of Rag-1 and Rag-2, Ig κ light 
chain gene rearrangement, and enhanced 
expression of CD25 at the cell surface (Muljo 
and Schlissel 2003). We therefore used v-Abl 
transformed proB cells to test whether OBF-1 is 
essential for STI571-induced expression of the 
Spi-B gene. For this, WT or OBF-1-/- proB cells 
were treated for 10 hours with STI571 and 
expression of the Spi-B gene was measured by 
real-time PCR with primer pairs that discrimi-
nate mRNA originating from P1 or P2. As 
shown in Figure 6, Spi-B transcription from 
promoter 2 was efficiently induced in WT cells, 
but not in cells lacking OBF-1. In addition, pro-
moter 1 was marginally induced by STI571 in 
WT cells, but not in mutant cells, suggesting 
that OBF-1 may also influence moderately the 
activity of promoter 1. This is not unreasonable, 
as the start sites of the two transcripts are only 
about 600 bp apart.  
 
 
Figure 6.  In Abelson proB cells OBF-1 is necessary 
for STI571-induced expression of Spi-B. WT or 
OBF-1-/- Abl proB cells were cultured in the presence 
(open bars) or absence (solid bars) of STI571 
(Gleevec, 10 µM) for 10 hrs and total RNA was 
extracted. After cDNA synthesis, expression of the 
Spi-B gene was measured by real-time PCR with 
primers specific for RNA originating from P1 or P2. 
The histograms show the mean ± SD of 3 
independent experiments.  
Figure 7.  Absence of Spi-B 
expression in OBF-1-/- follicular B 
cells. Ten days after immunization 
with DNP-KLH splenic 
cryosections were prepared. 
Formation of GCs was monitored 
by staining of B cells with an anti-
B220 antibody (green) together 
with Peanut Agglutinin (PNA, red). 
Spi-B expression was detected by 
immunohistochemistry with a 
specific riboprobe (antisense, blue 
staining) and nuclei were 
counterstained with Nuclear Fast 
Red (red staining). A control with a 
sense Spi-B probe is shown.  
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Impaired in vivo Spi-B expression in splenic follicles 
of immunized mice in the absence of OBF-1 
 
We and others have shown previously that OBF-1 
deficient mice completely fail to form germinal 
centers upon challenge with a T cell dependent 
antigen such as DNP-KLH (Schubart et al. 1996a) 
and this arguably represents the most conspicuous 
phenotype of these mice. We therefore examined 
whether absence of OBF-1 influences expression of 
Spi-B in splenic follicles. 
As shown in Fig. 7, in immunized WT mice peanut 
agglutinin (PNA) positive GC B cells can be 
detected in the secondary follicles, and these cells 
also distinctly express Spi-B mRNA. By contrast, in 
immunized OBF-1 deficient mice no GC B cells can 
be evidenced and Spi-B expression is completely 
absent from the follicles.  
 
 
Discussion 
 
Here, we present compelling evidence that, in the 
mouse, the coactivator OBF-1 is necessary for 
efficient transcription of the Spi-B gene in T and B 
cells. Overexpression of OBF-1 from the lck 
promoter in transgenic mice did not lead to major 
changes in T cell development or function but 
modulated expression of specific genes (data not 
shown). One of them, encoding the gene for the 
transcription factor Spi-B, was identified as a 
physiologically relevant candidate.  
While ectopic overexpression might represent an 
artificial situation, the comparison with OBF-1 
deficient thymocytes strongly enhances the 
relevance of our findings. In the absence of OBF-1, 
a general reduction of Spi-B mRNA levels was 
observed in thymocytes, mainly reflecting a 
reduction in the use of promoter 2 (Figs 2 and 3). 
The normal physiological significance of these 
findings still remains to be elucidated, since OBF-1 
protein is undetectable in total thymic extracts and 
the absence of OBF-1 (and of Spi-B) does not 
notably affect T cell development. It is possible, 
however, that low levels of endogenous OBF-1 
protein exist in a subset of thymocytes, be it T or 
thymic B cells.  
A number of in vitro experiments showed that OBF-
1 can bind to Spi-B P2 and transactivate transcription 
from that promoter (Fig. 4). The importance of the 
perfect octamer site present in Spi-B P2 is clearly 
visible in EMSA and transient transfection experi-
ments, strongly suggesting a direct binding of OBF-
1 on the Spi-B promoter. This was confirmed in vivo 
by ChIP experiments. A weak effect of OBF-1 
expression was noticed on P1 as well (Fig. 6), which 
seemed to be independent of the P2 octamer site, but 
could reflect activation of the nearby P2 promoter. 
Furthermore, chromatin immunoprecipitation assays 
clearly showed a specific association of the trans-
genic OBF-1 with the Spi-B promoter P2 in vivo (Fig. 
5).  
While it is still possible that OBF-1 also regulates 
additional gene(s) required for the proper expression 
of Spi-B, our data clearly illustrate that OBF-1 
directly controls Spi-B promoter activity via a 
consensus octamer site important for its expression. 
Other possible low affinity OBF-1 sites in the Spi-B 
promoter may explain why the octamer mutations 
created in our reporter constructs (P2-S-luc and P2-M-luc) 
do not completely abolish transcription activation in 
transient assays. 
Given the fact that OBF-1 expression is mainly 
required in B lymphocytes, we directed our focus to 
the more physiologically relevant B cell 
compartment. It was recently shown that Spi-B is 
induced upon treatment of v-Abl transformed proB 
cells with the v-Abl kinase inhibitor STI571 (Muljo 
and Schlissel 2003). We show here that OBF-1 is 
absolutely crucial for this induction – which is 
caused mainly by strongly increased transcription 
from Spi-B P2 (Fig. 6). Although necessary, the 
presence of OBF-1 is in itself not sufficient for 
induction of Spi-B transcription in these cells, and 
the OBF-1 protein or RNA levels in v-Abl 
transformed B cells are not noticeably altered by 
STI571 treatment (data not shown). This indicates 
that inhibition of the v-Abl kinase does not influence 
OBF-1 expression, but rather prevents Spi-B 
transcription through a different mechanism. For 
example, v-Abl activity could repress Spi-B 
transcription by directly phosphorylating OBF-1 
thereby leading to inhibition of ternary complex 
formation or coactivation, or by phosphorylating 
other targets, such as Oct-1 or Oct-2. In the case of 
Oct-2 it has been proposed that phosphorylation of a 
residue in the POU domain interferes with binding 
of Oct-2 to the non-canonical octamer sequence in 
the murine BLR-1 promoter (Pevzner et al. 2000). 
While v-Abl transformed proB cells are useful to 
establish the requirement for OBF-1 in Spi-B 
transcription in B cells, these cells do not correspond 
to the developmental stage at which the main 
phenotype has been described in mice lacking either 
Spi-B or OBF-1. Neither of these two factors 
appears to be essential at this early stage of B cell 
development, at which they might be redundant: In 
the absence of Spi-B other related Ets factors, such 
as PU.1 or Spi-C could compensate for Spi-B 
function.  
It is interesting to note that Spi-B levels are also 
reduced in the bone marrow of OBF-1 knockout 
mice (data not shown), and that loss of OBF-1 
expression has effects on early B lymphopoiesis that 
have been recognized earlier. There is a reduction of 
transitional B cells in the spleen of OBF-1 deficient 
mice (Schubart et al. 2000; Hess et al. 2001), 
possibly caused by apoptosis during the negative 
selection of self-reactive B cells occurring at this 
stage (Carsetti et al. 1995; Sater et al. 1998). 
Interestingly, OBF-1 deficiency also has an impact 
on the Ig κ repertoire (Jankovic and Nussenzweig 
2003) and leads to a reduction of a subset of 
immunoglobulin kappa genes (Casellas et al. 2002), 
suggesting the involvement of OBF-1 in the 
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selection of transitional B cells. This effect of OBF-
1 deficiency might be independent of Spi-B and 
could be caused by direct binding of OBF-1/Oct-1 
or-2 complexes to specific octamer sites in some of 
the Ig κ promoters. In contrast, constitutive 
overexpression of OBF-1 in B cells from a µ 
enhancer-V region promoter results in a severe block 
of B cell development in the bone marrow of 
transgenic mice (our unpublished data), further 
supporting the notion that tight control of OBF-1 
level is  critical for early B cell development.  
There are several lines of evidence for the in-
volvement of OBF-1 in modulating BCR signaling 
strength. Firstly, OBF-1-/- B cells are unable to 
induce BCR-triggered Ca2+ mobilization; this defect 
was restored in CD22-/- OBF-1-/- double deficient 
animals (Samardzic et al. 2002a). CD22 is a 
negative regulator of BCR signaling, and CD22 
deficient mice display a lowered activation threshold 
for BCR crosslinking and increased Ca2+ 
mobilization upon BCR stimulation (Nitschke et al. 
1997). Secondly, OBF-1-/- B cells also showed a 
reduced proliferation following anti-IgM stimulation 
(Sun et al. 2003). It is thus very tempting to assume 
that the B cell differentiation defect in the bone 
marrow of OBF-1-/- mice is BCR-signal dependent. 
Second, Spi-B itself, together with PU.1, was 
implicated in signaling downstream of the BCR, 
probably by controlling the transcription of a 
component coupling Syk to downstream targets, 
such as PLCγ and BLNK (Garrett-Sinha et al. 1999). 
In addition, increased apoptosis in the bone marrow, 
possibly caused by the increased sensitivity of OBF-
1-/- transitional B cells to BCR cross-linking ob-
served in vitro (Jankovic and Nussenzweig 2003) 
could explain the receptor specific block at the T1 
stage of B cell development in OBF-1 mutant mice. 
These effects, but also the reduced numbers of MZ B 
cells found in one specific OBF-1 deficient mouse 
strain (Samardzic et al. 2002b) can be explained by a 
model in which OBF-1 is required for setting the 
normal threshold for immature B cell development 
and selection in the bone marrow.  
A second function of OBF-1, its crucial role for the 
development of GCs in the spleen, reflects a 
different mechanism, since OBF-1-/- CD22-/- double 
deficient mice were still unable to mount humoral 
immune responses and to form germinal centers, 
although their BCR activation threshold was similar 
to the WT situation (Samardzic et al. 2002a). The 
data presented here indicate that the expression of 
Spi-B, controled by the upregulation of OBF-1 
protein in the GC B cells may be a key element in 
the GC formation. To conclude, we have identified 
Spi-B as the most physiologically relevant in vivo 
target of OBF-1 to date. These findings greatly help 
to extend our understanding of how OBF-1 is 
involved in B cell activation and GC formation and 
place it directly upstream of Spi-B in a 
transcriptional cascade. 
 
 
 
Materials and Methods 
 
Mouse strains and cell lines 
The Lck-OBF-1 construct used to generate trans-
genic mice contains an N-terminally HA epitope-
tagged human OBF-1 cDNA under the control of the 
murine proximal lck promoter (-3100 to +23 relative 
to the transcription start site). Transgenic mouse 
lines were obtained and bred in B6CF1 x C57BL/6 
background and were bred to a wild type partner of 
the same genetic background. OBF-1 deficient mice 
were in 129SV-C57BL/6 background. All animal 
work and experiments were done in compliance with 
local and institutional regulations. Mice were sacri-
ficed, the thymi were taken, rinsed in PBS and 
immediately homogenized in TRIZOL reagent (Life 
Technologies). Total RNA was prepared using TRI-
ZOL reagent and purified on RNeasy Miniprep col-
umns (Qiagen) according to the manufacturers' 
instructions. Sequence data is available upon re-
quest. 
Cell lines: Abelson pro-B cell lines were derived 
from wild type and OBF-1-/- mice and were de-
scribed previously (Schubart et al. 1996b) 
 
PCR 
To determine the OBF-1 genotype, genomic DNA 
was isolated from tail biopsies and used as a tem-
plate for polymerase chain reaction (PCR). The PCR 
assay for the OBF-1 wild type and OBF-1 mutant 
loci was carried out with the following primer 
combinations, respectively: 5’-GCT CCC TGA CCA 
TTG AC-3’, 5’-TCC TGT  CCC ATC CCC CTG 
TAA-3’ and 5’-GGC TTA GAT AAC AAA GCG 
TGT GCT C-3’, 5’-GCG TGC CCA TCT TGT TCA 
ATG G-3’. The size of the PCR products for the WT 
allele was 560bp and for the mutant allele 830bp.  
Transgenic OBF-1-HA was detected using the 
following primer combinations: 5’-GGT TGA GTG 
GTG GGG GTA GGG-3’ and 5’-CAC ACG GAC 
GCC CTG GTA TGG-3’ (for genotyping), 5’-CAC 
TCT CTC TGT GGA AGG CTT TG-3’ and 5’-TTC 
TCA GCT CTA GAC GGC GTA GT-3’ (for QPCR).  
Spi-B was detected with the PCR primers 5’-CAG 
TTC TCC TCC AAG CAC AAG-3’, 5’-CCA GCC 
ATT CAT CTC GCA TAG-3’ (standard RT-PCR for 
all isoforms and splice variants, also used to gener-
ate a probe for Northern blotting), 5’-CTC TGA 
ACC ACC ATG CTT GCT-3’, 5’-TCC TTC TGG 
GTA CAA ACA GCT TAA-3’ (QPCR for form 1), 
5’-AGG GCG GCC CTG ACA T-3’, 5’-TCC TTC 
TGG GTA CAA ACA GCT TAA-3’ (QPCR for form 
2). To amplify Spi-B promoter 2 in chromatin 
immunoprecipitations (ChIP) samples, the primers 
5’-GCG CCC AGC CTT CTC CTC CA-3’ and 5’-
AAA TGT CCC CCA CTC TCC CTG-3’ were used. 
To amplify the BLR-1 promoter in ChIP samples, 
the following primers were used: 5’-TGT AGA GGA 
GGC TGG GAG TA-3’ and 5’-CGA GAA GGT 
TTG TGC TGG TG-3’. 
GAPDH (QPCR): 5’-ACC TGC CAA GTA TGA 
TGA CAT CA-3’, 5’-GTA GCC CAA GAT GCC 
CTT CAG T-3’. β-actin (for Northern blot probe): 
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5’-ATG GAT GAC GAT ATC GCT GCG CTG-3’, 
5’-CTA GAA GCA CTT GCG GTG CAC GAT-3’. 
Quantitative real-time PCR (QPCR) was performed 
on an ABI PRISM 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA) using a 
SybrGreen-based kit from Applied Biosystems.  
 
Cell culture and protein expression in eukaryotic 
cells 
Adherent cells were maintained in DMEM plus 10% 
fetal calf serum. All B cell lines were grown at 37ºC 
and 10% CO2 in RPMI supplemented with 10 % 
FCS (Life Technologies, Inc.), penicil-
lin/streptomycin and 50 mM β-mercaptoethanol 
(Fluka).  
HEK293T cells were transfected in 6-well-plates 
using FuGENE6 (Roche, Basel, Switzerland) 
according to the manufacturers instructions.  
 
Protein extract, western blotting and luciferase as-
say 
For western blotting, B and T cells were lysed by 
repeated cycles of freeze and thaw in 20 mM 
HEPES pH7.9, 20 % glycerol, 400 mM NaCl, 0.5 
mM EDTA, 0.25 mM EGTA, 0.025 % NP-40, 1 mM 
DTT, 0.5 mM NaF and ‘complete’ protease inhibitor 
cocktail (Roche). Protein concentrations were deter-
mined with Bradford reagent (BioRad) and 30 mg of 
protein for each sample was resolved by SDS-PAGE 
with subsequent transfer onto Immobilon membrane 
(Millipore). HA-tagged proteins were detected with 
the monoclonal antibody 12CA5, and endogenous 
OBF-1 was detected using a polyclonal antibody that 
was raised in rabbits against the C-terminal 154 
amino acids of murine OBF-1. Bands were visual-
ized with the ECL system (Amersham). 
To measure luciferase activity, reporter plasmids 
were cotransfected and cells were lysed in 0.1 M 
potassium phosphate buffer, pH7.8 containing 1 mM 
DTT by repeated cycles of freeze and thaw. The cell 
lysates were measured in a Bertold Luminometer 
according to standard protocols. The reporter plas-
mids P1-luc (D2393) and P2-luc (D2397) were kindly 
provided by D. Tenen and are described elsewhere 
(Chen et al. 1998). In brief, P1-luc consists of the 
170 bp Spi-B promoter 1 driving the firefly 
luciferase gene in the pXP2 expression vector. P2-luc 
is based on the same vector, but contains the 800 bp 
Spi-B promoter 2 instead of the Spi-B promoter 1. 
P2-S-luc and P2-M-luc are identical to P2-luc, but contain 
specific mutations in the octamer site (Figure 4b 
shows the exact mutations, which are identical to the 
mutations in the oligonucleotides P2-M and P2-S). For 
transient transfections, 600 ng of OBF-1 expression 
vector (Strubin et al. 1995) or empty expression vec-
tor and equimolar amounts of luciferase reporter 
vectors were used. Samples were filled up with 
empty vector to a total amount of 1200 ng DNA per 
transfection. 
 
Electrophoretic mobility shift assay (EMSA) 
In vitro translated proteins were prepared as de-
scribed previously (Sauter and Matthias 1998). 
Binding reactions contained equimolar amounts of 
proteins, 1 mM EDTA, 250 µg/ml BSA, 20 mM 
HEPES (pH 7.9), 50 mM KCl, 4% Ficoll, 6.25 x 105 
cpm/ml of 32P-labeled double-stranded oligonucleo-
tide probe, 25 µg/ml single stranded DNA, and ei-
ther 25 µg/ml poly(dI·dC) (Amersham Pharmacia 
Biotech). Protein-DNA complexes were resolved on 
a 4% (30:1) polyacrylamide:bisacrylamide, 0.25 x 
TBE gel at 200 V for 1 h, dried, and subjected to 
autoradiography. 
The following double-stranded synthetic 
oligonucleotides were used: 
P2 probe: 5’-CCC CCA GCG TCT GTG CAT GCA 
AAT CCC AGG GAG AGT GGG GG-3’ , 5’-CCC 
CCA CTC TCC CTG GGA TTT GCA TGC ACA 
GAC GCT GGG GG-3’ 
P2-S probe: 5’-CCC CCA GCG TCT GTG CAT GCT 
AAT CCC AGG GAG AGT GGG GG-3’ , 5’-CCC 
CCA CTC TCC CTG GGA TTA GCA TGC ACA 
GAC GCT GGG GG-3’ 
P2-M probe: 5’-CCC CCA GCG TCT GTG CCG 
GCA CCT CCC AGG GAG AGT GGG GG-3’ , 5’-
CCC CCA CTC TCC CTG GGA GGT GCC GGC 
ACA GAC GCT GGG GG-3’ 
 
Northern blotting 
RNA was prepared by Trizol (Life Technologies, 
Inc.) according to the manufacturer’s instructions. 15 
mg of total RNA was analyzed by Northern blotting 
using Hybond-XL membranes (Amersham Phar-
macia Biotech). OBF-1 was visualized with a radio-
labelled full length probe. Quantification of signal 
intensity was performed on a Molecular Dynamics 
PhosphorImager using Image Quant software. 
 
RNase protection assay 
RNase protection was performed as described earlier 
(Schubart et al. 1996b). In brief, a probe was in vitro 
transcribed from a vector containing the murine Spi-
B promoter and 5’ coding region (kindly provided by 
D. Tenen, described in (Chen et al. 1998)). The gel-
purified radiolabeled probe was afterwards hybrid-
ized with 20 mg of total RNA at 50 °C over night. 
After RNase digestion, RNA was resolved on a 5% 
polyacrylamide gel and autoradiographed. The pro-
tected part of the murine Spi-B RNA is shown in 
Figure 3A. In the same assay, a control probe of S16 
mRNA was used for normalization of loaded RNA 
quantity. Signal intensity was quantified on a 
Molecular Dynamics PhosphorImager using Image 
Quant software. 
 
Immunofluorescent staining and flow cytometry 
(FACS) analysis 
Single cell suspensions of freshly prepared thymo-
cytes were prepared, stained and analyzed according 
to standard procedures (Rolink et al. 1994). FACS 
analysis was performed on a FACSCalibur (BD 
Biosciences, San Jose, CA), and fluorescence data 
were collected on 30,000 events by gating on living 
cells and typical forward-side scatter appearance of 
lymphocytes. CellQuest software was used for 
collecting and analyzing data. Cell sorting was per-
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formed on a MoFlo (DakoCytomation) with a purity 
of at least 94 %.  
The mAbs 7D4 (anti-CD25; biotinylated), 53-6.7 
(anti-CD8a; PE-labeled) and GL3 (anti-γδ-TCR; PE-
labeled) were purchased from Pharmingen (BD 
Biosciences), San Diego, CA.; RA3-6B2 (anti-B220; 
FITC labeled (IHC)), and GK1.5 (anti-CD4; FITC-
labeled), anti-CD122-FITC (#1905-02), and strepta-
vidin-RPE were purchased from Southern 
Biotechnology Associates (Birmingham, USA). 
Biotinylated peanut agglutinin (PNA-biotin, Vector 
Lab) was used for immunohistochemistry 
 
Immunohistochemistry and in situ hybridization 
Young adult mice were sacrificed, the thymi were 
taken, rinsed in PBS and fixed for 16 hours in 4% 
paraformaldehyde. After a series of washes in PBS, 
0.85% NaCl, 50% ethanol in PBS and 70% ethanol 
in PBS, the thymi were paraffin embedded according 
to standard procedures and 6 µm sections were pre-
pared for histochemistry.  
For in situ hybridization, a 450 bp probe from the 3’ 
UTR of the murine Spi-B cDNA and the correspond-
ing antisense probe were DIG-labeled with the DIG 
RNA labeling kit (Roche) according to the manufac-
turer’s instructions.  
 
Chromatin immunoprecipitation (ChIP) 
ChIP was performed as described previously 
(Masternak et al. 2003). In brief, 4 x 107 thymocytes 
(or 5 x 106 STI571-treated Abelson B cells) were 
harvested, suspended in 40 ml (4 ml) RPMI 1640 
and crosslinked for 10 minutes at room temperature 
with 4 ml (400 µl) 11% formaldehyde / 0.1 M NaCl / 
50 mM Hepes pH 7.9. Crosslinking was stopped by 
addition of 6.5 ml (650 µl) 1 M glycine pH 8 and 
incubation for 5 minutes at room temperature. Cells 
were washed with 50 ml (5 ml) cold PBS containing 
protease inhibitors (Complete, Roche, Basel, 
Switzerland), resuspended in 40 ml (4 ml) ice cold 
cell lysis buffer (5 mM Pipes, pH8.0 / 85 mM KCl / 
0.5% NP40) + Complete (Roche) and vortexed. Nu-
clei were spun down immediately for 7 minutes at 
2,500 rpm, then lysed for 10 minutes at room 
temperature in 2.2 ml Nuclei lysis buffer (50 mM 
Tris, pH8.0 / 10 mM EDTA / 1% SDS). Chromatin 
was sonicated with a Branson 250 sonicator: 3 X 20” 
pulses constant power output setting 7, precleared by 
centrifugation at 12000 rpm for 10 minutes at 4°C. 
Chromatin was transferred to fresh vials and stored 
at -80°C.  
To immunoprecipitate chromatin with specific 
antibodies, 10 µg (3 µg) of chromatin were diluted 
with immunoprecipitation (IP) buffer (20 mM Tris-
HCl, pH 8.0, 200 mM NaCl, 2 mM EDTA, 0.1% 
sodium deoxycholate, 0.1% SDS and the protease 
inhibitor complex Complete) containing 50 g/ml 
salmon sperm DNA, 100 g/ml Escherichia coli 
tRNA and 1 mg/ml bovine serum albumin. 
Immunoprecipitation was performed with an anti-
HA antibody (12CA5) in case of the thymocytes and 
with the monoclonal OBF-1 antibody C-20 (SC-955 
X, Santa Cruz Biotechnology, CA) in case of the 
Abelson cell lines. Immune complexes were cap-
tured at room temperature with protein A-Sepharose 
beads. Beads were washed twice with IP buffer, 
twice with IP buffer containing 500 mM NaCl, twice 
with 20 mM Tris-HCl, pH 8.0, 0.25 M LiCl, 2 mM 
EDTA, 0.5% NP-40, 0.5% sodium deoxycholate and 
once in TE containing 0.1% NP-40. Immunoprecipi-
tated chromatin fragments were eluted with 100 mM 
Tris-HCl, pH 8.0, 1% SDS for 10 min at 65 °C, di-
luted twofold with 400 mM NaCl, 200 g/ml pro-
teinase K, digested for 1 h at 37 °C and incubated 
overnight at 65 °C to reverse the crosslinks. After 
extraction with phenol-chloroform and chloroform, 
DNA was precipitated with isopropanol in the pres-
ence of glycogen, washed in 80% ethanol and resus-
pended in TE. Immunoprecipitated DNA derived 
from 100 ng of input chromatin DNA and a stan-
dards containing 10 ng of total input chromatin DNA 
were analyzed by PCR. 
 
Affymetrix Microarrays MG-U74 and MG-U74v2 
RNA preparation and microarray hybridization: 
Cells were harvested. Total RNA from thymus was 
immediately isolated with the Trizol method (Life 
Technologies, Inc.), followed by a purification using 
the RNeasy kit from Qiagen according to the 
manufacturer’s instructions. Microarray analysis was 
performed using MG_U74A version 2 GeneChips™ 
(Affymetrix). 10 µg of total RNA was reverse tran-
scribed using the SuperScript Choice system for 
cDNA synthesis (Life Technologies) according to 
the protocol recommended by Affymetrix. 
Data processing: Chip analysis was performed using 
the Affymetrix Microarray Suite v5 and GeneSpring 
5.1 (Silicon Genetics). Changes in gene expression 
were assessed by looking for concordant changes 
between replicates using a signed Wilcoxon rank test. 
The “change” p-value threshold was < 0.003. Genes 
whose detection p-value was > 0.05 (absent) in all 
conditions were also discarded. Detailed information 
conforming to MIAME standards is provided upon 
request. 
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2.2 Lck-OBF-1 transgenic 
mice 
 
2.2.1 Generation of lck-OBF-1 
transgenic mice 
 
In vivo, OBF-1 was found to be expressed mostly 
in a B cell-restricted manner, but its expression was 
also induced in T cell lines and primary murine 
thymocytes by in vitro stimulation with PMA and 
ionomycin. However, the physiological role of OBF-
1 in T cells has remained unclear and in OBF-1 
deficient mice T cell development and function were 
found to be normal (Qin et al., 1998; Schubart et al., 
1996a). To further define the potential function of 
OBF-1 in T cells, we generated transgenic mice 
expressing an HA epitope-tagged OBF-1 cDNA 
under the control of the murine proximal lck 
promoter. This T cell-specific promoter is highly 
active in thymocytes throughout their development 
and then has low activity in peripheral T cells 
(Shimizu et al., 2001). The expression cassette was 
cloned into pBluescript II KS+ from previously 
described plasmids containing the proximal lck 
promoter (p1017, kindly provided by R. Perlmutter), 
and human OBF-1 cDNA with an additional C-
terminal HA tag (pCDNA-OBF-1, pEV OBF-
1/9HA). The DNA sequence of this T cell-specific 
construct is available online in digital form at 
http://www.fmi.ch/groups/matthias.p/Bartholdy.html. 
A plasmid map is shown in Figure 15.  
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Figure 15  Lck-OBF-1 construct used to generate 
transgenic mice constitutively expressing HA-tagged 
hOBF-1 in a T cell-specific manner. (A) Construct, (B) in 
the context of the expression vector (important restriction 
sites are indicated). 
  
 
2.2.2 Genotyping of transgenic 
mouse lines and expression 
analysis 
 
At first, potential founder mice were screened by 
PCR analysis and by Southern blotting. The positive 
founders were subsequently crossed to WT mice of 
the same background to establish distinct transgenic 
lines. Transgenic offspring from these lines was used 
to determine the mRNA and protein expression 
pattern of the transgene.  
In agreement with the expected activity pattern 
of the lck promoter, high levels of transgenic OBF-1 
mRNA and protein were found in the thymus and 
lower levels were found in the spleen (Fig. 16). By 
contrast, transgenic OBF-1 mRNA and protein were 
barely detectable in non-lymphoid organs of these 
transgenic lines (Fig. 17). Several independent 
transgenic mouse lines were generated, which 
showed the same phenotype described below. We 
focused on the lines #13 and, later, #466, which had 
the highest transgene expression and the most 
pronounced phenotype.  
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Figure 16  (A) mRNA expression of lck-OBF-1 and 
endogenous OBF-1 in lymphoid tissue (northern blot). β-
actin was used as a loading control. (B) Expression of 
transgenic OBF-1 protein in the lymphoid compartment of 
6-8 weeks old mice. Western blot analysis was performed 
with the monoclonal anti-HA antibody 12CA5. The upper 
band is unspecific, but shows that equal amounts of WT 
and transgenic protein were loaded for each tissue. 
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2.2.3 FACS analysis 
 
To study the effect of OBF-1 overexpression in T 
cells, flow cytometric analyses were performed of 
cells from several lymphoid organs, such as the bone 
marrow, spleen, thymus and lymph nodes. For that,  
 
 
 
 
marker description 
c-kit 
(CD117) 
Stem cell factor receptor, 145 kDa 
transmembrane tyrosine kinase encoded by the c 
Kit proto-oncogene. c Kit acts to regulate a 
variety of biological responses including cell 
proliferation, apoptosis, chemotaxis and 
adhesion. Expressed on some multipotent 
hematopoietic cells. 
493 antigen 
(C1qRp, 
AA4.1) 
Complement component C1q like receptor 
C1qRp; expressed on immature B cells in the 
bone marrow and in the spleen. 
 
B220 Isoform of CD45, a major cell-membrane 
glycoprotein expressed on all hematopoietic cells 
except mature erythrocytes. B220 primarily 
recognizes only cells of B-lineage form pro-B 
cell through mature B lymphocytes; pan-B cell 
marker. 
CD3 TCR-associated CD3 complex expressed on all T 
cells; pan-T cell marker. 
CD4 Transmembrane glycoprotein expressed on most 
thymocytes and on mature T helper cells. 
CD5  
(Ly-1) 
Major ligand of CD72, found on thymocytes, T 
cells, and a subset of B cells (the B-1 B cells), 
but not NK cells. 
CD8 Differentiation antigen found on most 
thymocytes and the mature cytotoxic T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
marker description 
CD25 
(IL2-Rα; 
TAC) 
IL-2 receptor α chain, expressed on activated T 
and B cells. Resting T and B cells and NK cells 
do not express CD25. Transiently expressed 
during B-cell development in the bone marrow 
(during pre-B/preB-II stage). Expressed at higher 
levels during very early stage of T-cell 
development in fetal and adult thymus. 
CD90 
(Thy-1) 
Surface glycoprotein of the Ig superfamily, in all 
mammalian brain and HSCs. Pan-T cell marker, 
found on thymocytes, peripheral T cells, and 
some intraepithelial T lymphocytes. 
CD122 
(IL-2Rβ)  
Expressed by early T cell progenitors, some 
peripheral T cells, and NK cells. Upregulated by 
activation. Associates with CD25 and CD132 (γc) 
to form the high affinity IL-2 receptor. 
 
 
γδ-TCR Specific TCR expressed by a subset of T cells 
found mainly in gut epithelium and skin. 
IgD Immunoglobulin D (isoform found on mature B 
cells). 
IgM Immunoglobulin M (isoform that is found bound 
to the membrane of immature and mature B 
cells). 
NK1.1 Expressed on all NK cells and it initiates 
transmembrane signals that activate cytotoxicity.  
Figure 17  Analysis of the expression pattern of lck-OBF-1 in transgenic mouse lines. A. RT-PCR/Southern blot analysis of the 
lck-OBF-1 transgene in several transgenic mouse lines. B. Protein expression measured by western blot analysis of spleen and 
thymus extracts of the same mouse lines. The (HA-tagged) transgenic OBF-1 protein was detected with a monoclonal anti-HA 
antibody (12CA5). C. and D. Control reactions detecting the expression levels of endogenous OBF-1 mRNA (C) and β-actin 
mRNA (D). 
the expression of a number of cell surface
markers characteristic of discrete stages of B and T
cell development was monitored by FACS. A list of
the surface markers that were used for this study is
presented in Table III.  
Table III  Cell surface markers used to study B and T cell development.
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As expected, B cell development in the spleen 
and bone marrow was unaffected by expression of 
the transgene in T cells (data not shown), and normal 
numbers of B lymphocytes of all developmental 
stages were present in the lymphoid system of the 
transgenic animals.  
 
2.2.3.1 Normal development of 
conventional T cells 
After observing that the B cell compartment 
appeared to be unaltered, we turned our attention to 
the T cell compartment of the lck-OBF-1 transgenic 
mice. The main pathway of T cell development, as 
judged by the cell surface expression of the CD4 and 
CD8 coreceptors on the maturing thymocytes, 
appeared to be normal (see Section 2.1, Figure 1), 
and normal numbers of mature cells were measured 
in the peripheral lymphoid organs. However, a small 
subpopulation of CD4+ CD8+ cells appeared in the 
spleen of the transgenic mice that was undetectable 
in WT littermates (Fig. 18).  
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Figure 18  Presence of CD4+ CD8+ splenocytes in 
transgenic mice (encircled in red). Splenocytes from 11-12 
week old mice were isolated and analyzed by FACS with 
FITC-labelled anti-CD4 and PE-conjugated anti-CD8 
antibodies. The dot plot of one representative mouse of 
each genotype is shown. In the upper part of the Figure 
the results from 6 animals of each genotype have been 
pooled and the data are presented ± SD (average of 3 
independent experiments, each time in duplicate). 
 
2.2.3.2 Massive increase in CD25+ 
thymocytes 
Prompted by the appearance of this abnormal T 
cell subset, we analyzed the T cell compartment of 
the lck-OBF-1 transgenic mice in greater detail and 
found a number of alterations in its composition. 
The most obvious change was the appearance of a 
population of thymocytes expressing CD25, the IL-2 
receptor alpha chain, on the cell surface (Fig. 19). 
Usually, immature thymocytes express CD25 at the 
CD4- CD8- (double negative, DN) stages, which 
correspond to the CD122- CD25hi population in 
Figure 19. While this population is only slightly 
upregulated in the transgenic thymus, most of the 
~7-fold increase in CD25+ cells is caused by the 
appearance of CD4+ CD8+ (double positive, DP) 
cells that express CD25. Usually, these DP cells 
have downregulated CD25 expression which gets 
only reinitiated in activated peripheral T cells.  
Interestingly, the expression of CD25 on mature 
T cells in the spleen and in the lymph nodes was not 
increased in the transgenic animals. This is in 
concordance with the finding that other T cell 
activation markers, such as CD69 and HSA were 
also normal (not shown). 
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Figure 19  Increase in CD25+ thymocytes in lck-OBF-1 
transgenic mice. Thymocytes from 11-12 weeks old mice 
were prepared and analyzed by FACS with FITC-
conjugated anti-CD122 and PE-conjugated anti-CD25 
antibodies. The dot plot of one representative mouse of 
each genotype is shown. In the upper part the results from 
6 mice of each genotype have been pooled and the data 
are presented ± SD. The CD25high or CD25intermediate cells 
correspond to the dot plot areas circled in blue or red, 
respectively (average of 3 independent experiments with 
11-12 week old mice (each time in duplicate)). 
 
2.2.3.3 Alterations in gammadelta T cell 
development 
Another T cell subpopulation that was 
upregulated in lck-OBF-1 transgenic thymus were 
the gammadelta T cells. These cells do not express a 
conventional T cell receptor composed of an alpha 
and a beta chain, but use the gamma and delta chain 
instead. As shown in the introduction (Fig. 2), these 
cells branch off from the main T cell pathway early 
in thymic T lymphopoiesis. In the transgenic mice, a 
4- to 5-fold increase in γδ-TCR+ T cells was found in 
the thymus (Fig. 20). Additional FACS analyses 
2.2  Lck-OBF-1 transgenic mice 
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showed that these cells were CD4+ CD8+, and 
mostly CD25+ as well.  
It is of interest to note that the number of γδ T 
cells is normal in the spleen and is only slightly 
increased in the bone marrow of lck-OBF-1 mice 
(Fig. 21). Another site where γδ T cells are found 
frequently is the gut epithelium as part of the 
intestinal intraepithelial lymphocytes (iIEL). Murine 
iIEL contain predominantly CD8+ T cells, but also 
some CD4- CD8- DN T cells. About 50% of the T 
cells express the γδ TCR. In the lck-OBF-1 
transgenic mice there was only a marginal increase 
in these γδ T cells in the gut (not shown).  
 
TCR
0
0.1
0.2
0.3
0.4
0.5
wt lck-OBF-1
WT


-
TC
R
m
illi
on
ce
lls
WT
lck-OBF-1
lck-OBF-1


-
TC
R
CD122CD122
  
Figure 20  Increase in γδ-TCR+ thymocytes in lck-OBF-1 
transgenic mice. Thymocytes from 6-9 weeks-old mice 
were isolated and analyzed by FACS with FITC-labelled 
anti-CD122 and PE-conjugated anti-γδ-TCR antibodies. 
The dot plot of one representative mouse of each genotype 
is shown. In the upper part of the Figure the results from 6 
mice of each genotype have been pooled and the data are 
presented ± SD. The gated area for the quantification is 
indicated in red (average of 3 independent experiments, 
each time in duplicate). 
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Figure 21  Moderately increased levels of γδ-TCR+ T cells 
in the bone marrow of transgenic mice. Isolated bone 
marrow cells were stained with FITC-labelled anti-CD3 
and PE-conjugated anti-γδ-TCR antibodies. While the 
total T cell number (CD3 total) and the number of 
“conventional” γδ-TCR- T cells (right column) were 
normal in the lck-OBF-1 transgenic bone marrow 
population, the γδ-TCR+ T cells (middle column) were 
moderately increased in the transgenic animals. The 
results from 3 mice of each genotype have been pooled 
and the data are presented ± SD. 
 
 
In contrast, dendritic epidermal T cells (DETC), 
which are a specific subset of γδ TCR+ T cells (that 
use the Vγ3 gene segment), were lacking completely 
in the skin of the transgenic mice (Fig. 22). Vγ3 cells 
are making up the first wave of TCR+ cells that can 
be found in the fetal thymus around day 14-16 of 
gestation. In adult mice, they are found exclusively 
in the epidermis, where they represent the main T 
cell population.  
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Figure 22  Absence of dendritic epidermal T cells in the 
skin of transgenic mice (encircled in red). Isolated 
dendritic epidermal T cells (DETCs) were stained with 
FITC-labelled anti-CD3 and PE-conjugated anti-γδ-TCR 
antibodies. The dot plot of one representative mouse of 
each genotype is shown. As one can clearly see, CD3+ γδ-
TCR+ DETCs are virtually absent in the skin of the 
transgenic animals but can be readily detected in WT mice 
(and also in OBF-1 deficient mice, data not shown). 
 
2.2.3.4 NK cells 
Other cell populations that arise from a common 
lymphoid progenitor are the natural killer (NK) and 
NKT cells. Similarly to B cells and T cells, this cell 
population critically depends on interleukin 
signaling through receptors that share the common γ 
chain (γc), such as IL-2, IL-4, IL-7, IL-9, IL-15, and 
IL-21. Consequently, γc deficient mice have a 
marked impairment of B, T, and NK cell 
development. The defective B and T cell 
development observed in γc deficient mice seems to 
reflect the lack of IL-7R signaling, while the defect 
in NK cell development is due to the absence of IL-
15R signaling. Mice lacking IL-7 or its receptor IL-
7R have major defects in B and T cell development, 
but an uncompromised NK cell development (see 
also the review in Section 2.5). Studies in mice 
deficient in IL-15 or IL-15Rα have confirmed a 
critical role for IL-15 in regulating the development 
and/or expansion of NK cells, NK-T cells, and 
distinct intestinal intraepithelial lymphocyte 
populations (Kennedy et al., 2000; Lodolce et al., 
1998).  
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It appeared thus possible that the NK 
development in the transgenic mice could also be 
altered, since a dramatic increase in IL-2Rα (CD25) 
in the thymus of these animals might interfere with 
signaling though the IL-15R, which also uses the 
IL2-Rβ chain (CD122). The number of NK cells in 
the thymus of lck-OBF-1 mice was indeed ~3-fold 
higher, constituting approximately 2.8% of the 
thymic lymphocytes, compared to 0.9% in the WT 
animals. This increase does not seem to be caused by 
one specific subset of NK or NKT cells, since all 
NK1.1+ cell populations differing in the expression 
of the pan-T cell marker CD3 were affected 
similarly (Fig. 23). 
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Figure 23  Increased number of NK1.1+ cells in the 
thymus of lck-OBF-1 transgenic mice. Thymocytes from 6-
9 weeks-old mice were isolated and analyzed by FACS 
with FITC-labelled anti-NK1.1 and PE-conjugated anti-
CD3 or anti-c-kit antibodies. The total number of NK1.1+ 
cells was increased ~3-fold among the lck-OBF-1 
transgenic thymocytes. This increase was due to an 
increase in both NKT cells expressing high or intermediate 
levels of CD3, and in NK cells that do not express CD3 
(CD3low cells). A part of these NK1.1+ cells was also c-
kit+. The Figure shows the results from cells of 3 mice of 
each genotype and the data are presented ± SD. 
 
In contrast to the thymus, the numbers of NK and 
NKT cells in the spleen were normal (Fig. 24).  
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Figure 24  Normal ratio of T cells (first column), NKT 
cells (second column) and NK cells (last column) in the 
spleen of lck-OBF-1 transgenic mice. The Figure shows 
the results from cells of 3 mice of each genotype and the 
data are presented ± SD. 
 
 
2.2.4 Microarray experiments 
 
We have seen previously that OBF-1 
overexpression in the T cell compartment leads to 
very specific effects on a number of minor T cell 
subsets, but does not overtly perturb normal T cell 
development. Because overall T cell development 
and total T cell numbers were largely unchanged by 
the expression of OBF-1 we decided to use 
thymocytes RNA for microarray experiments, in 
order to identify potential OBF-1 target genes. To 
this end two independent comparisons were 
performed: (i) transgenic vs WT total thymocytes, 
and (ii) transgenic thymocytes, CD4+CD8+CD25+ vs 
CD4+CD8+CD25- cells (see Figure 18). 
Microarray data complying with MIAME 
standards can be found in electronic form on the web 
at the public ArrayExpress database at 
http://www.ebi.ac.uk/arrayexpress. A table listing 
the genes that were differentially regulated in the 
same manner in all microarray experiments is listed 
in Appendix (Section 6.1).  
The most interesting candidates that we 
identified by the microarray experiments comparing 
WT to lck-OBF-1 total thymic RNA are listed in 
Table IV. In the present context, “interesting” genes 
are preferentially fulfilling the following criteria: (i) 
they are upregulated (or downregulated) in the 
transgene tissue, and, respectively, downregulated 
(or upregulated) in OBF-1 deficient tissue, (ii) they 
are usually expressed in lymphocytes, just like OBF-
1, and (iii) they contain an octamer site in their gene 
regulatory regions to which OBF-1 can bind.  
The genes listed in Table IV were those genes 
that were upregulated and that contained certain 
common motifs in their promoter region. Besides the 
octamer motif that was identified in 18 of 36 genes 
(50%), other motifs appeared several times in this 
analysis. One such motif is a PU.1 binding site, thus 
also a putative Spi-B binding site. Another recurring 
motif is the combination of binding sites for ICSBP 
(IRF-8) and AR (androgen receptor), and another is 
the site for MLTF (Adenovirus Major Late 
Transcription Factor, USF1).  
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Figure 25  FACS sorting of CD25high vs CD25low 
CD4/CD8 DP thymocytes. (A) Thymocytes from 15 lck-
OBF-1 transgenic mice were pooled and stained with 
FITC-labelled anti-CD4, PE-labelled anti-CD8 and APC-
conjugated anti-CD25 antibodies. Subsequently, cells 
double-positive for CD4 and CD8 (green) were separated 
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in CD25high (red) or CD25low (blue) subsets using a MoFlo 
FACS sorter. RNA from the different fractions was 
purified and used for an Affymetrix GeneChip analysis. 
(B) Total protein was isolated in parallel from the 
corresponding cell populations and western blot analysis 
using a polyclonal antibody against OBF-1 were used to 
measure the OBF-1 protein levels in the sorted T cell 
subsets. Unsorted thymocytes were included as a control. 
 
 
Table IV  Genes upregulated in lck-OBF-1 transgenic 
mice and and recurring transcription factor binding sites 
in the gene promoter region. The table refers to motifs 
found in the promoters of human orthologs.  
n.d.: not determined; no data for the promoter was 
available for the analysis.  
/: not found; a sequence resembling the consensus binding 
sequence of the respective transcription factor was not 
detected in the gene promoter region. 
Gene Oct-1 PU.1 AR/ 
ICSBP 
MLTF 
Spi-B perfect no yes no 
CD25 tTGCAAAT yes yes yes 
RW1 / no no yes 
FCRIIb ATGCAAT yes yes no 
AW548096 
(C/EBP-induced) 
n.d. n.d n.d. n.d. 
TCR gamma 2/4 / yes yes no 
Hcph perfect yes no yes 
STAT4 perfect no yes yes 
CD44 perfect yes no yes 
S100A8 / yes no yes 
Syp/PLCgamma2 / no yes yes 
Atp2a3 (Serca) n.d. n.d n.d. n.d. 
AA409502 n.d. n.d n.d. n.d. 
DKFZP5643116 n.d. n.d n.d. n.d. 
ODC ATGCAATa yes yes yes 
160122_at ATGCAAAA
A 
yes yes yes 
Tcf4 n.d. n.d n.d. n.d. 
Myla / yes yes yes 
Ly6D perfect no no yes 
DC12 ortholog n.d. n.d   
160820_at ATGCAAAg yes yes yes 
Gadd45beta ATGCAAAa
T 
yes yes yes 
Mef2b / yes yes no 
Crip n.d. n.d n.d. n.d. 
XBP-1 / no yes yes 
Akap12 ATGCAAgc no no no 
96158_at ATGCAAt, 
ATGCAtt,AT
GtAAAT, 
ATGaAAAT 
yes yes no 
CIKS (96221_at) ATGCAAAc, 
cTGCAAAT 
yes yes yes 
Egln2 perfect no yes yes 
Notch1 perfect yes no no 
Hip1R (97551_at) / yes yes yes 
97853_at ATGCAAt yes yes yes 
Zfpm/FOG / yes yes yes 
Casp7 perfect yes yes yes 
99366_at n.d. n.d n.d. n.d. 
lbp2 / yes no yes 
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2.3 Eµ-VH-OBF-1 transgenic 
mice 
 
2.3.1 Generation of Eµ-VH-OBF-1 
transgenic mice 
 
In order to learn more about the function of 
OBF-1 in B cells, we generated another line of 
transgenic mice overexpressing human HA-tagged 
OBF-1. We made use of promoter/enhancer elements 
that were characterized previously to confer B cell-
specific expression (Banerji et al., 1983; Dreyfus et 
al., 1987; Gillies et al., 1983; Grosschedl and 
Baltimore, 1985; Mason et al., 1985), starting early 
in B cell ontogenesis: the V heavy-chain promoter 
and the µ enhancer.  
The expression cassette (depicted in Figure 26) 
was cloned into pBluescript II KS+ from previously 
described plasmids containing the VH promoter 
(plasmid S-19), the µ Enhancer (plasmid 1-27), and 
the human OBF-1 cDNA with an additional C-
terminal HA tag (plasmids pCDNA OBF-1, pEV 
OBF-1/9HA). The sequence of the B cell-specific 
construct (Eµ-VH-OBF-1 vector) is available online 
in digital form at 
http://www.fmi.ch/groups/matthias.p/Bartholdy.html). 
A plasmid map featuring essential restriction sites is 
shown in Figure 26 B.   
 
2.3.2 Genotyping of transgenic 
mouse lines and expression 
analysis 
 
2.3.2.1 Identification of transgenic 
founders 
The construct was cloned, excised from 
pBluescript II KS+ by SfiI digestion, separated by 
agarose gel electrophoresis followed by 
electroelution, and subsequently injected into the 
A 
 
 
 
 
 
B 
 
 
Figure 26  Eµ-VH-OBF-1 construct used to generate 
transgenic mice constitutively expressing HA-tagged 
hOBF-1 in a B cell-specific manner. A. Structure of the 
construct used for generation of transgenic mice. B. 
Plasmid map of the vector containing the Eµ-VH-OBF-1 
construct. The location of primers (c through g) used 
for PCR analysis is indicated. The sequence of these 
primers can be found in Section 4.  
 
 
 
 
 
 
 
 
 
male pronuclei of mice. Transgenic founders were 
screened by PCR and Southern blot analysis. Figure 
27 shows the results of this screening. 
 
Figure 27  PCR analysis of tail DNA from Eµ-VH-OBF-1 transgenic founders. Founders that gave positive PCR reactions
indicating the presence of the transgene are marked in bold. Additional PCR reactions with the primers c through g
were performed in the indicated combinations (below) to verify full-length integration of the transgene.  
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2.3.2.2 Eµ-VH-OBF-1 expression in the 
transgenic mouse lines 
Expression of the transgenic OBF-1 was 
determined by western blot, northern blot and RT-
PCR/SB techniques (Figures 28 and 29). Three 
mouse lines had integrated the full length transgene 
into their genome and were further characterized for 
OBF-1 expression: the lines #8, #30 and #33. The 
transgenic mice were viable and had a normal 
appearance, although line #30 showed at first a 
reduced rate of transgenic founders compared to the 
expected mendelian ratio. After embryo transfer, 
however, this changed to a normal distribution. 
Transgene mRNA was detected in the spleen, in 
the bone marrow, but – at highest levels – in the 
thymus of the Eµ-VH-OBF-1 mice of the lines #8, 
#30 and #33. The high expression in the thymus and 
relatively low expression in the B cell compartment 
was unexpected, although activation of similar V 
heavy-chain promoter-µ enhancer constructs was 
reported previously (Wasylyk and Wasylyk, 1986). 
However, the protein expression pattern reflected the 
mRNA expression; HA-tagged OBF-1 protein was 
only detected in the thymus of the Eµ-VH-OBF-1 
mice (Fig. 29). The construct is thus expressed 
specifically in lymphoid cells, not only in B cells, 
but to an even greater extent in T cells.  
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Figure 29  mRNA and protein expression of two Eµ-VH-
OBF-1 transgenic mouse lines. (A) mRNA expression of 
lck-OBF-1 and endogenous OBF-1 in lymphoid tissue 
(northern blot). A full length OBF-1 probe was used, 
which detects both endogenous (upper band) and 
transgenic (tg) OBF-1 mRNA (lower band). β-actin was 
used as a loading control. (B) Expression of the western 
blot analysis was performed using the monoclonal HA-
antibody 12CA5. 
 
Figure 28  RT-PCR-Southern Blot analysis of Eµ-VH-OBF-1 mRNA expression. A probe specific for the transgenic OBF-1
(tg OBF-1) was used to monitor the expression of the transgene in the indicated mouse tissues. β-actin was used as 
loading control. 
: Kidney RNA was taken from a mouse of line #8 that had one inflamed kidney (first RNA on the blot) and one normal looking one
(second RNA on the blot). Thus, no OBF-1 expression was observed in either of the two kidneys.-
--actin
Spleen Thymus Bone marrow Heart Liver Lung Brain Kidney
tg OBF-1
30 8 33wt 30 8 33wt 30 8 33wt30 8 33wt 30 8 33wt 30 8 33wt 30 8 33wt 30 8wt line #
RESULTS 
 
 
39 
2.3.3 FACS analysis 
2.3.3.1 Early block in B cell development 
in the bone marrow 
The cellular composition of the B cell 
compartment of each mouse line was determined by 
flow cytometry and using monoclonal antibodies 
directed against various B and T cell surface 
molecules. These include anti-B220, anti-c-Kit, anti-
CD19, anti-CD25, anti-IgM, anti-IgD, 493, anti-
CD90, anti-CD4, and anti-CD8. For a description of 
the antigens recognized by these antibodies, see 
Table V. In brief, the expression of specific  
 
combinations of cell surface molecules can be 
monitored by fluorescence-labeled antibodies and 
allows the distinction of cells from different 
developmental stages or different cell lineages. 
Eµ-VH-OBF-1 mice of the lines #8 and #33 
showed no gross perturbations of their lymphoid 
compartment, but line #30 had a clearly reduced 
number of B cells in the lymphoid organs. Figure 30 
shows the strongly impaired B cell development in 
the bone marrow of the transgenic mice from line 
#30. We focused on line #30 for further analysis of 
the B cell compartment, since we observed the most 
pronounced effect on B cell development in this line.  
 
Figure 30  FACS analysis of of the lymphoid compartment of the bone marrow of Eµ-VH-OBF-1 mice (line #30). Distinct 
developmental stages of B cell development are distinguished by specific cell surface staining with fluorescent antibodies 
shown in the upper part of the figure. A quantification of these cell populations is presented in the graph below. The
histograms represent the mean ± SD of four mice from two independent experiments. Cells from distinct B cell stages are
encircled in colors in the upper part og the figure, and the same colors were used to highlight these populations in the
quantification. PreBII cells consist of the subgroup of B220+ CD25+ cells that do not express IgM; they cannot be directly 
highlighted as one population in the upper graphs, therefore there is no color code attibuted to this population. 
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2.3.3.2 Strongly reduced splenic B cell 
compartment 
As shown in Figure 31, the reduction of B cells 
in Eµ-VH-OBF-1 mice of line #30, which first occurs 
in the bone marrow, is propagated to the spleen, 
where it is even more pronounced with a remaining 
amount of approximately 12-13% of the normal B 
cell numbers. The T cell numbers are also slightly 
reduced. 
 
 
 
 
Figure 31  FACS analysis of Eµ-VH-OBF-1 mice (line #30). Cellular composition of the spleen. Distinct developmental 
stages of B cell development are distinguished by specific cell surface staining with fluorescent antibodies shown in the 
upper part of the figure. A quantification of these cell populations (color coded) is presented in the graph below. The
histograms represent the mean ± SD of two independent experiments (five mice per genotype). 
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2.3.3.3 Abnormal CD25+ cells in the 
thymus of Eµ-VH-OBF-1 mice 
The western blot expression analysis (Fig. 29) 
already showed a strong expression of the transgenic 
OBF-1 in the thymus of the mice from line #30, 
similar to the lck-OBF-1 mice. To find out whether 
this expression has similar effects in both transgenic 
mouse lines, we also performed FACS analysis of 
the thymus of Eµ-VH-OBF-1 mice. As for the lck-
OBF-1 mice, there was the appearance of CD25+ 
CD4+ CD8+ cells in the thymus (Fig. 32). However, 
the other abnormal cell populations, such as γδ 
TCR+ and NK1.1+ cells, but also CD4+ CD8+ cells in 
the spleen did not appear in the Eµ-VH-OBF-1 mice.  
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Figure 32  Appearance of a CD25+ CD4+ CD8+ T cell 
population in the thymus of Eµ-VH-OBF-1 transgenic 
mice (circled in red). 
 
It has to be stressed at this point that this project 
is still at a preliminary state, given that most results 
were obtained exclusively the line #30 of Eµ-VH-
OBF-1 mice. Therefore, one has to be careful about 
the interpretation of the results. We observed some 
variation of the phenotype, which could be due to 
different copy numbers and sites of integration, 
ultimately leading to variations in the transgene 
expression level. For instance, mice from lines #30 
and #33, showed increased numbers of of CD25-
expressing thymocytes, similar to the lck-OBF-1 
mice. Other lines, such as the lines #8, #21, #487 
and #543 did not show such an obvious increase in 
this cell type. However, mice from the lines #543 
and #487 also have a reduced number of B cells in 
the spleen and in the bone marrow, but the effect is 
less severe than in mice from line #30. We still need 
to carefully analyze the transgene expression in 
other mouse lines to assure that the observed 
phenotype in the line #30 is fully attibutable to OBF-
1 expression in B cells.  
2.4 Functional assays of both 
transgenic mouse lines 
 
2.4.1 Immunization with a TD 
antigen 
 
To assess the status of the immune system of 
both lck-OBF-1 and Eµ-VH-OBF-1 transgenic mice, 
these animals were immunized intraperitoneally with 
a T cell dependent antigen (DNP-KLH) and the 
immunoglobulin levels in the blood were measured 
at day 0, 3, 5 and 8 of immunization by ELISA. The 
results are depicted in Figure 33. The lck-OBF-1 
mice show a normal response to DNP-KLH, 
whereas the Eµ-VH-OBF-1 mice only respond 
weakly to the antigen stimulation. This is most 
probably due to the reduced number of B cells in the 
spleen of these mice.  
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Figure 33  Immune response against a TD antigen (DNP-
KLH). WT and both Eµ-VH-OBF-1 and lck-OBF-1 
transgenic mice were immunized intraperitoneally and 
total Ig levels in the blood were measured at day 0, 3, 5 
and 8 of immunization. The histograms represent the mean 
± SD of three mice per genotype.  
 
 
2.4.2 Cytokine expression analysis 
 
In addition, the cytokine profile of the transgenic 
animals was investigated by a multiprobe RNAse 
protection assay. This assay helps to see differences 
in the level of a number of cytokines, including the 
interleukins IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-
15, and interferon gamma (IFNγ), in the lymphoid 
organs. We also included RNA from WT and OBF-1 
deficient mice in our assay for comparison. As 
shown in Figure 34, IL-2 levels were normal in all 
mice, showing that the upregulation of CD25 is not 
brought about by increased levels of IL-2. 
The most striking difference in chemokine levels 
was the increased level of IL-10 mRNA in OBF-1 
deficient spleen. This result was confirmed in a 
second RNase protection experiment (not shown).  
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Figure 34  Cytokine profile of the lymphoid organs of WT, OBF-1 deficient and OBF-1 transgenic (Eµ-VH-OBF-1 and lck-
OBF-1) mice. The raw data from the RNase protection is shown in the upper part of the figure. The graphs below show a 
quantification by phosphorimaging and normalization to the expression level of GAPDH. The only clear difference of 
cytokine levels observed was an increase in IL-10 levels in OBF-1-/- compared to WT splenic RNA (highlighted in red in the 
upper part of the figure). 
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Abstract
The generation, development, maturation and selection of mammalian B lymphocytes is a complex process that is initiated in the embryo
and proceeds throughout life to provide the organism an essential part of the immune system it requires to cope with pathogens. Transcriptional
regulation of this highly complex series of events is a major control mechanism, although control is also exerted on all other layers, including
splicing, translation and protein stability. This review summarizes our current understanding of transcriptional control of the well-studied
murine B cell development, which bears strong similarity to its human counterpart. Animal and cell models with loss of function (gene ‘‘knock
outs’’) or gain of function (often transgenes) have significantly contributed to our knowledge about the role of specific transcription factors
during B lymphopoiesis. In particular, a large number of different transcriptional regulators have been linked to distinct stages of the life of B
lymphocytes such as: differentiation in the bone marrow, migration to the peripheral organs and antigen-induced activation.
D 2003 Elsevier B.V. All rights reserved.
Keywords: Transcriptional; B cell; Development
1. Introduction
The development of B lymphocytes from pluripotent
progenitors is a tightly regulated process that originates in
the fetal liver and in the adult bone marrow and further
proceeds in the secondary lymphoid organs. Commitment to
the B cell lineage and subsequent rearrangement of the
immunoglobulin (Ig) heavy chain gene is followed by ex-
pression of the pre-B cell receptor (pre-BCR), which is
composed of the heavy chain and the surrogate light chains
E5 and VpreB. Signaling through the pre-BCR leads to a
transient phase of cellular proliferation, and triggers the
transition from early pre-B cells to late small pre-B cells.
Recombination of the n and E light chain loci is initiated at the
pre-B cell stage. Successful pairing of one of the light chains
with the heavy chain results in surface expression of IgM, the
hallmark of immature B cells. IgM-expressing cells then exit
the bone marrow and complete their maturation in the spleen.
Antigen encounter then leads to activation of mature B cells
and their differentiation into memory B cells or antibody-
secreting plasma cells (PCs), the final mediators of the
humoral immune response.
The entire developmental program of B lymphopoiesis is
tightly regulated, and one of the most important regulatory
mechanisms is the transcriptional control executed by a large
number of cell-specific or ubiquitous factors that drive cells
into the B lineage, lead to their selection and differentiation
or to cell death, or maintain them in a defined differentiation
stage. Gene targeting studies revealed that several transcrip-
tion factors are essential for early B cell development: Their
absence leads to a block in differentiation primarily at either
of two stages: (i) at the initiation of B lineage commitment
and (ii) at the onset of VHDJH recombination (see Fig. 1 and
Table 1). Successful initiation of immunoglobulin gene
rearrangement is thus a critical checkpoint in B lymphopoi-
0378-1119/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.gene.2003.11.008
Abbreviations: Ig, immunoglobulin; BCR, B cell receptor; TCR, T cell
receptor; SC, stem cell; HSC, hematopoietic stem cell; CLP, common
lymphoid progenitor; DC, dendritic cell; FDC, follicular dendritic cell; NK
cell, natural killer cell; AFC, antibody-forming cell; IDC, interdigitating
cell; PC, plasma cell; TdT, terminal deoxynucleotidyl transferase; bHLH,
(basic) helix– loop–helix; CSR, class switch recombination; SHM, somatic
hypermutation; M-CSF, macrophage colony-stimulating factor; IFN-g,
interferon-g; LPS, lipopolysaccharide; PALS, periarteriolar lymphoid
sheath; MZ, marginal zone; GC, germinal center; TD, T cell-dependent;
TI, T cell-independent; HDAC, histone deacetylase; HAT, histone acetyl
transferase; LCR, locus control region; MHC, major histocompatibility
class; MAR, matrix attachment region; UPR, unfolded protein response;
ER, endoplasmatic reticulum.
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esis. Other factors have been found to be dispensable for
early B cell development but to affect function of mature
peripheral cells. In addition, sophisticated conditional gene
targeting strategies have revealed that some factors execute
their function at several discrete stages of B cell development
and it remains to be seen how general this may be.
There is little doubt that the highly ordered combinatorial
interplay of DNA-binding transcription factors controls the
stepwise development of B cells that is accompanied by their
sequential acquisition of novel properties (e.g., DNA rear-
rangement, BCR signaling, etc. . .). In many cases, however,
the molecular explanations are still lacking, and the critically
affected target genes that may ultimately explain the pheno-
types of the mutant mice have not yet been identified
unambiguously. Furthermore, at a mechanistic level, the
mode of operation of the critical transcription factors has
often not been dissected in their natural B cell context and
there are certainly multiple ways how one and the same
transcription factor can regulate gene expression, depending
on the cellular and/or developmental context.
Evidently, the regulation of gene expression is a multi-
level process requiring at the minimum opening of the
locus, binding of transcription factors to their target sequen-
ces in promoter and enhancers and recruitment of the basal
transcription machinery. Each one of these steps can be rate-
limiting and offers a possibility for regulation. In addition,
superimposed, epigenetic mechanisms that regulate the
accessibility of a locus and lead to local or global changes
in chromatin structure are being increasingly examined and
will be addressed briefly in the last section of this review.
For the sake of clarity, this review is organized chronolog-
ically, following the principal stages of B cell differentia-
tion: commitment to the B lineage, early B lymphocyte
development in the bone marrow, homing to the secondary
lymphoid organs, T cell-dependent (TD) responses (B cell
activation and germinal center (GC) formation), T cell-
Fig. 1. Lineage commitment in the bone marrow. The position of the transcription factors on the scheme represents the stage at which their absence (based
usually on knockout studies) leads to a developmental block. Proteins normally acting as inhibitors of the differentiation pathways are depicted in red. Physical
interactions between transcription factors are indicated by double-pointed blue arrows. SC, stem cell; HSC, hematopoietic stem cell; CLP, common lymphoid
progenitor; NK, natural killer cell.
Table 1
Genes controlling murine early B cell development
Developmental
transitions
Pro-B to pre-B-I Pre-B-I to large pre-B-II Large pre-B-II to
small pre-B-II
Small pre-B-II
to immature B
Immature to
mature B
Centrocyte to
plasma cell
Hallmark events DH- to JH-rearrangement VH- to DJH-rearrangement VL- to JL-rearrangement IgM surface
expression
IgD surface
expression
Important transcription
factors
Sox-4, E2A, EBF, Pax-5 Pax5 IRF-4/IRF-8 OBF-1/Aiolos OBF-1, Oct-2,
NF-jB
Blimp-1, XBP-1,
Aiolos (?)
Other important genes RAG-1, -2, SCID, BLNK,
JH, lmb; Igb, IL-7;
IL-2Rb
Syk, PI3K, k5,
VpreB1/VpreB2
DNA Polymerase
Mu, Btk/Tec
j/k L chain Btk
B. Bartholdy, P. Matthias / Gene 327 (2004) 1–232
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independent (TI) responses (marginal zone (MZ) and B1 B
lymphocytes) and plasma cell differentiation.
2. B lineage commitment
An initial step in lymphopoiesis is the commitment of
pluripotent hematopoietic progenitors to the lymphoid line-
age, in other words the generation of common lymphoid
progenitors (CLPs) from hematopoietic stem cells (HSCs).
The IL-7R+ common lymphoid progenitor (Kondo et al.,
1997b) gives rise exclusively to lymphocytes (T, B and NK
cells), although it can still be impelled to differentiate into the
myeloid lineage by signaling through ectopically expressed
IL-2 or GM-colony-stimulating factor (CSF) receptors. Tran-
scriptional control of such cytokine receptors may therefore
be an important step in the cell lineage decision, as pointed
out by Kondo et al. (2000). Targeted mutation of the IL-7Ra
gene (Peschon et al., 1994; Maki et al., 1996), which is
primarily expressed in the common lymphoid progenitors in
fetal liver and bone marrow, in T lineage cells and in
developing B cells (Sudo et al., 1993; Kondo et al., 1997a;
Mebius et al., 2001), results in a severe early block in B and T
cell development. In this context, ectopic expression of the
anti-apoptotic gene bcl-2 partially restores ah+ Tcell, but not
B cell development (Akashi et al., 1997; Kondo et al., 1997a;
Maraskovsky et al., 1997). These findings suggest that IL-7
signaling is required not only for survival and proliferation of
B lineage progenitors but also for their differentiation into B
cells.
Recent reports revealed that lymphocytes and subsets of
dendritic cells (DCs) originate from a common myelo-lym-
phoid progenitor (Lu et al., 2002); the loss of developmental
potential to the DC lineage appears to be the final step in B-
lineage commitment of the precursor cells (Izon et al., 2001).
It is therefore tempting to suggest that expression of IL-7
could act as a regulator of cell fate decisions in multipotent B/
dendritic cell precursors by driving these cells to differentiate
into B lineage-committed cells (reviewed in Prohaska et al.,
2002).
Given the fact that IL-7 signaling is so crucial for B cell
development in mice, it is hardly surprising to note that this
cytokine exhibits similar positive effects on proliferation and
development of human B lineage cells in vitro (Uckun et al.,
1991; Dadi et al., 1993). Yet, in vivo, the situation appears to
be more complex, as evidenced from the impaired T cell
development—but normal B cell development—observed in
individuals with a defective IL-7 receptor gene (Fugmann et
al., 1998; Puel et al., 1998; Puel and Leonard, 2000).
2.1. PU.1
Recently, the Ets family transcription factor PU.1 has been
shown to directly regulate the expression of IL-7Ra in
lymphoid progenitors and thereby to play a pivotal role in
the myeloid versus lymphoid lineage decision (DeKoter et
al., 2002). Low PU.1 expression levels promote the lymphoid
versus myeloid cell development, whereas high levels sup-
press it (DeKoter and Singh, 2000). PU.1 null mice die during
fetal development at day 18.5 of gestation and lack B, T, and
myeloid progenitors. (Scott et al., 1994, 1997). PU.1  /
fetal livers also contain reduced numbers of multipotential
lymphoid-myeloid progenitors (AA4.1+, Lin). Further-
more, these mutant progenitors fail to proliferate and differ-
entiate into pro-B cells in response to stromal contact and IL-
7 (Scott et al., 1997). Retroviral transduction of IL-7Ra into
PU.1  / progenitors restores their IL-7-dependent prolif-
eration and, at low frequency, their differentiation into pro-B
cells that express the mb-1, B29, VpreB, E5, RAG-1 and
RAG-2 genes and undergo IgH D-J rearrangement. In addi-
tion to this critical role in early lymphoid development, PU.1,
as well as other Ets family members, has also been reported to
be crucial at later stages of B cell development; this will be
discussed within the context of these stages.
2.2. GATA factors
The transcriptional activity of PU.1 can be modulated by
its interaction with other hematopoietic regulators. Such an
interaction was reported between GATA proteins and PU.1
(Zhang et al., 1999). GATA family members are transcription
factors that contain a two-zinc finger domain and share a
consensus binding sequence-WGATAR-. Interaction of
GATA-1 with PU.1 leads to repression of PU.1-dependent
transcription (Nerlov et al., 2000).
PU.1 in turn inhibits the in vitro or in vivo acetylation of
GATA-1 by CREB-binding protein (CBP) (Hong et al.,
2002) and can negatively regulate expression of the
GATA-2 gene, thereby promoting distinct myeloid cell fates
(Walsh et al., 2002). A similar mechanism could operate in
the lymphoid compartment, where PU.1 and GATA-3 are
exclusively expressed and where they are required for the
development of B cells and T cells (Scott et al., 1994;
McKercher et al., 1996; Ting et al., 1996). Both factors
might thus play a pivotal role in the B- versus T-lymphoid
decision (Nerlov et al., 2000). Another GATA family mem-
ber, GATA-2, is essential at the earliest stages of hemato-
poiesis, since mice with a targeted deletion of this gene fail to
generate a sufficient number of primitive erythroid cells and
die at day 10–11 of gestation (Tsai et al., 1994).
The PU.1–GATA interactions can serve as examples of
negative regulatory interactions between hematopoietic tran-
scription factors. Other examples include the inhibition of
Ets-1 on erythroid promoters by MafB5 and the inhibition of
GATA-1 transactivation by Friend of GATA-1 (FOG)-medi-
ated recruitment of the CtBP corepressor (Fox et al., 1999).
2.3. Ikaros
The Ikaros gene encodes a number of Kru¨ppel-type zinc
finger proteins, generated by alternative splicing, which act
as lymphoid-specific transcription factors required at an
B. Bartholdy, P. Matthias / Gene 327 (2004) 1–23 3
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early stage of lymphopoiesis. In the absence of Ikaros,
lineage restriction of multipotent hematopoietic progenitors
towards the lymphoid pathways is severely affected. Ikaros-
deficient mice lack all B, natural killer (NK) and fetal T cells
as well as the earliest described lymphoid progenitors
(Wang et al., 1996). Like several other transcription factors,
Ikaros was shown to act either as a repressor or a potentiator
of gene transcription depending on the context.
In lymphocytes, Ikaros exists as an integral component of
chromatin-remodeling complexes, including the Mi-2h/nu-
cleosome remodeling and deacetylation (NuRD) complex. In
line with this, Ikaros, together with these associated activities,
can cause repression of target genes. Recent reports showed
that Ikaros is involved in repression of the E5 gene in mature
B cells and of the terminal deoxynucleotidyl transferase
(TdT) gene in CD4+ CD8+ thymocytes (Koipally et al.,
1999; Sabbattini et al., 2001; Trinh et al., 2001). In addition,
several Ikaros family proteins, including Ikaros (Koipally and
Georgopoulos, 2000), Eos and TRPS1 (Perdomo and Cross-
ley, 2002), also utilize CtBP corepressors to inhibit gene
expression. Conversely, Ikaros-containing chromatin remod-
eling complexes may also increase gene expression in cycling
cells (Koipally et al., 2002). It has been shown that Ikaros is
capable of enhancing gene expression as a potentiator of bona
fide transcriptional activators rather than by functioning itself
as a classical activator. Potentiation by Ikaros requires its
intact DNA binding and dimerization domains, both of which
are also necessary for its recruitment into a pericentromeric-
heterochromatin-associated nuclear compartment in cycling
cells (Cobb et al., 2000).
2.4. c-Myb
Another transcription factor involved in very early cell
fate decisions is c-Myb. Foetuses lacking c-Myb die at E15
as they fail to switch from embryonic yolk sac erythropoiesis
(during which c-Myb is not expressed; Sitzmann et al., 1995)
to adult hepatic erythropoiesis; a generalized defect in
haemopoiesis is also apparent (Mucenski et al., 1991).
c-Myb cooperates with several other transcription factors
to achieve transactivation of its target promoters. For exam-
ple, it associates with the histone acetyl transferase (HAT)
CBP/p300, which interacts with v-, c- and A-Myb via
sequences encompassing the conserved central activation
domain and acts as transcriptional coactivator (Dai et al.,
1996; Oelgeschlager et al., 1996a; Facchinetti et al., 1997;
Yamamoto et al., 2002). Other interaction partners include
the CCAAT binding proteins (C/EBP) alpha and beta (Burk
et al., 1993; Mink et al., 1996; Klempt et al., 1998), the Ets
factors Ets-2 (Dudek et al., 1992) and PU.1 together with C/
EBPa (Oelgeschlager et al., 1996b), the runt homology
domain factor AML-1/Runx-1 (Zaiman and Lenz, 1996;
Britos-Bray and Friedman, 1997), as well as GABP, a
heteromeric transcription factor complex of the Ets family
(Nuchprayoon et al., 1997). Interestingly, interaction be-
tween the hematopoietic Ets transcription factor Spi-B and
the coactivator CBP is associated with negative cross-talk
with c-Myb (Yamamoto et al., 2002), revealing another part
of this intricate network of transcriptional regulation of
lymphopoiesis.
3. Antigen independent stages of B cell development
3.1. Initiation of B lymphopoiesis in the bone marrow
Ig heavy chain gene rearrangement occurs at the pro-B cell
stage where DH to JH joining in the early pro-B cells precedes
VH to DJH joining in the late pro-B cells. A productive VDJH
joining leads to the expression of the A chain, which is the
hallmark of the pre-B cell stage. A fraction of the AH chain is
expressed at the cell surface of large pre-B cells where it
forms the pre-BCR by pairing with a surrogate light chain
consisting of E5 and VpreB, and with the signalingmolecules
Iga (mb-1) and Igh (B29) (Fig. 2 and Table 1).
3.1.1. E2A, EBF and Pax5
Three transcription factors have been identified by gene
targeting to play crucial roles at the onset of B cell
development: the basic helix-loop-helix (bHLH) proteins
early B cell factor (EBF), E2A, and the paired domain factor
B cell-specific activator protein (BSAP), also known as
Pax5. Both E2A and EBF act upstream of Pax5 in the
genetic hierarchy of B cell development (Bain et al., 1994;
Lin and Grosschedl, 1995) and are equally expressed in
Pax5 / and wild-type pro-B cells (Nutt et al., 1997).
Mutation of Pax5 is considered to dissociate the initial
activation of B-lineage-specific gene expression by E2A
and EBF from the Pax5-dependent control of B lineage
commitment (Nutt et al., 1999). Inactivation of any of these
three genes leads to a block in B lymphopoiesis before
complete rearrangement of the IgH gene and only DJ
segments are found to be recombined (Bain et al., 1994;
Urbanek et al., 1994; Zhuang et al., 1994; Lin and Gros-
schedl, 1995; Nutt et al., 1997). Ectopic expression of E2A
proteins in lymphoid cell lines leads to the upregulation of
EBF, Pax5, VpreB and RAG1 (Kee and Murre, 1998).
Forced expression of both E2A and EBF in hematopoietic
precursor cells leads to the upregulation of an entire B cell
differentiation program (O’Riordan and Grosschedl, 1999)
including Pax5, the surrogate light chain genes E5 and
VpreB (Sigvardsson et al., 1997; Persson et al., 1998;
Sigvardsson, 2000), the signaling molecules Iga and Igh
and the recombination-activating RAG1 and RAG2 genes
(Fuller and Storb, 1997; Sigvardsson et al., 1997; Kee and
Murre, 1998; Kishi et al., 2002; Maier et al., 2003).
Remarkably, ectopic expression of E2A or EBF in concert
with RAG1 or RAG2 in nonlymphoid cells is sufficient to
promote Ig gene rearrangement and leads to the generation
of a diverse repertoire of DH-JH recombinations (Romanow
et al., 2000). However, as in Pax5-deficient B cells, no V-
DHJH rearrangement takes place; thus, other lymphoid
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factors are necessary to obtain a true immunoglobulin
repertoire. In addition, other transcription factors involved
in the regulation of the RAG gene expression are NF-Y,
Ikaros, and c-Myb (Brown et al., 1997; Kishi et al., 2000,
2002).
3.1.2. Pax5
Pax5 directly acts as a transcriptional activator of several
lymphoid genes such as CD19, N-myc, Iga and LEF-1 (Nutt
et al., 1998). It has been shown to bind to the VpreB and
lambda5 promoters as well as to the KI and KII sites
upstream of the J kappa genes (Tian et al., 1997) and
possibly contribute to their activation. In addition, Pax5 acts
as a transcriptional repressor of lineage-inappropriate genes,
including the M-CSF receptor gene, and thus commits the
progenitor cells to the B-lymphoid lineage and maintains that
commitment by suppressing alternative cell fates (Kee and
Murre, 1998; Nutt et al., 1999; O’Riordan and Grosschedl,
1999; Busslinger et al., 2000; Mikkola et al., 2002). In line
with this, Pax5-deficient pro-B cells maintain a broader
developmental potential than wild type pro-B cells and can
still differentiate in vitro into natural killer cells, dendritic
cells, macrophages, osteoclasts and granulocytes (Nutt et al.,
1999). In addition, in these Pax5-deficient pro-B cells—but
not in wt pro-B cells—ectopic expression of C/EBPa and
GATA factors induces a switch to the myeloid lineage
(Heavey et al., 2003). Interaction with distinct proteins that
act as corepressors (Groucho and perhaps also TBP, Rb and
PTIP) or coactivators (Daxx; Emelyanov et al., 2002) is
regarded as the key to the differential transcriptional activity
of Pax5.
Intriguingly, the transcription factor PU.1 is a direct target
of the Pax5-mediated repression and, inversely, PU.1 can
inhibit Pax5 transactivation (Maitra and Atchison, 2000).
In transgenic mice, pan-hematopoietic Pax5 expression
under control of the Ikaros locus strongly promotes B cell
development at the expense of T lymphopoiesis. This is
achieved by interfering with T lineage commitment and early
thymocyte development through repression of the transcrip-
tion of Notch1, a key regulator of T cell specification
(Souabni et al., 2002).
3.1.3. Notch1 versus E2A
A regulatory network of repressors has emerged, which
has a strong influence on cell lineage decision and might also
be implicated in regulating ‘‘trans-differentiation’’.
Notch signaling has first been identified as the crucial
component of lateral inhibition in the nervous system and
was implicated in the regulation of cell fate determination
in various organisms ranging from nematode to man
(reviewed in Guidos, 2002; Portin, 2002). Notch is a
family of large (ca. 3000 aa) transmembrane proteins
expressed at the surface of cells in the nervous and
lymphoid systems. Activation of Notch by interaction with
one of its ligands leads to cleavage (by g-secretase) of the
intracellular domain, which can then enter the cell nucleus
where it binds to DNA in conjunction with CBF1/RBP-Jk
and act as a bona fide transcription factor. Recently, Notch
signaling was described as an early event in T cell
commitment from a common lymphoid progenitor at the
expense of B cell development: Overexpression of active
Notch1 directs bone marrow stem cells to differentiate into
immature T cells in the bone marrow and inhibits B cell
development (Pui et al., 1999), whereas, inversely, deletion
of Notch1 promotes B lymphopoiesis in the thymus
(Wilson et al., 2001). These differential effects of Notch
signaling appear to be mediated by distinct Notch ligands.
Inhibition of Notch signaling by the Notch modifier
Fig. 2. Murine B cell development. Discrete stages of B cell development have been defined based on (a) cell cycle status and cell size, (b) the status of Ig
heavy (H) and light (L) chain rearrangement and (c) the expression of specific molecules on the cell membrane or in the cytoplasm (especially factors of the
rearrangement machinery (Rag-1,-2, TdT) and of the pre-BCR and BCR complex (IgH chain, (surrogate) IgL chain, Iga and Igh chains). Some of the markers
are only indicated where their expression/inexpression is required to identify a specific B cell subset. Immature B cells are depicted overlapping the bone
marrow and the spleen because these cells are present in both organs.
B. Bartholdy, P. Matthias / Gene 327 (2004) 1–23 5
2.5  Transcriptional control of B cell development (Review) 
 
48 
Lunatic Fringe leads to a phenotype similar to the inacti-
vation of Notch1 (Koch et al., 2001). Similarly, enforced
expression of Deltex1, another Notch modifier, in hema-
topoietic progenitors results in B cell development at the
expense of T cell development in fetal thymic organ
culture and in vivo, most likely by antagonizing Notch1
signaling via inhibition of coactivator recruitment (Izon et
al., 2002). At the molecular level, Notch signaling
induces expression of Hes1, a transcriptional repressor,
which can heterodimerize with E47, a bHLH protein
encoded by the E2A gene and antagonize its function
in early B cell development (Sasai et al., 1992; Jarriault
et al., 1995).
3.1.4. Id genes
While E2A proteins act as transcriptional activators,
the Id transcription factors form another class of HLH
proteins which lack the basic region essential for DNA
binding and operate as inhibitory molecules. All known
mammalian Id proteins, Id1 through Id4, can heterodi-
merize with E2A and other bHLH proteins, thereby
inhibiting their DNA binding and consequently function-
ing as dominant negative antagonists of bHLH transcrip-
tion factors (Benezra et al., 1990; Ellis et al., 1990;
Christy et al., 1991; Sun et al., 1991; Riechmann et al.,
1994). Id proteins are expressed in lymphoid tissues
including fetal liver, bone marrow, spleen and thymus
(Christy et al., 1991; Riechmann et al., 1994; Rivera et
al., 2000; Ikawa et al., 2001). In vivo interactions
between Id and E2A proteins (Deed et al., 1998), and
also Pax5 have been described (Roberts et al., 2001).
While no obvious defect in the B cell differentiation
pathway was noted in Id1-deficient mice (Yan et al., 1997),
probably due to compensation by Id3, overexpression of Id1
in tissue culture models was found to antagonize E-protein-
mediated activation of Ig enhancers (Pongubala and Atch-
ison, 1991; Wilson et al., 1991). In addition, overexpression
of Id1 in the B cells of transgenic mice was found to block B
cell differentiation at the pro-B cell stage, a phenotype
similar to that caused by E2A deficiency (Bain et al.,
1994; Zhuang et al., 1994; Sun, 1994). Since Id1 expression
in B cells ceases after the pro-B cell stage, whereas E2A
gene products are present at all stages, it is tempting to
speculate that Id proteins keep the existing E proteins
inactive at the pro-B cell stage, while in subsequent stages
when Id expression is turned off, E proteins are allowed to
enhance the expression of their downstream targets required
for further B cell differentiation (Jacobs et al., 1993;
Pongubala and Atchison, 1991; Sun et al., 1991; Wilson
et al., 1991). In agreement with this model, transgenic mice
expressing Id1 or Id2 in T cells under the control of the lck
proximal promoter show developmental defects similar to
those described for E2A- and HEB-deficient mice (Kim et
al., 1999; Morrow et al., 1999), while Id2-deficient mice
have a severely impaired NK development (Yokota et al.,
1999) and an increased E2A activity accompanied by an
abnormally high IgE class switch recombination (CSR)
frequency in B cells (Sugai et al., 2003).
3.1.5. Ets factors
The Ets family of transcription factors encompasses
over 30 members that are characterized by the presence
of a conserved DNA-binding domain (the ETS-domain), a
motif of 85 amino acids which forms a unique helix-loop-
helix structure that binds purine-specific DNA sequences
(Crepieux et al., 1994; Sharrocks, 2001). Tissue-specific
knockouts have emphasized the key role of Ets-1 in T cell
survival and for the production of NK cells (Bories et al.,
1995; Muthusamy et al., 1995). Other Ets family members
important for hematopoiesis include the aforementioned
PU.1, and its closest relatives Spi-B and Spi-C, which will
be discussed later in this review. Ets factors act as nuclear
targets of signal transduction pathways and thereby usually
collaborate with other proteins. For example, it was re-
cently found that concomitant overexpression of Spi-B and
its interaction partner PIP/IRF-4 in Abelson pre-B cells
leads to DNA rearrangement and induction of Ign tran-
scription (Muljo and Schlissel, 2002), thereby overcoming
the differentiation block elicited by the Abl kinase. In
addition, IRF-4, together with the related factor IRF-8, is
required for Ig light-chain gene transcription and rearrange-
ment. In mice deficient for both transcription factors, B cell
development is arrested at the pre-B to B cell transition
and the mutant cells fail to down regulate the pre-BCR (Lu
et al., 2003).
3.1.6. LEF-1 and Wnt signaling
The Wnt signal transduction pathway induces the nuclear
translocation of membrane-bound beta-catenin and plays a
key role in cell-fate determination. Recently, a regulatory
function of Wnt signaling in B cell proliferation through
lymphoid enhancer-binding factor-1 (LEF-1) has been iden-
tified (Reya et al., 2000). LEF-1 is a member of a family of
proteins containing an HMG-box as their DNA-binding
domain. These include LEF-1, TCF-3, TCF-4 and the Sry-
like transcription factor Sox-4, which is important for very
early B cell differentiation. It was known previously that
LEF1  / mice have several developmental defects, includ-
ing a defect in pro-B cell differentiation (van Genderen et al.,
1994). Recently, it was shown that LEF-1 binds and acti-
vates the RAG-2 promoter together with c-Myb and Pax-5 in
immature B cells (Jin et al., 2002). Signaling through the
BCR can regulate beta-catenin levels via a phospholipase C/
protein kinase C/GSK-3 pathway (Christian et al., 2002),
and Wnt/h-catenin signaling has been shown to be essential
for the self-renewal of hematopoietic stem cells in vivo
(Reya et al., 2003).
Sox-4 is highly expressed in the central nervous system,
and to a lesser extent in heart, lung and thymus throughout
embryogenesis. Mice deficient for Sox-4 die at embryonic
day E14 due to cardiac malformation. In adult mice, Sox-4
acts as a crucial transcriptional activator in lymphocytes and
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is expressed in bone marrow and thymus, but also in the
gonads. In transfer experiments using Sox-4  / fetal liver
cells to reconstitute the lymphoid compartment of lethally
irradiated recipients, B cell development was shown to be
blocked almost completely at the pro-B cell stage (Schilham
et al., 1996).
3.2. Homing to secondary lymphoid organs and cell
adhesion
Immature IgM+ IgD B cells that previously have made
successful in-frame rearrangements at the heavy and light
chain locus and were positively selected, acquire the ability
to exit the bone marrow and to home to the red pulp of the
spleen. It has been estimated that only about 10% of the 15–
20 million immature B cells generated each day in the mouse
bone marrow emerge as mature B cells in the periphery. A
considerable part of this loss is probably caused by the
deletion of autoreactive B cells in the bone marrow. Addi-
tional loss could either be caused by an emigration defect
from the bone marrow or a failure to properly home to the
secondary lymphoid organs.
While this review focuses primarily on transcriptional
control of B cell development, it is worth mentioning here
the importance of several chemokines, cytokines and their
receptors, the expression of which in turn is often controlled
by lineage-specific transcription factors. A number of genes
have been implicated in B cell motility and homing. Essen-
tially, the cytokines lymphotoxins and tumor necrosis factor
(Fu and Chaplin, 1999), interferon-g (IFN-g) (Flaishon et al.,
2000), as well as homeostatic chemokines, such as Exodus-2
(Hromas et al., 1997; Gunn et al., 1998), BCA-1 (Legler et al.,
1998), SLC (Campbell et al., 1998; Nagira et al., 1998; Ngo et
al., 1998; Gunn et al., 1999), MIP-3h (Kim et al., 1998),
LARC (Tanaka et al., 1999) and chemokine receptors (Forster
et al., 1996, 1999) were all shown to regulate lymphocyte
trafficking and positioning in the subcompartments of lym-
phoid organs.
Most importantly, CCR7 and CXCR5 (BLR1) and their
respective ligands, SLC or MIP-3h and BCA-1, are known
to be essential for B cell homing (Forster et al., 1996,
1999; Cyster, 1999; Melchers et al., 1999; Ansel et al.,
2000; Bowman et al., 2000). It appears that balanced
responsiveness to chemoattractants from adjacent zones
determines the B cell position in the follicle (Reif et al.,
2002): Increased expression of CCR7 is sufficient to direct
B cells to the T zone while overexpression of CXCR5
overcomes the antigen-induced B cell movement to the T
zone. BCA-1 is also required for B1 cell homing to
peritoneal and pleural cavities, natural antibody production,
and body cavity immunity by the B1 lymphocytes (Ansel
et al., 2002).
While the transcription factors regulating CCR7 expres-
sion are largely unknown, CXCR5 expression is controlled,
at least in part, by Oct-2, OBF-1 and NF-nB (Wolf et al.,
1998).
Additionally, the levels of the cytokine interferon-g
secreted in autocrine fashion by B cells also modulate their
homing and adhesion properties. IFN-g is transcribed and
secreted by immature B cells in which it negatively regu-
lates homing, but its transcription is drastically downregu-
lated in mature B cells (Flaishon et al., 2000). Low levels of
IFN-g down regulate the integrin-dependent adhesion of B
cells by activating a pathway that interferes with cytoskel-
eton rearrangement (Flaishon et al., 2001). Thus, immature
B cells could prevent premature encounter with antigen on
their way to the spleen by downregulating their own
migration to lymph nodes or inflammatory sites. Transcrip-
tion factors regulating IFN-g transcription in T cells include
CREB/ATF1, Jun/ATF2, NFAT, YY1, AP-1, NF-nB and
GATA-3 (Campbell et al., 1996; Sica et al., 1997; Sweetser
et al., 1998; Zhang et al., 1998; Ferber et al., 1999; Nakahira
et al., 2002).
4. Antigen-dependent stages of B cell development
A number of transcription factors play important roles in
late-stage B cell differentiation. The fact that the same factors
can be important at several different developmental stages
and can interact in various combinations on a particular gene
promoter reflects a high regulatory complexity that is cur-
rently only partly understood. In fact, several different
approaches using various techniques, including single or
multiple gene knockouts, conditional knockouts, knock-
ins, reconstitution studies and specific overexpression medi-
ated by various promoters, have helped to clarify functions
of factors such as Pax-5, E2A or NF-nB that would not have
been revealed using one single approach. For example, B
cells that lack E2A activity (which is normally induced
during B cell activation and has been mentioned earlier)
are blocked in their ability to express secondary Ig isotypes.
This defect lies at the level of DNA rearrangements between
the Ig switch regions suggesting that E2A is an essential
target during B cell activation and its induction is required to
promote Ig class switch recombination (Quong et al., 1999).
4.1. T cell-dependent antigen responses
Most antigens can only activate B cells to proliferate and
differentiate into antibody-secreting cells in the presence of
an additional signal from CD4+ helper T (TH) cells. These T
cell-dependent immune responses take place in a specialized
microenvironment, the GCs (Fig. 3).
4.1.1. B cell activation and germinal center formation
4.1.1.1. Oct-1, Oct-2 and OBF-1. B cell-specific expres-
sion and rearrangement of immunoglobulin genes is con-
trolled by variable region promoters (VH and VL), intronic
enhancers (EA or En) and 3V enhancers, all of which are
selectively active in B cells. The V region promoters appear
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to be quite simple and contain a highly conserved octamer
element (5V-ATGCAAAT-3V, or its reverse complement),
located upstream of a TATA box. Several in vitro and in vivo
studies have demonstrated the crucial importance of the
octamer site for the activity and B cell specificity of V
region Ig promoters (Dreyfus et al., 1987; Wirth et al., 1987;
Jenuwein and Grosschedl, 1991). The best studied transcrip-
tion factors that interact specifically with the octamer motif
in B cells are the POU homeodomain proteins Oct-1 and Oct-
2. While Oct-1 is ubiquitous, Oct-2 is predominantly
expressed in B cells, as well as in activated T cells and in
the nervous system. Another factor, OBF-1 (also called
OCA-B or Bob-1), is a proline-rich B cell-specific transcrip-
tional coactivator that interacts with the POU domains of
Oct-1 or Oct-2 and with DNA to form a ternary complex on a
subset of octamer sites. Because of their B cell-restricted
expression pattern, Oct-2 and OBF-1 have been considered
to be the principal candidates for mediating the activity of
immunoglobulin promoters in B cells and initial cell trans-
fection experiments have supported this postulate. Yet,
individual inactivation of the Oct-2 or OBF-1 gene in mice
failed to demonstrate an essential role for these factors in Ig
transcription (Corcoran et al., 1993; Kim et al., 1996; Nielsen
et al., 1996; Schubart et al., 1996). The analysis of Oct-2-
deficient mice showed that this factor is required for B cell
maturation and also, surprisingly, for postnatal survival
(Corcoran et al., 1993; Corcoran and Karvelas, 1994). In
addition, Oct-2 was found to be essential for cell prolifera-
tion following lipopolysaccharide (LPS) stimulation and also
for development of B1 B cells (Humbert and Corcoran,
Fig. 3. B cell maturation in the spleen. Immature B cells enter the spleen from the blood at the level of the MZ where they are selected for self-reactivity in the
periphery (and enter an anergic state), or they mature further. Subsequently, the (naı¨ve) B cells cross the marginal sinus and migrate via the periarteriolar
lymphoid sheath (PALS) to the lymphoid follicles, which are areas specialized in antigen retention and presentation. Upon encounter with TD antigens such
mature IgM+ IgD+ B cells become activated and proliferate with T cell help and predominantly differentiate into low affinity antibody-forming cells (AFCs).
AFCs are short-lived plasmacytes that initially secrete IgM, but subsequently switch to secondary isotypes and die by apoptosis within 2 weeks of antigen
encounter. Some cells from the expanded B cell pool do not become AFCs but migrate into the adjacent follicles, which are subsequently transformed into
germinal centers (GCs). GC B cells undergo iterative cycles of proliferation, somatic hypermutation and apoptosis in cooperation with antigen-primed T cells
and follicular dendritic cells (FDCs), a process resulting in the selection of B cell clones that make an antibody with high affinity for a cognate antigen.
Additionally, Ig class switching occurs during the GC reaction. These steps expand, refine and diversify the repertoire of the early immune response to assure
the long-term maintenance of protective immunity. Two types of terminally differentiated B cells eventually emerge from the GC reaction: non-secreting, Ig
surface-positive memory B cells and high affinity antibody-secreting plasmablasts that no longer carry immunoglobulins at their surface. TH, T helper; IDC,
interdigitating cell.
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1997). Similarly, mice deficient for the coactivator OBF-1
show defects in late stage B cell differentiation resulting in
the disruption of antigen-dependent immune responses and
in complete absence of germinal center formation (Kim et
al., 1996; Nielsen et al., 1996; Schubart et al., 1996).
Following stimulation of the BCR, CD40 or IL-4 signaling
pathways OBF-1 is upregulated specifically in GC B cells
where it acts as an integrator essential for full differentiation
and function of these cells (Qin et al., 1998). In vivo,
accumulation of OBF-1 protein in GC B cells is controlled
largely at the post-transcriptional level and the Ring finger
protein Siah, which is the homolog of Drosophila Sina and
interacts with OBF-1, may be part of the regulatory mech-
anism (Boehm et al., 2001; Tiedt et al., 2001). In addition, a
myristoylated isoform of OBF-1 has been identified that is
membrane-bound and could play a role as a signal transducer
itself (Yu et al., 2001).
OBF-1-deficient mice also show a severe reduction of the
number of immature B cells in the spleen; this reduction is
even more dramatic in OBF-1/Oct-2 (Schubart et al., 2001)
and OBF-1/btk (Bruton’s tyrosine kinase) (Schubart et al.,
2000) compound mutant mice. The molecular mechanisms
underlying these defects are still unclear. However, a bcl-2
transgene expressed in the B lineage rescues, to a large
extent, the defect in OBF/btk double-mutant mice, suggest-
ing that lifespans of immature B cells may play a role in this
transition (Rolink et al., unpublished data), an effect that
might again be related to BCR signaling strength. In line
with this, it was very recently reported that Bcl-2 is down-
regulated in the bone marrow of OBF-1-deficient mice
(Brunner et al., 2003) Finally, mice lacking simultaneously
OBF-1 and the chromatin regulator Aiolos show a severe
developmental block in the bone marrow, at the transition
between pre-B and immature B cells (Sugai et al., 2003; Sun
et al., 2003). This phenotype is all the more surprising given
the fact the individual knockouts of these two factors show
defects only in late stages of B cell development, as
mentioned above. This observation underscores the concept
that the same factors may perform different functions (and
have therefore different targets?) at different developmental
stages.
In addition, recent studies have shown that even in the
absence of both Oct-2 and OBF-1, B cells were able to
develop normally to the IgM+ stage and immunoglobulin
gene transcription was still largely unaffected (Schubart et
al., 2001). These unexpected observations imply that the
ubiquitous factor Oct-1 may play a previously unrecognized
role in the control of immunoglobulin gene transcription and
suggest the possible existence of another, as yet unidentified,
cofactor. In line with this, it was found that on many IgH
promoters Oct factors bind as dimers in a way precluding
recruitment of OBF-1 (Tomilin et al., 2000). On the other
hand, it was very recently found that OBF-1 is critical for the
activity of a subset of IgL promoters (Casellas et al., 2002)
and also strongly enhances the expression of the osteopontin
gene in B cells (Lins et al., 2003).
4.1.1.2. CCAAT/enhancer binding protein (C/EBP). C/
EBPs are a family of transcription factors containing a
highly conserved C-terminal basic-leucine zipper domain,
which is involved in dimerization and DNA binding. Six
family members, C/EBPa to ~ have been isolated and
characterized. Additional diversity is brought about by
differential use of translation initiation sites and protein
interactions among the family members and with other
transcription factors, which may allow for differential
regulation of target genes in a tissue-specific and cell-
stage-specific manner. Gene targeting of several family
members has identified essential roles for C/EBPs in the
control of proliferation and differentiation, metabolism and
inflammation, particularly in hepatocytes, adipocytes and
hematopoietic cells. C/EBPs are critical components of the
transcriptional regulation of hematopoiesis (for review, see
Yamanaka et al., 1998; Hu et al., 2000; Ramji and Foka,
2002). For instance, C/EBPa was described as a master
regulator of myeloid progenitors, C/EBPh plays an impor-
tant role in macrophage and B cell development, C/EBPg is
involved in B cell development, and C/EBPy is upregulated
during myelopoiesis. Furthermore, C/EBPq is a regulator of
terminal differentiation of eosinophils and functional mat-
uration of neutrophils.
In the case of B cells, the C/EBP family of transcriptional
activators is functionally important at many stages of B
lymphopoiesis, as witnessed by: (i) the impaired generation
of bone marrow B lymphocytes in mice deficient in C/EBPh
(Chen et al., 1997), (ii) the requirement for C/EBP proteins
for the regulation of the pro-B cell-specific enhancer of the
Id1 gene (Saisanit and Sun, 1997), (iii) the requirement for
C/EBPa, together with PU.1, for the regulation of the
granulocyte-macrophage colony-stimulating factor receptor
alpha gene (Hohaus et al., 1995) and (iv) the requirement for
C/EBP proteins for Ig VH promoter activity in vivo and in
vitro (Cooper et al., 1992).
4.1.1.3. NF-jB/Rel family members. NF-nB was original-
ly described as a nuclear transactivator of the immunoglob-
ulin n-light chain enhancer (the nB enhancer), and is known
today to be a cytokine-inducible transcription factor govern-
ing the expression of an important set of genes involved in
inflammation and cell survival (Siebenlist et al., 1994; Beg
and Baltimore, 1996; Barnes and Karin, 1997; Karin, 1999).
Members of the NF-nB/Rel family of transcription factors
share a highly conserved 300 amino acid domain, the rel
domain, which is essential for DNA binding, dimerization
and interaction with other transcription factors. At least five
members of this family of ubiquitously expressed proteins
were shown to be involved in B cell development. These
include NF-nB1 (p105), NF-nB2 (p100), RelA (p65), RelB,
and c-Rel. NF-nB1 and NF-nB2 generate precursor proteins
that are proteolytically cleaved to give rise to the p50 and
p52 NF-nB subunits, respectively. These can homo- or
heterodimerize and bind their cognate DNA recognition
sequences.
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NF-nB2-deficient mice have defects in the microarchi-
tecture of secondary lymphoid organs and show impaired
humoral immune responses. The formation of B cell follicles
is impaired as well as the formation of follicular dendritic
cell (FDC) networks upon antigenic challenge of the mutant
mice. The defects in formation of B cell follicles may be
attributed, at least in part, to impaired production of the B
lymphocyte chemoattractant chemokine BCA-1, possibly a
result of defective FDCs (Caamano et al., 1998; Franzoso et
al., 1998; Poljak et al., 1999). RelB-deficient mice, in
contrast to nfkb1  / , but similar to nfkb2  / mice, are
unable to form GCs and FDC networks upon antigen
challenge in the spleen. RelB is also required for normal
organization of the marginal zone and its population by
macrophages and B cells. The expression of homing chemo-
kines, particularly of BCA-1, is strongly reduced in relB  /
spleen (Weih et al., 2001). Similarly to c-Rel and p50/NF-
nB, RelB plays a role in B cell proliferation, but in contrast to
these two factors, it is not critically involved in maturation to
Ig secretion or expression of Ig isotypes, although retroviral
expression of RelB in activated B cells inhibits switching to
IgG1, but not to IgE (Snapper et al., 1996; Bhattacharya et
al., 2002). The transcription of the RelB gene itself is
regulated by NF-nB family members, in particular by NF-
nB p50, RelA and RelB (Bren et al., 2001). B cells lacking
the c-Rel transactivation domain have selective defects in
germline CH transcription and Ig class switching, featuring
isotype induction profiles that differ from those of mice
deficient in p50/NF-nB (Zelazowski et al., 1997). In addi-
tion, in cellular model systems, the NF-nB family was found
to critically regulate rearrangement of the E light chain gene
(Bendall et al., 2001) and of the Ig n locus (O’Brien et al.,
1997), in the latter case partly by inducing a B cell-specific
demethylation of the Ig n locus (Kirillov et al., 1996).
4.1.1.4. IjB family. InB proteins associate with the NF-nB
transcription factors via their ankyrin repeat domain and are
involved in an important regulatory mechanism of NF-nB
activity by controlling the nuclear abundance of the various
NF-nB subunits, most likely in an independent manner. In
case of the prototypical InB proteins InBa, -h and -q, this
leads to the retention of NF-nB in the cytoplasm, and
consequently to the inhibition of NF-nB activity. Cellular
activation can lead to InB phosphorylation and its subse-
quent degradation via the ubiquitin-proteasome pathway.
NF-nB is released in this process and can translocate to the
nucleus where it acts as a transcriptional regulator. Among its
target genes are several InB family members, whose expres-
sion level is thus regulated, at least in part, by an autoregu-
latory feedback loop (Sun et al., 1993; Chiao et al., 1994;
Brasier et al., 2001). Another rather unusual InB family
member, the proto-oncogene Bcl-3, is primarily nucleoplas-
mic and can lead to enhanced NF-nB-dependent transcrip-
tion. Bcl-3 interacts with NF-nB1, NF-nB2, Jab1, Pirin,
Tip60 and Bard1. The latter are nuclear proteins which also
bind to other transcription factors including c-Jun, nuclear
factor I (NFI), HIV-1 Tat or the tumor suppressor and PolII
holoenzyme component Brca1, respectively. It is hypothe-
sized that Bcl-3 might act as an adaptor between NF-nB p50/
p52 and other transcription regulators and its gene activation
function may at least in part be due to recruitment of the
Tip60 histone actetylase (Dechend et al., 1999). Deletion of
Bcl-3 leads to a defect in GC formation (Schwarz et al.,
1997) (Table 2).
4.1.1.5. BCL-6. The proto-oncogene and transcriptional
repressor BCL-6 was characterized as a multifunctional
regulator of lymphocyte differentiation and immune
responses (reviewed in Dalla-Favera et al., 1999 and Staudt
et al., 1999). BCL-6 contains an N-terminal BTB/POZ
domain and Kru¨ppel-type zinc finger motifs in the COOH-
terminal region (Kerckaert et al., 1993; Ye et al., 1993;
Fukuda et al., 1995) and can function as a sequence-specific
transcriptional repressor (Chang et al., 1996a; Deweindt et
al., 1995; Seyfert et al., 1996; Baron et al., 1995; Kawamata et
al., 1994). Postulated BCL-6 target genes include Blimp-1,
CD69, CD44, EBI2, Id2, STAT1, MIP-1a, IP-10, p27kip1
and cyclin D2 (Shaffer et al., 2000). BCL-6-deficient mice
fail to form germinal centers during a T cell-dependent
immune response and exhibit a fatal inflammatory disease
distinguished by the presence of T helper type 2 (TH2) cells
(Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997).
Studies of BCL-6-deficient B cells recently showed that
BCL-6 and germinal center formation are essential for
somatic hypermutation (SHM), while generation of memory
B cells can occur independently of germinal center formation,
somatic hypermutation and Ig class switching (Toyama et al.,
2002).
BCL-6 protein expression in B cells is exquisitely regu-
lated following antigen encounter. Nascent pre-GC B cells
upregulate BCL-6 protein, migrate to the follicular area and
initiate GC formation. Antigen-specific B cells that do not
upregulate BCL-6 protein expression differentiate in the
PALS into plasmablasts and provide an initial burst of low-
affinity antibody. While plasmacytic differentiation within
the PALS, which allegedly takes place only in the absence of
BCL-6 expression (Falini et al., 2000), occurs normally in
BCL-6-deficient mice, GC differentiation is blocked (Fukuda
Table 2
Genes essential for GC reactions
Function Gene
GC B cell activation Bright, BCL-6, Spi-B, Oct-2, OBF-1,
STAT6, CD40, CD40L
FDC maturation BCL3, NF-kB p52, LT-a, LT-b, LT-bR,
TNFR-1, TNF-a
T cell activation CD24, CD28, B7, TCR, MHC class II
B cell homing
to follicle
BLR1, BCA-1
Class switch
recombination
NF-kB p52, c-Rel; Bcl-3; PU.1; BCL-6;
STAT6; T-bet; Pax-5; E2A; LR1
Somatic hypermutation BCL-6, LT-a, TNF-a
Transcription factors are listed in bold type, other proteins in normal type.
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et al., 1997). These observations suggest that BCL-6 con-
trols a cell fate decision made by antigen-specific B cells,
and thereby acts as a key regulator of terminal B cell
differentiation.
Mechanistically, BCL-6 binds to a number of STAT6
binding sites in vitro and regulates the transcription of a
subset of IL-4-inducible genes in transiently transfected cells
(e.g., Iq, but not CD23b). Furthermore, lack of BCL-6
deregulates IgE class switching in vivo. Thus, BCL-6 can
modulate the transcription of selective STAT6-dependent IL-
4 responses, including IgE class switching in B cells (Harris
et al., 1999). BCL-6 function is inhibited by p300-mediated
acetylation which disrupts the ability of BCL-6 to recruit
class II histone deacetylases (HDACs) (Lemercier et al.,
2002), thereby preventing it from repressing transcription
and inducing cell transformation (Bereshchenko et al., 2002).
4.1.1.6. STATs. As a competitor of BCL-6, STAT6 is a
signal transducer and activator of transcription (STAT) crit-
ically involved in regulating IL-4-responsive genes (Kohler
and Rieber, 1993; Kotanides and Reich, 1993; Hou et al.,
1994; Schindler et al., 1994; Kaplan et al., 1996; Shimoda et
al., 1996; Takeda et al., 1996; Davey et al., 2000; Zhu et al.,
2001). Notably, it plays an essential role in the IL-4-mediated
activation of germline g1 and q Ig gene transcription and class
switch recombination in B cells (Linehan et al., 1998).
Synergistic activation of Ig gene transcription was observed
between STAT6 and either NF-nB or PU.1 (Schaffer et al.,
1999; Stutz and Woisetschlager, 1999). Similar suppressive
effects of BCL-6 were observed for another STAT transcrip-
tion factor, STAT3 (Reljic et al., 2000).
Yet another member of the STAT family involved in class
switch recombination is STAT5, which has an essential role
in IL-5-dependent IgH switch recombination in mouse
(Horikawa et al., 2001), probably via NF-nB. It appears that
both Stat5a and Stat5b are essential for IL-5-dependent A to
g1 CSR and Ig secretion (Nakamura et al., 2002).
4.1.1.7. T-bet. T-bet, a recently discovered member of the
T-box transcription factor family, which is rapidly induced
by IFN-g in lymphoid and myeloid cells (Lighvani et al.,
2001), was shown to directly regulate Th1 lineage commit-
ment by CD4 T cells (Szabo et al., 2000). In addition, it acts
as a selective transducer of IFN-g-mediated T-independent
IgG2a class switching in B cells (Peng et al., 2002; Gerth et
al., 2003).
4.1.1.8. Spi-B. The Ets family member Spi-B is closely
related to PU.1 through structural homology and by its ability
to transactivate identical target genes as PU.1 in vitro (Ray et
al., 1992; Ray-Gallet et al., 1995). In vivo, however, the target
genes of Spi-B and PU.1 overlap only partially (Rao et al.,
1999). Both PU.1 and Spi-B are required for normal BCR
signaling (Garrett-Sinha et al., 1999), but while Spi-B can
functionally replace PU.1 in myeloid development, it cannot
replace PU.1 in lymphoid development (Dahl et al., 2002).
Spi-B-deficient mice exhibit severe abnormalities in B cell
function and selective T cell-dependent humoral immune
responses accompanied by a dramatic defect in germinal
center formation and maintenance. Spi-B  / mice have a
BCR signaling defect and appear to initiate the production of
germinal centers within splenic primary B cell follicles, but
these structures decay prematurely due to BCR-mediated
apoptosis (Su et al., 1997). Recent data from our laboratory
showed that Spi-B expression in GC B cells is under the
control of OBF-1, and this observation may explain a crucial
part of the phenotype of OBF-1-deficient mice (Bartholdy
and Matthias, manuscript submitted).
4.1.1.9. CIITA. Class II transactivator (CIITA) activates
the expression of multiple genes involved in antigen presen-
tation and is believed to be required for both constitutive and
IFN-g-inducible expression of these genes. Importantly, the
expression of major histocompatibility complex (MHC)
class II, which is required for antigen presentation to T cells
and GC formation, is regulated by CIITA (Silacci et al.,
1994). CIITA-deficient mice are impaired in T-dependent
antigen responses and MHC class II-mediated allogeneic
responses (Chang et al., 1996b). Mechanistically, CIITA, in
conjunction with the regulatory factor X (RFX), binds to the
promoter-proximal S-Y motifs of MHC class II genes and
activates transcription by inducing local histone acetylation
and recruitment of the transcription machinery, as well as
long-range histone acetylation and chromatin remodeling
over a large domain by binding to the distal MHC class II
locus control region (LCR) (Masternak et al., 2003). CIITA
arguably has a role not only in class II, but also in class I
MHC gene induction (Martin et al., 1997).
4.1.1.10. Bright. Bright, the B cell regulator of Ig heavy
chain transcription, represents a new family of DNA-binding
proteins that shares regions of high homology with the yeast
SWI1 and Drosophila dri proteins (Herrscher et al., 1995;
Gregory et al., 1996) that are part of chromatin remodeling
complexes (Peterson and Herskowitz, 1992). Bright has been
found to interact with regions of the murine Ig heavy chain
locus that contain matrix attachment regions (MARs) (Webb
et al., 1991b) and may be yet another important regulator of
Ig expression at late stages of differentiation (Webb et al.,
1998). MARs are A +T-rich DNA sequences that have also
been implicated in organizing chromatin into transcription-
ally active domains (Fey et al., 1991; Getzenberg, 1994).
Bright binding is associated with increases in Ig transcription
(Webb et al., 1991a; Herrscher et al., 1995), and one study
suggested that the MARs flanking the intronic heavy chain
enhancer are indeed critical for Ig expression (Oancea et al.,
1997).
4.1.2. Plasma cell differentiation.
Centrocytes that receive survival signals during affinity
maturation exit the GC and continue to mature as either
long-lived plasma cells (PCs) or memory B cells (reviewed
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in Gray et al., 1996; O’Connor et al., 2003). PC precursors
complete their terminal differentiation either within the
GCs, or after having reached the bone marrow (O’Connor
et al., 2002). Plasma cells are terminally differentiated, post-
mitotic, antibody-producing cells. A small number of these
cells remain in the bone marrow where they can survive and
secrete antibodies for many months.
The regulation of several transcription factors is crucial
for lymphocyte differentiation into plasma cells: The expres-
sion of a number of B cell-specific transcription factors
required in earlier stages of B cell development is decreased
or extinguished in plasma cells. These include EBF, Pax5, A-
Myb, BCL-6 and CIITA. Concomitantly, a large set of B cell-
specific surface proteins is downregulated at the plasma cell
stage, including MHC class II, B220, CD19, CD21, CD22
and the chemokine receptors BLR1 and CCR7. In contrast, a
smaller number of transcription factors are upregulated in
plasma cells, including the bona fide key regulators of
plasma cell differentiation, XBP-1, Blimp-1 and IRF-4.
4.1.2.1. Blimp-1. Blimp-1 (B lymphocyte-induced matura-
tion protein-1) is a zinc finger protein that was first identified
as a plasmacytoma-specific repressor that binds to a negative
element in the murine c-myc promoter and was subsequently
found to repress c-myc in B cells (Kakkis et al., 1989; Lin et
al., 1997). Transcriptional repression mediated by Blimp-1
involves the recruitment of histone deacetylases (Yu et al.,
2000). Blimp-1 expression is sufficient to drive terminal
differentiation of BCL-1 cells into plasma-like cells, making
it a good candidate for being a master regulator of plasma cell
development (Turner et al., 1994). However, repression of c-
myc by Blimp-1 is necessary, but not sufficient, for differen-
tiation of mature B cells into plasma cells (Lin et al., 2000),
hinting at the importance of other Blimp-1 target genes.
Blimp-1 determines plasma cell fate by triggering both the
inhibition of earlier GC B cell activities and the activation of
plasma cell functions. After downregulation of BCL-6, which
directly represses Blimp-1 at the GCB cell stage (Reljic et al.,
2000; Shaffer et al., 2000; Vasanwala et al., 2002), Blimp-1 is
induced and directly represses several genes required for B
cell receptor signaling and GC reactions [such as Id3, c-Myc
(Lin et al., 1997, 2000), Spi-B, CIITA and Pax5 (Shaffer et
al., 2002)]. In a feedback loop, Blimp-1 also represses BCL-6
transcription, and this leads to terminal plasmacytic differen-
tiation (Fig. 4; for a review, see Calame, 2001).
4.1.2.2. XBP-1. XBP-1 (X-box-binding protein-1) is a
ubiquitously expressed basic-region leucine zipper protein
of the CREB/ATF (cyclic AMP response element binding
protein/activating transcription factor) family of transcrip-
tion factors, which binds to a specific DNA sequence called
an X-box, first identified in the regulatory region of an
MHC class II gene (Liou et al., 1990). Mice lacking XBP-1
die as embryos as a result of liver abnormalities and severe
anaemia (Reimold et al., 2000). In a complementation
experiment using RAG-2/XBP-1-deficient chimaeric mice,
it was shown that XBP-1 is required specifically for plasma
cell development (Reimold et al., 2001). XBP-1 gene
expression is repressed by Pax5, which is essential for early
B cell development but downregulated in plasma cells
(Barberis et al., 1990; Reimold et al., 1996).
Importantly, XBP-1 appears to function as a transcrip-
tional activator that amplifies the unfolded protein response
(UPR) during differentiation of antibody-secreting B cells
Fig. 4. Transcription factors in plasma cell differentiation. At the GC B cell stage, BCL-6 represses Blimp-1, a key regulator of plasma cell differentiation.
Another transcription factor crucial in plasma cells, XBP-1 is repressed by Pax-5. Upon transition to the plasma cell stage, Blimp-1 expression leads to the
repression of BCL-6 transcription, and thereby to the inhibition of earlier GC B cell activities, including the transcription of a number of B cell specific
transcription factors, such as Pax-5. As a consequence of Pax-5 downregulation, XBP-1, specifically required for plasma cell development, is expressed.
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(Gass et al., 2002); in addition, the UPR and plasma cell
differentiation appear intricately linked via XBP-1 (Iwakoshi
et al., 2003). Upon UPR activation, XBP-1 mRNA becomes
cleaved in a site-specific manner to remove a 26-nucleotide
intron. This generates a spliced XBP-1 mRNA with an
altered reading frame encoding a 54-kDa bZIP transcription
factor, p54XBP-1, which is a more potent and more stable
transcriptional activator than the 30-kDa protein translated
from unprocessed XBP-1 mRNA (Shen et al., 2001; Yoshida
et al., 2001; Calfon et al., 2002). p54XBP-1 can bind
endoplasmatic reticulum stress response elements (ERSEs)
and may also act through a second cis-acting element to
regulate promoter activity (Yoshida et al., 2001).
4.1.2.3. IRF-4/MUM-1/Pip. Another protein that is very
important for late B cell functions, Pip [Pu.1 interacting
protein, also termed IRF-4 (interferon regulatory factor 4),
LSIRF, NF-EM5 or ICSAT], is a lymphoid-specific transcrip-
tional activator (Eisenbeis et al., 1995). It is recruited to DNA
by interaction with the Ets factors PU.1 or Spi-B through a
regulatory domain that is important for formation of a ternary
complex, and for autoinhibition (Brass et al., 1996). Recently,
the crystal structure of the ternary PU.1/IRF-4/DNA complex
has been solved and shows that the phosphorylated PEST
region of PU.1 interacts with the autoinhibitory domain of
IRF-4 and thereby stabilizes the complex (Escalante et al.,
2002). IRF-4 is expressed in GC centrocytes and plasma-
blasts/plasma cells and is also involved in the late stages of B
cell differentiation as well as in T-cell activation (Falini et al.,
2000). Deletion of this transcription factor in mice revealed
that it is essential for the function and homeostasis of both
mature B andmature T lymphocytes (Mittrucker et al., 1997).
Interestingly, Pip also cooperatively binds to DNA in asso-
ciation with the E2A protein E47. This cooperative interac-
tion leads to a very strong transcriptional synergy between
Pip and E47 (Nagulapalli and Atchison, 1998).
4.2. T cell-independent antigen responses, MZ B and B1
cells
Both the preactivated splenic marginal zone B cells and
B1 B cells are part of a ‘‘natural memory response’’ and
provide a bridge between the very early innate and the later
appearing adaptive immune response by generating an initial
wave of IgM producing plasmablasts during the first 3 days
of a primary response to particulate bacterial antigens
(Martin and Kearney, 2000a; Martin et al., 2001).
4.2.1. B1 cells
B-1 cells are found predominantly in the peritoneal and
pleural cavities and can be distinguished from the conven-
tional (B-2) B cells by their self-renewal capacity and unique
surface proteins. In contrast to other B cell populations, they
are CD45 (B220lo), IgMhi, CD23, CD43+ and IgDlo. While
the origins of B-1 cells remain controversial, it is well
established that they secrete natural antibodies important
for innate immunity—preferentially low-affinity, poly-reac-
tive, mostly self-reactive antibodies (Hayakawa et al., 1984,
1990; Forster and Rajewsky, 1987; Mayer and Zaghouani,
1991; Shirai et al., 1991). It appears that they arise either as a
distinct lineage from committed fetal/neonatal precursors
(Hayakawa et al., 1985; Lam and Stall, 1994), or from
follicular B-2 cells in response to BCR ligation (Haughton
et al., 1993; Clarke and Arnold, 1998; for a detailed review of
B1 cells, see Berland and Wortis, 2002). In either case, it
appears that BCR specificity and surface density together are
also decisive factors in the development of B-1 versus B-2
cells (Lam and Rajewsky, 1999).
The B-1a cells subset expresses CD5, but is otherwise
almost indistinguishable from the B-1b cells (Kantor et al.,
1992; Stall et al., 1992). An NFAT-dependent enhancer has
been found to be necessary for anti-IgM-mediated induction
of murine CD5 expression in primary splenic B cells (Ber-
land and Wortis, 1998).
4.2.2. Marginal zone B cells
MZ B cells consist mainly of a large, mostly non-circu-
lating subset of mature B cells that are localized in the
marginal zone of the spleen. As mentioned above, they have
an important function in the early stages of the immune
response. This could be due to the fact that MZ B cells appear
to have a lower activation threshold and are therefore more
easily triggered into proliferation or differentiation than
immature or recirculating mature B cells. Several recent
reviews discuss these properties in more detail (Martin and
Kearney, 1999, 2000a, 2002; Bendelac et al., 2001).
A number of genes that are crucial for the generation or
maintenance of the MZ B cell compartment have been
identified by targeted disruption or overexpression studies.
One group of mutations that specifically affect MZ B cells
is modulating the BCR signal strength. For example, mice
with a targeted disruption of the Aiolos transcription factor
have a strongly reduced number of MZ B cells, most likely
due to an increase in BCR signal strength in the absence of
Aiolos (Cariappa et al., 2001). In Lyn / mice and in mice
with a mutated Iga ITAM motif, MZ B cell numbers are also
strongly decreased, and both Lyn and Iga are known to
negatively regulate BCR signaling. Conversely, MZ B cell
numbers are enhanced in mice lacking the CD21 coreceptor,
and this enhancement correlates with an expected decrease in
BCR signal strength (Cariappa et al., 2001). In the absence of
the BCR costimulatory molecule CD19, MZ B cells are
lacking completely (Hiemstra et al., 1999; Martin and
Kearney, 2000b).
Apart from altered BCR signal strength, several other
genes are presumably required for the migration of precursors
to the MZ, such as NFnB p50, Pyk2 and Lsc, or for the
development and maintenance of the splenic microarchitec-
ture and microenvironment (such as Lta, Lth, LthR, NFnB
p52, RelB and Dock2) (reviewed in Cariappa and Pillai,
2002). Another recent finding using conditional mutagenesis
of the transcription factor RBP-J (recombination signal
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binding protein-J) in B cells demonstrates that Notch-RBP-J
signaling is involved in cell fate determination of marginal
zone B cells (Tanigaki et al., 2002). It has been suggested that
Notch-RBP-J signaling regulates the lineage commitment of
mature B cells into follicular versus MZ B cells (Table 3).
5. Conclusions and perspectives
As described here, the control of gene expression is a
multi-level process that offers multiple possibilities for
regulation. Apart from the competition of transcription
factors for binding sites and interacting proteins, and the
regulation of protein and mRNA stability, superimposed
mechanisms that regulate the accessibility of a locus, such
as local changes in chromatin structure through modifica-
tions in histone acetylation or demethylation of CpG dinu-
cleotides—or even global changes in the condensation of
chromatin, silencers and locus control regions (Ernst and
Smale, 1995)—are absolutely essential for the initiation of
transcription.
Several transcription factors, coactivators and corepres-
sors have been shown to directly interact with HDACs, or
HATs and thereby modulate chromatin remodeling and
promoter activity of B cell-specific genes. Some examples
were already mentioned in previous chapters: Repression via
association with histone deacetylases was observed with
Ikaros, PU.1, BCL-6, Blimp-1 and Notch (Kao et al.,
1998). Activation via complex formation with the HAT
CBP/p300 was described for Pax5–Daxx complexes, c-
Myb, CIITA and several bHLH proteins, including E2A
(Eckner et al., 1996; Qiu et al., 1998; Fontes et al., 1999;
Romanow et al., 2000; Emelyanov et al., 2002; Yamamoto et
al., 2002). In line with this, V(D)J recombination, which
partly depends on E2A activity, is also stimulated by histone
acetylation (Kwon et al., 2000; McBlane and Boyes, 2000).
While effects of chromatin structure and remodeling activ-
ities on V(D)J recombination are hardly surprising, many
questions remain about how the remodeling activities are
recruited to the right recombination sites, in the right cells, at
the right times.
Fascinating recent findings about the regulation of the
immunoglobulin kappa locus underline the importance of
nuclear architecture for cell stage and cell type-specific
transcription. They encompass a role of DNA demethylation
and increased chromatin accessibility in the process of
allelic exclusion at the kappa chain locus (Goldmit et al.,
2002), which seems to be also regulated by a differential
subnuclear localization (Skok et al., 2001; Kosak et al.,
2002). Interestingly, all of the B cell receptor loci (A, n and
E) and also the T cell receptor (TCR) h locus replicate
asynchronously, a phenomenon that can be considered an
epigenetic mark for allelic exclusion, since the early-repli-
cating allele is almost always selected to initially undergo
rearrangement in B cells (Mostoslavsky et al., 2001). The
identification of factors that target these remodeling activ-
ities will no doubt be a focus of intense research in the near
future, as will be the kinetics of chromatin opening relative
to the initiation of recombination. Transcription itself might
very well participate in the initiation of chromatin opening
for recombination. The subsequent ‘‘closing’’ of chromatin
at nonproductive sites once a productive recombination
event has been achieved raises additional questions that
are critical to our overall understanding of the regulation and
coordination of chromatin remodeling events in B cell
development.
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Table 3
Genes implicated in marginal zone development or maintenance
Model MZ phenotype Reference
Aiolos / Decreased MZ and B1 B cells; hyperactive B cells (Cariappa et al., 2001)
RelB /  Decreased MZ B cells (Weih et al., 2001)
RelA /  /c-rel / Decreased MZ B cells (Grossmann et al., 2000)
NFkB p50 / Lack of MZ B cells (Cariappa et al., 2000)
RBP-J / Lack of MZ B cells (Tanigaki et al., 2002)
CD19 / Lack of MZ B cells; defects in TD and TI responses (Martin and Kearney, 2000b)
CD21 / , Iga /  Increased MZ B cells (Cariappa et al., 2001)
Lt a /  , Lt a / , Lt b R /  Reduced MZ B cells; disorganized B/T areas (Matsumoto et al., 1996, 1997;
Ngo et al., 1999; Ansel et al., 2000;
Korner et al., 2001)
Dock2 / Low MZ and B1 B cells; reduced chemokine migration (Fukui et al., 2001)
Pyk2 / Lack of MZ B cells; normal B1 cells; hyporesponsivity
to chemokines
(Guinamard et al., 2000)
Lyn / Lack of MZ B cells (Seo et al., 2001)
Lsc / Low MZ B cells; normal B1 cells (Girkontaite et al., 2001)
XID/Btk / Decreased MZ B cells (Khan et al., 1995)
Transcription factors are listed in bold type, other proteins in normal type.
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3 Discussion 
 
 
3.1 Overexpression of OBF-1 
in T cells 
 
We have generated transgenic mice specifically 
overexpressing OBF-1 in T cells. The observed 
expression pattern (Figs. 16 and 17) corresponds to 
the published pattern of a GFP transgene driven by 
the same lck proximal promoter construct as the one 
that was used in the present study (Shimizu et al., 
2001). Expression was highest in the thymus, but 
also present in the spleen of young adult mice. Due 
to the method used to generate transgenic animals, 
the gene expression can differ among different 
mouse lines. This can be caused by different num-
bers of gene copies that have integrated in the ge-
nome, or by the accessibility and intrinsic activity of 
the site of integration. The phenotype that we ob-
served was most pronounced in the lines that had the 
highest transgene expression, and we carried out our 
experiments with two independent lines with high 
transgene expression that showed a very similar phe-
notype.  
The transgenic mice were viable, healthy, and 
did not show any obvious signs of immune prob-
lems. They had normal serum Ig levels, and a nor-
mal induction of an immune response to DNP-KLH, 
a T cell dependent antigen, was witnessed by en-
zyme-linked immunosorbent serologic assay 
(ELISA) (Fig. 32). The numbers of B and T cells in 
the lymphoid organs were found to be normal and no 
obvious signs of autoimmunity, decreased lifespan 
or similar immune-dependent diseases were 
discernible. The cytokine expression profile in the 
lymphoid organs was normal, as far as it was investi-
gated (Fig. 33). Thus, the ectopic expression of 
OBF-1 in T cells of transgenic mice did not lead to 
major alterations of T cell development or function. 
In a similar manner, it was found earlier in mice 
deficient for OBF-1 that the observed defects were B 
cell-intrinsic, as OBF-1-/- T cells behaved normally 
in WT background (REF.). To conclude, neither the 
presence, nor the absence of OBF-1 in T cells ap-
pears to have a fundamental impact on the immuno-
competence in mice.  
 
 
3.1.1 Phenotypic abnormalities  
 
However, some phenotypic abnormalities and a 
skewed repertoire and distribution of specific 
lymphocyte subpopulations, most prominently of γδ 
T cells and NK cells, have been discovered and are 
described in Section 2.2.3.2. These abnormalities did 
not visibly affect the well-being and immune status 
of the mice, probably because those more special-
ized immune cells that were affected were not re-
quired in the environment of the mouse facility. 
However, specifically challenging these cells might 
reveal abnormalities in the transgenic mice that 
could be caused by the skewed repertoire of these 
minor cell populations.  
 
3.1.1.1 CD4+ CD8+ CD25+ thymocytes 
The most striking phenotype observed in lck-
OBF-1 mice was the appearance of T cell popula-
tions featuring an abnormal cell surface marker 
expression pattern. Most obvious was the appear-
ance of CD4+ CD8+ double positive (DP) thymo-
cytes expressing CD25, the IL-2 receptor alpha 
chain (Fig. 19). This receptor component is usually 
expressed only in early CD4- CD8- double-negative 
(DN) thymocytes where commitment to the T cell 
lineage has been established, but subsequently it is 
dramatically downregulated for the remainder of T 
cell development. It was shown recently that the 
downregulation of CD25 transcription correlated 
with (i) loss of the basal transcriptional machinery 
from the core promoter; (ii) dissociation of histone 
acetylase p300 and BRG1, a member of the ATP-de-
pendent SWI/SNF chromatin remodeling complex; 
and (iii) the dephosphorylation and deacetylation of 
histone tails (Yeh et al., 2002). The CD25 expression 
at the DP stage in the transgenic animals might 
therefore be caused rather by the sustained cell sur-
face expression of this protein, than by its reexpres-
sion. This phenomenon might directly depend on 
lck-OBF-1 expression, which starts early in T cell 
development and might assist in keeping the CD25 
locus in an active conformation. The early CD4- 
CD8- (DN) thymocytes expressing CD25 at high 
levels were slightly increased in numbers in the 
transgenic animals, but the bulk of CD25 surface ex-
pression occurred on DP thymocytes. Considering 
the relatively mild differences in gene expression 
patterns between these DP CD25+ and conventional 
DP (CD25-) thymocytes in a microarray experiment 
using lck-OBF-1 transgenic mice (discussed later), 
this population is probably not reflecting a novel 
population, but rather normal thymocytes that have 
specifically upregulated the expression of the CD25 
gene.  
We speculated that these CD25+ thymocytes 
might be more easily activated and more prone to 
apoptosis, but we could not find any indication for 
this hypothesis. Preliminary experiments using total 
thymocytes of lck-OBF-1 and of WT mice in a 
proliferation assay did not reveal any significant 
differences in proliferation (not shown). Given the 
fact that DP thymocytes are undergoing massive 
apoptosis, we cannot exclude the possibility that a 
slightly increased rate of apoptosis in transgenic 
mice could have remained unnoticed. Therefore, it 
would be of interest to specifically monitor the 
apoptosis of CD25-expressing cells in vivo, or to 
compare sorted CD25+ vs. CD25- thymocytes in a 
proliferation assay.  
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3.1.1.2 CD4+ CD8+ DP splenocytes 
Another T cell population with an abnormal cell 
surface marker expression pattern that was found in 
the transgenic animals were CD4+ CD8+ DP spleno-
cytes (Fig. 18). T cells that leave the thymus to 
circulate in the body or to migrate to secondary lym-
phoid organs, such as the spleen, are usually 
committed either to the T helper cell fate and ex-
press only CD4 (not CD8), or to the cytotoxic T cell 
fate and express only CD8 (not CD4). A small 
population of peripheral CD4+ CD8+ T lymphocytes 
was described in mice and in rats, where they repre-
sent a minor thymus-derived subpopulation in the 
adult animals. These peripheral DP T cells in rats ap-
pear among the first T cells that colonize the periph-
eral lymphoid organs during fetal life, and represent 
about 40% of peripheral T cells around birth. Their 
proportion then decreases to reach the low values 
seen in adulthood. These cells are resistant to un-
dergo apoptosis in response to glucocorticoids, but 
show poor proliferative responses upon CD3/TCR 
stimulation due to their inability to produce IL-2 
(Jimenez et al., 2002). For mice, it was hypothesized 
before that this DP population consists of prema-
turely exported immature thymocytes that could 
potentially cause autoimmunity (Bonomo et al., 
1994).  
The splenic DP T cells observed in our study 
behave similarly to the DP T cells described in rats. 
They do not seem to proliferate much and do not 
feature an activated phenotype characterized by 
CD69 or CD25 expression. Autoimmune responses 
were not tested, but the average lifespan of the trans-
genic animals was not shorter than the lifespan of 
their WT littermates.  
It has to be pointed out that the majority of the 
peripheral T cells had a normal phenotype and that 
the cytokine profile of the spleen was normal in the 
transgenic animals. The total numbers of T cells as 
well as the percentage of CD4 single positive (SP) 
and CD8 SP T cells were also normal (Section 2.1, 
Fig. 1).  
 
3.1.1.3 γδ T cells 
Another cell population that is generally 
established very early during embryogenesis was 
strongly affected in the lck-OBF-1 mice: The Vγ3 
subset of γδ T cells, constituting the vast majority of 
dendritic epidermal T cells (DETC), was missing 
completely in the skin of young adult transgenic ani-
mals (Fig. 22). It was recently postulated that 
DETCs play a role in tissue repair (Jameson et al., 
2002), since they produce keratinocyte growth fac-
tors (KGFs) and chemokines upon activation. 
DETCs that bear γδ TCRs on the cell surface are 
found frequently in murine skin and they produce 
cytokines and proliferate in response to damaged or 
stressed keratinocytes, indicating a functional 
interaction between these two neighboring cell types 
in vivo. The complete lack of DETCs in the trans-
genic mice could therefore lead to defects in tissue 
repair and wound healing. This hypothesis has not 
been deliberately tested. However, it was not obvi-
ous, e.g. in injuries caused by fights among male 
littermates. 
Aside from the DETC population, other γδ T 
cells were affected as well by OBF-1 overexpres-
sion, as shown in Figures 20 and 21. In the thymus 
of lck-OBF-1 mice, the γδ T cells were approxi-
mately fourfold increased. This T cell lineage might 
be favored by the upregulated CD25 expression in 
the transgenic thymus (see Table V and Section 6.1). 
Interestingly, the deregulated expression of 
CD25, the IL-2R alpha chain, in the transgenic mice, 
could be explaining part of the observed abnormali-
ties of the γδ T cell and NK cell lineages. It is possi-
ble that the inappropriate expression of CD25 influ-
ences the lineage commitment to NK cells, which 
rely on IL-15 signaling. As mentioned in the results 
section (Section 2.2.3.4), the IL-15 receptor also 
uses CD122, the IL-2 receptor beta chain as one of 
its components. It is thus conceivable that 
inappropriately expressed IL-2Rα competes with IL-
15Rα for their common beta chain.  
 
 
3.1.2 Possible target genes identified 
by microarray analysis 
 
In order to identify genes directly regulated by 
OBF-1, we first performed microarray analysis com-
paring WT to transgenic thymocytes. Given the fact 
that the overall T cell development was normal and 
the major T cell populations were present at normal 
ratios in the transgenic animals, we assumed that the 
comparison of RNA from the entire organ should re-
flect mostly the main differences in gene expression 
within the T cells expressing the transgene, rather 
than reflecting merely a change in cellular composi-
tion of the thymus. The analysis revealed a rather de-
fined set of differentially regulated genes in the total 
thymocyte populations of transgenic animals com-
pared to WT mice. In a second microarray experi-
ment we used fluorescence-sorted thymocytes from 
lck-OBF-1 transgenic mice and compared CD25+ 
CD4+ CD8+ cells to CD25- CD4+ CD8+ cells. The 
gene expression analysis of these sorted subpopula-
tions of transgenic T cells showed an expression pro-
file largely overlapping with the profile found in the 
first microarray experiment, thus demonstrating that 
the observed changes in global gene expression are 
rather T cell-intrinsic, and not caused by other (non-
T) cells that contribute to the gene expression pat-
tern of total thymocyte RNA. 
It should be pointed out at this point that the 
overexpression of OBF-1 in T cells can be consid-
ered as a useful model, especially when compared 
with cells from OBF-1 deficient mice. In some 
cases, overexpression can yield clearer effects; the 
findings can then be studied in WT and OBF-1 defi-
cient background, thus bringing into focus the genes 
that are the most closely co-regulated with OBF-1. 
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Figure 35  Model integrating OBF-1 
in a transcriptional cascade leading 
to activation of downstream effectors 
of BCR signaling in activated B 
cells. OBF-1 transcription is induced 
upon signals coming from CD40, IL-
4 and the BCR, and OBF-1 protein 
expression modulates Spi-B 
transcription which, in turn, acts 
upon an unknown target X that 
couples BCR activation and Syk 
phosphorylation to downstream 
phosphorylation events, such as 
BLNK, Btk and PLCγ
phosphorylation. 
Using a genome-wide expression analysis to identify 
potential target genes can be a very successful ap-
proach, provided that the experimental setup is suit-
able. Given the fact that OBF-1 expression is mainly 
required in B cells, while we study its overexpres-
sion in T cells, the most interesting potential target 
genes should have a defined function in B cells, and 
the effect that OBF-1 deficiency has on their expres-
sion level should ideally be the opposite. 
 
3.1.2.1 Spi-B 
We have indeed successfully applied the 
microarray analysis technique to compare the global 
gene expression of the lck-OBF-1 transgenic thymus 
to WT thymus. As discussed earlier, OBF-1 
overexpression lead to the modulated expression of a 
small number of specific genes (see Table V and Ap-
pendix (Section 6.1). Without setting any threshold 
for differentially expressed genes, other than 
eliminating background noise by replicate 
experiments, we found about 69 genes upregulated 
and 123 genes downregulated (out of approximately 
12,000 genes and ESTs) in the transgenic 
thymocytes, compared to WT littermates. One of 
these genes, encoding the transcription factor Spi-B, 
was identified as a physiologically relevant 
candidate. The comparison with OBF-1 deficient 
thymocytes, which have markedly decreased Spi-B 
mRNA levels (Section 2.1, Fig.2), strongly enhances 
the relevance of our findings. The results are 
presented and discussed in greater detail in the 
publication in Section 2.1 of the thesis. They 
constitute the main findings of this work and present 
compelling evidence that OBF-1 is necessary for 
efficient transcription of the Spi-B gene in T and B 
cells of the mouse. We show that OBF-1 exerts its 
effect by directly binding to the Spi-B promoter 2, 
thereby enhancing its transcription.  
Spi-B was upregulated almost 9-fold in 
transgenic thymus – that was the most highly 
upregulated gene on the array. Our data suggest that 
the expression of Spi-B, directly controlled by the 
upregulation of OBF-1 protein in germinal center 
(GC) B cells, may be a key element in the formation 
of GCs The target gene Spi-B could in fact explain a 
substantial part of the observed phenotype of OBF-1 
deficient mice, since the lack of Spi-B leads to 
significant defects in GC formation and maintenance 
(Su et al., 1997). OBF-1 acting directly upstream of 
Spi-B transcription might thus serve as an important 
regulator of this transcriptional cascade. Spi-B can 
therefore be considered as the most physiologically 
relevant in vivo target of OBF-1 identified to date.  
Figure 35 presents a model that places OBF-1 at 
the crossroads between being an integrator of CD40, 
interleukin and BCR signaling and being an effector 
molecule controlling, via Spi-B, the coupling of 
BCR signaling events to downstream pathways.  
Interesting new findings have shown that in Spi-
B-/- PU.1-/- IL-7 and stromal cell dependent proB cell 
lines, transcription of the Ig lambda light chain is re-
duced, but transcription of other putative Spi-B tar-
gets, such as Ig kappa light chain and Ig heavy chain 
(IgH) genes, is not reduced, or even increased 
(Schweitzer and DeKoter, 2004). The OBF-1 levels 
were not investigated in this work, but it is tempting 
to speculate that OBF-1 levels might not be affected 
by the lack of PU.1 and Spi-B, or might even be 
upregulated in a compensatory manner. This could 
explain the higher levels of CD25 and the increase in 
IgH and Igκ transcription, which appear to be inde-
pendent of Spi-B/PU.1, but perhaps dependent on 
OBF-1. In contrast, transcription of Igλ, which takes 
place at the preB cell stage after successful 
rearrangement of IgH, is impaired in PU.1/Spi-B 
double deficient B cell lines. The authors hypothe-
size that interference with PU.1 and/or Spi-B 
activity in proB cells promotes differentiation to a 
stage intermediate between late proB cells and preBI 
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cells. In this context, Spi-C (Prf), a close relative of 
Spi-B and PU.1, might serve as a negative regulator 
of Spi-B/PU.1 activity. In fact, Spi-C is specifically 
expressed in B cells between the preB cell and the 
mature B cell stages, but not in plasma cells. It is a 
very weak transcriptional activator that can bind to 
PU.1 DNA binding sites, but unlike PU.1 and Spi-B, 
it cannot interact with IRF-4 (Pip, LSIRF, NF-EM5) 
to synergistically activate gene expression on Ets-
IRF composite elements (EICE) (Bemark et al., 
1999; Carlsson et al., 2003; Hashimoto et al., 1999). 
Perhaps, Spi-C can normally interfere with 
PU.1/Spi-B activity starting at the preBI stage of B 
lymphopoiesis, and this negative regulation might be 
required for normal B cell development.  
This hypothesis is suitable to explain defects that 
we observed in the Eµ-VH-OBF-1 transgenic mice 
that overexpress OBF-1 in B cells. In these animals, 
B cell development is blocked at the preB cell stage. 
This block might be directly due to higher expres-
sion levels of Spi-B. To investigate this, RNA 
expression analysis of sorted proB cells of WT and 
Eµ-VH-OBF-1 transgenic mice would be a suitable 
approach. It would also be useful to stain the B220+ 
c-kit+ proB cells with a marker for apoptosis, such as 
Merocyanin-540.    
The related interferon regulatory factors IRF-4 
and IRF-8 (ICSBP) were identified as additional im-
portant players besides Spi-B/PU.1 in the preB to B 
cell transition (Lu et al., 2003; Muljo and Schlissel, 
2003). IRF-4 and IRF-8 are selectively expressed in 
the lymphoid and myeloid cells of the immune sys-
tem. Both can be recruited to IRF DNA binding sites 
by interaction with other transcription factors that 
bind close to the IRF site. In particular, it was shown 
that Spi-B and PU.1 can recruit IRF-4 or IRF-8 to 
Ets-IRF composite elements (EICE) present in the Ig 
κ 3' and λ enhancers, where they play a role in the 
control of Ig light chain gene transcription (Brass et 
al., 1999; Eisenbeis et al., 1995; Escalante et al., 
2002; Pongubala et al., 1992). 
In the microarray experiments, IRF-4 and IRF-8 
were not affected by OBF-1 expression in transgenic 
thymocytes. On the other hand, the promoter analy-
sis of the genes that were upregulated in the T cells 
overexpressing OBF-1 revealed a high incidence of 
IRF-8 binding sites (Table IV). It is possible that the 
overexpression of Spi-B that we observed contrib-
uted to an increased stabilization of IRF-8 on EICEs.  
In proB cell lines transformed with the Abelson 
virus, enforced expression of Spi-B and IRF-4 was 
shown to be sufficient to induce Igκ germline tran-
scription and to promote B cell differentiation 
(Muljo and Schlissel, 2003). In this experimental 
system, transcription of Spi-B and of IRF-4 is 
upregulated upon treatment with the Abl kinase 
inhibitor STI571 (Gleevec). We show that the 
upregulation of Spi-B transcription critically de-
pends on OBF-1 (Section 2.1, Fig. 6). We observe 
that inhibition of the v-Abl kinase does not influence 
OBF-1 expression, but rather prevents Spi-B 
transcription through a different mechanism, since 
the presence of OBF-1 is not sufficient in itself for 
induction of Spi-B transcription in these cells, and 
the OBF-1 protein or RNA levels in v-Abl trans-
formed B cells are not noticeably altered by STI571 
treatment (not shown). Neither Spi-B, nor OBF-1 
appear to be essential at this early stage of B cell 
development, at which they might be redundant: 
Other related Ets factors, such as PU.1 or Spi-C 
could compensate for Spi-B function in the absence 
of Spi-B.  
 
3.1.2.2 CD25 
As mentioned previously, the cell surface 
expression of CD25 was greatly increased on a sub-
population of thymic T cells, thus it was hardly sur-
prising to observe a 2.4-fold upregulation of CD25 
mRNA levels on the microarray. The upregulation of 
this gene also provided an internal control to the mi-
croarray experiment. Interestingly, a high expression 
of transgenic OBF-1 was detected in sorted CD25+ 
DP thymocytes, showing a direct correlation be-
tween these two molecules (Fig. 25). In addition, en-
dogenous OBF-1 mRNA was expressed at detectable 
levels in the CD25+ population, but not in the CD25- 
population. This finding raises the possibility of a 
positive feedback loop in which the overexpression 
of OBF-1 protein would promote its own gene 
transcription.  
The CD25 promoter is well-studied, and there is 
no evidence that OBF-1 might directly lead to its 
activation. The regulatory elements of the CD25 pro-
moter are discussed in (Kim and Leonard, 2002).  
 
Figure 36  Regulatory elements of the IL-2Rα gene 
(CD25). The scheme depicts the transcription factor  
binding sites in the five positive regulatory regions (PRRI 
to PRRV (CD28-responsive enhancer, CD28rE). It shows 
how PRRI, PRRII and PRRIV are regulated for optimal 
TCR activation whereas PRRIII and PRRIV are regulated 
for IL-2 inducibility. Figure from (Kim and Leonard, 
2002). No octamer or PU.1 binding sites were identified. 
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They are summarized in Figure 36. It is generally 
believed that a number of transcription factors 
belonging to unrelated families work in cooperation 
to activate the CD25 gene by interacting with the 
five positive regulatory regions (PRRI to V). How-
ever, octamer sites to which OBF-1 could bind were 
not identified in the studies of the CD25 gene 
regulatory regions. OBF-1 could have an influence 
on CD25 expression via an effect on IL-2 expres-
sion, but we found IL-2 levels to be was unaltered in 
the transgenic thymocytes (Fig. 35). It is possible 
that binding of other transcription factors, such as 
AP-1, NF-κB, NFAT, CREB, Stat5, SRF, HMG-
I(Y), GATA-1-Like, or Elf-1 to their recognition 
sites in the CD25 promoter could be modulated by 
OBF-1, but we have no evidence for that.  
 
3.1.2.3 PLCγ2 
Yet another interesting candidate target gene that 
has been identified in the microarray analysis is the 
phospholipase C gamma 2 (PLCγ2), whose 
transcription was 7.2-fold upregulated in transgenic 
thymocytes. This enzyme catalyzes the hydrolysis of 
phosphatidylinositols to generate diacylglycerol 
(DAG) and inositol phosphates, including inositol 
1,4,5-trisphosphate (IP3). DAG activates protein 
kinase C (PKC), while IP3 mediates the mobilization 
of Ca2+ from internal stores, resulting in a transient 
intracellular Ca2+ flux (Rhee and Bae, 1997). 
Expression of PLCγ2 was more than 7-fold upregu-
lated in lck-OBF-1 transgenic thymus compared to 
WT thymus. We could not identify a perfect octamer 
site in the putative promoter sequence, therefore it 
still needs to be tested whether PLCγ2 is a direct 
OBF-1 target, or whether the effect is indirect.  
PLCγ2 is a very interesting molecule that is re-
quired for B cell development and survival. It was 
shown recently that coupling between the BCR and 
PLCγ2 is essential for mature B cell development. 
(Hikida et al., 2003). The ablation of PLCγ2 leads to 
a block in proB cell differentiation, reduced numbers 
of follicular mature B cells, B1 B cell deficiency, 
and to poor responses to T-independent type 2 (TI-2) 
antigens. PLCγ2-/- mice have defects in the IgM-in-
duced Ca2+ flux and in the mitogen-induced pro-
liferation. FcγR and FcεR signaling are also defec-
tive, resulting in a loss of collagen-induced platelet 
aggregation, mast cell FcεR function, and NK cell 
FcγRIII and 2B4 function, as well as to resistance to 
FcεR-mediated, as well as to FcγR-mediated, 
cutaneous inflammatory skin reaction (Hashimoto et 
al., 2000; Wang et al., 2000; Wen et al., 2002).  
 
3.1.2.4 FcγRIIβ 
In this context, it is interesting to note that one 
downstream target of PLCγ2, FcγRIIβ, is also 
upregulated (2.2-fold) in the thymocytes 
overexpressing OBF-1. Fc receptors (FcR) belong to 
the Ig receptor superfamily and recognize the Fc 
portion of immunoglobulins. They couple humoral 
and cellular immunity by directing the interaction of 
antibodies with effector cells. Distinct FcRs exist for 
each Ig isotype: FcγR binds IgG; FcαR binds IgA, 
and FcεR binds IgE. In addition, the FcRs are classi-
fied by their binding affinities: High affinity FcRs 
are referred to as FcRI, and these are able to bind 
noncomplexed, monomeric immunoglobulins. Low 
affinity FcRs bind only aggregated immunoglobulins 
or antibodies complexed to multivalent antigens, and 
they are referred to as FcRII/III (Ravetch, 1997; 
Ravetch and Clynes, 1998). FcγRs are widely ex-
pressed in most hematopoietic cells, and are capable 
of triggering several cell signaling pathways via 
activation of cytoplasmic protein tyrosine kinases, 
such as the Src, Syk and Tec family kinases (Durden 
et al., 1995; Eiseman and Bolen, 1992; Hutchcroft et 
al., 1992; Kawakami et al., 1994; Pignata et al., 
1993). The PLCγ/Ca2+/PKC pathway has been 
shown to be involved in the activation of all types of 
mitogen-activated protein kinases (MAPK; ERKs, c-
Jun N-terminal kinases (JNKs), and p38 MAPKs) 
(Hashimoto et al., 1998; Jiang et al., 1998; Ueda et 
al., 1996). The PLCγ/Ca2+/PKC pathway leads to the 
activation of transcription factors, including NFAT, 
CREB, and Ets transcription factors, such as Elk-1 
(Jain et al., 1993; Vaishnav et al., 2003; Wasylyk et 
al., 1998). Ultimately, activation of the FcR can lead 
to phagocytosis, Ab-dependent cell cytotoxicity,  
respiratory burst, degranulation, production of 
inflammatory cytokines, and enhanced Ag presenta-
tion (Ravetch, 1997). 
 
Other potential target genes that were identified 
in the microarray experiments include muscle-spe-
cific genes, such as the MADS box transcription fac-
tor myocyte enhancer factor 2B (MEF2B), and the 
myosin alkali light chain gene 4 (Myl4), which is 
expressed in the cardiac atria and in the embryonic 
muscle.  
 
3.1.2.5 MEF2B 
The members of the MEF2 family of 
transcription factors (MEF2A to MEF2D) bind to a 
conserved A/T-rich sequence in the control regions 
of many skeletal and cardiac muscle genes. MEF2B 
transcripts are expressed during mouse embryogene-
sis in the developing cardiac and skeletal muscle 
cells, but not in the adult mouse, in a pattern distinct 
from but overlapping with those of the other Mef2 
genes (Edmondson et al., 1994). It was shown that 
MEF2B, unlike the other Mef2 family members, is 
part of a smooth muscle-specific complex that binds 
to an A/T-rich element important for smooth muscle 
myosin heavy chain gene expression (Katoh et al., 
1998). Both the mef2B and mef2C genes are ex-
pressed in the B cells of the peripheral white pulp of 
the postnatal spleen, but are not detected above 
background in the plasma cells present in the red 
pulp (Swanson et al., 1998). MEF2 proteins have 
also been shown to interact with other transcription 
factors, including myogenic bHLH factors and the 
ETS transcription factor PEA3 to express muscle-
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specific genes in muscle cell culture (Molkentin et 
al., 1995; Taylor et al., 1997). MEF2 proteins could 
possibly interact with E2A bHLH and other ETS 
transcription factors, such as Spi-B, in a synergistic 
manner. 
In our microarray experiments, MEF2B mRNA 
was 6.7-fold upregulated in lck-OBF-1 thymocytes 
compared to WT samples. We could not identify an 
octamer site in its promoter, but PU.1 and IRF-8 
binding sites were present. The increased expression 
of Spi-B as a direct result of lck-OBF-1 expression 
in the transgenic thymus might be the cause of en-
hanced expression of MEF2B.  
 
3.1.2.6 Myosin alkali light chain gene 4 
(Myl4) 
MEF2B was identified as a component of a 
smooth muscle-specific complex important for 
smooth muscle myosin heavy chain gene expression. 
Myosin is the major component of the thick filament 
of striated muscle, and it is formed by two myosin 
heavy chain molecules and four myosin light chains 
(MLC). There are two types of light chains, the 
regulatory (MLC2-type, or phosphorylatable) light 
chains, and the alkali (MLC1- and MLC3-type, or 
essential) light chains. Different isoforms of both 
heavy and light chains exist in different striated mus-
cle types. The alkali light chains are associated with 
the head region of the myosin molecule (Waller and 
Lowey, 1985) and are in close contact with actin 
(Henry et al., 1985; Labbe et al., 1986). They appear 
to play a role in the actomyosin interaction (Barton 
et al., 1988) and to be involved in the stabilization 
and regulation of the myosin structure.  
The 7.6-fold upregulation of Myl4 that we 
observed in transgenic thymocytes is at the same 
highly elevated level as the upregulation of MEF2B. 
It is possible that their gene expression is linked, 
controlled by the same signaling events that trigger 
the expression of a muscle-specific gene program. 
One important factor known to modulate gene 
expression in muscle-specific genes is intracellular 
calcium signaling. Indeed, an increased activity of 
PLCγ2 might lead to increased Ca2+ release from 
internal stores. This might be one way how the ex-
pression of Myl4 can be activated in the transgenic 
thymocytes, which expressed higher levels of PLCγ2 
than WT thymocytes.  
 
3.1.2.7 Gadd45β 
Gadd45 beta is a growth-arrest and DNA-
damage-inducible gene that gets activated in re-
sponse to various cellular stress signals, and also by 
inflammatory cytokines, such as IL-6, IL-18 and IL-
12, TNF and TGF-β1. It can also be induced by 
treatment with lipopolysaccharide (LPS). Gadd45β 
is involved in cell cycle arrest and apoptosis and is 
required for the generation of TH1 cells in vivo (Lu 
et al., 2001). Gadd45 is transcriptionally upregulated 
by p53 via an intronic p53 consensus-binding site in 
the Gadd45 gene (Kastan et al., 1992), but it also can 
be regulated in a p53-independent manner (Zhan et 
al., 1996). It was shown recently that the Gadd45 
promoter contains binding sites for Oct-1 and NF-Y 
which are required for and concertedly contribute to 
the p53-independent activation of Gadd45 following 
binding of BRCA1 (Fan et al., 2002) and following 
treatment with the HDAC inhibitor TSA (Hirose et 
al., 2003). Moreover, Gadd45β expression is regu-
lated by NF-κB (Jin et al., 2002), resulting in the 
suppression of JNK signaling by targeting 
MKK7/JNKK2 and inhibiting its enzymatic activity 
This inhibition is crucial for the suppression of TNF-
α induced apoptosis and links the NF-κB signals to 
the MAPK pathway (De Smaele et al., 2001; Papa et 
al., 2004; Tang et al., 2001).  
In our microarray analyses, Gadd45β was mildly, 
but consistently upregulated (1.4-fold) in the trans-
genic thymocytes. This could be explained by the di-
rect binding of OBF-1 together with Oct-1 on the 
perfect octamer site present in the Gadd45β pro-
moter. As we have seen previously, Oct-1 and NF-Y 
act in concert on the Gadd45β promoter. Binding of 
OBF-1 could interfere with binding of either 
BRCA1 or other ternary factors and thereby modu-
late the transcriptional activity of the Gadd45β pro-
moter. Thus, Gadd45β might be a direct target gene, 
although the physiological importance of OBF-1 un-
der these conditions remains unclear. It might be a 
purely artificial transcriptional increase resulting 
from ectopic overexpression of this coactivator, but 
it might just as well be a mechanism that operates 
under certain physiological conditions in cells in 
which stress or DNA-damage signals, such as single 
or double strand breaks occur – as it happens in T 
and B cells undergoing Ig rearrangement.  
 
3.1.2.8 Other upregulated genes 
Another expected result was the increased 
expression of TCR gamma (we detected a 1.8-fold 
increase in Vγ2 transcription), a component of the 
TCR of γδ T cells. As shown in Figure 20, the γδ T 
cell population was increased in the thymus of trans-
genic animals. We assume that the enhanced Vγ2 ex-
pression is caused solely by the altered thymic 
composition, and not by a direct activation of γδ 
TCR transcription by OBF-1.  
Similarly, the hyaluronate binding protein CD44 
was 2.8-fold upregulated in transgenic thymocytes. 
This increase might be due to the increased number 
of early T cells from the CD44+ CD25- or the CD44+ 
CD25+ CD4- CD8- (DN) populations that we ob-
served by FACS analysis (Fig. 19).  
 
3.1.2.9 Downregulated genes 
Aside from genes that were upregulated in the 
thymus of lck-OBF-1 transgenic mice, we found an 
even larger portion of genes that were downregu-
lated compared to WT thymus. So far, OBF-1 has al-
ways been characterized as an activator of transcrip-
tion, and not as a repressor. The manner in which 
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OBF-1 may achieve downregulation of genes can be 
indirect via the induction of a repressor protein, or 
direct, e.g. by competing with another Oct-binding 
factor, such as the small nuclear RNA-activating 
protein complex (SNAPc), or by stabilizing Oct-
1/Oct-2 on promoters, and thereby allowing or pre-
cluding the binding of another transcription factor on 
an adjacent or overlapping binding site. One exam-
ple for such an interaction of OBF-1/Oct-1 com-
plexes with another transcription factor is the 
association of the CCAAT/enhancer-binding protein 
(C/EBP) with octamer factors on Ig promoters. This 
association presumably contributes to the repressory 
action of the inhibitory isoform C/EBPβ-3 on Ig pro-
moters, which occurs mainly through the octamer 
elements (Hatada et al., 2000).  
 
While a number of genes were less expressed in 
lck-OBF-1 transgenic thymus than in WT thymus, 
the relative decrease was generally less pronounced 
than the increase in several putative target genes, 
such as Spi-B, MEF2b, Myl4, and PLCγ2. Most 
strikingly, several genes encoding lymphoid-specific 
cell adhesion molecules were downregulated, 
including CD6, CD5, lymphotoxin beta (LTβ) and 
LFA-1. 
3.1.2.9.1 CD6 
The CD6 cell surface glycoprotein is 
preferentially expressed by T lymphocytes and B1a 
cells, and functions both as a co-stimulatory and 
adhesion receptor on T cells. It interacts with CD166 
(ALCAM) on thymic epithelial cells and keratino-
cytes, and probably other ligands expressed on such 
antigen presenting cells. It was shown that CD6 
expression increases as double-positive thymocytes 
are selected to a single-positive stage and that it 
correlates with expression of the selection marker 
CD69 (Singer et al., 2002). In addition, CD6 medi-
ates binding of a transformed CD4+ T cell line to 
gamma-interferon activated keratinocytes (KCs) 
(Singer et al., 1997), and could therefore have a 
function in the immune responses in the skin.  
The expression of CD6 was downregulated 
approximately 2.2-fold in the transgenic thymocytes.  
3.1.2.9.2 CD5 
CD5, a lymphocyte surface protein of the 
scavenger receptor cysteine-rich superfamily, closely 
related to CD6 and highly homologous in the 
extracellular region, was also downregulated to a 
similar extent (1.8-fold) as CD6. Both can physically 
interact on the cell surface of lymphocytes and 
colocalize at the immunological synapse upon 
lymphocyte activation (Gimferrer et al., 2003).  
3.1.2.9.3 Ltβ 
Yet another cell adhesion molecule, Ltβ 
(lymphotoxin beta), which is important for B cell 
homing to the germinal center, was found to be 
downregulated (2.3-fold) in the transgenic thymo-
cytes. LTβ-deficient mice have a disrupted marginal 
zone, lack splenic germinal centers and follicular 
dendritic cells, as well as Peyer's patches and 
peripheral lymph nodes (Koni et al., 1997). Mice 
with a B cell-specific deletion of Ltβ retained the 
morphological defects in marginal zone and germi-
nal center formation (Tumanov et al., 2002). Similar 
defects, notably in the GC formation, but in one spe-
cific mouse strain also in the MZ formation 
(Samardzic et al., 2002b), were also observed in 
mice deficient for OBF-1. It would therefore be 
interesting to study the expression of Ltβ in the 
spleen OBF-1 deficient mice. 
3.1.2.9.4 Integrin alpha L (LFA-1) 
LFA-1 is exclusively expressed on leukocytes 
and interacts with its ligands ICAM-1, -2, and -3 to 
promote a variety of homotypic and heterotypic cell 
adhesion events required for normal and pathologi-
cal functions of the immune systems. The integrin 
LFA-1, together with alpha 4 beta 1, has an impor-
tant function in promoting lymphocyte entry into the 
splenic white pulp and the retention of B cells in the 
marginal zone (Lo et al., 2003; Lu and Cyster, 
2002). It is downregulated 1.7-fold in transgenic thy-
mocytes.  
In this context, it is interesting to note that 
PGRL, a CD81-associated protein on lymphocytes is 
upregulated (2.3-fold) in the transgenic thymocytes. 
CD81 is a costimulatory molecule that is reported to 
influence adhesion, morphology, activation, 
proliferation, and differentiation of B, T, and other 
cells. Anti-CD81 antibody was shown to activate 
LFA-1 on human thymocytes and can also affect B-
T cell interactions through an increase in IL-4 
synthesis by T cells responding to antigen presented 
by B cells (Levy et al., 1998). In view of the re-
ported function of CD81, it appears possible that the 
increased expression of the CD81-associated mole-
cule PGRL leads to the reduction of LFA-1, and 
possibly also other cell adhesion molecules. 
 
3.1.2.10 Previously identified putative 
OBF-1 target genes 
Direct OBF-1 target genes known to date include 
the BLR1 gene (Wolf et al., 1998), the CCR-5 gene 
(regulated by OBF-1 and Oct-1) in T cells (Moriuchi 
and Moriuchi, 2001), the B cell-specific B29 and 
mb1 genes (Malone and Wall, 2002). Recently, the 
Kcnn4 promoter, the Lck distal promoter (Kim et al., 
2003b) and the Adh2-like promoter (Brunner et al., 
2003a) have been identified to be directly bound and 
activated by OBF-1 in early B cell cultures. In addi-
tion, the osteopontin gene was characterized as be-
ing an OBF-1 target gene (Lins et al., 2003). In the 
microarray experiments of lck-OBF-1 transgeneic 
thymocytes, the expression of these genes was un-
changed. It is possible that these genes are not OBF-
1 target genes in early T cells, and that the presence 
of other, B cell lineage-specific and B cell stage-
specific factors is required for coactivation by OBF-
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1. It is also possible that additional signaling events 
are necessary to change the phosphorylation status 
of either OBF-1 directly, or of other targets, such as 
Oct-1 or Oct-2. In the case of Oct-2 it has been pro-
posed that phosphorylation of a residue in the POU 
domain interferes with binding of Oct-2 to the non-
canonical octamer sequence in the murine BLR-1 
promoter (Pevzner et al., 2000).  
 
 
3.2 Overexpression of OBF-1 
in B cells  
 
OBF-1 expression is mainly required in B cells, 
and therefore we generated transgenic mice that ex-
press OBF-1 under the control of the µ enhancer and 
the VDJ promoter, which were characterized previ-
ously to confer B cell-specific expression. In con-
trast to the endogenous OBF-1 promoter, however, 
the transgenic promoter/enhancer construct should 
activate transcription from early stages of B cell 
development on, where OBF-1 is normally not yet 
expressed. Upon generating B cell-specific OBF-1 
transgenic mice, we hypothesized that expression of 
this transcriptional coactivator might lead to an 
activated phenotype, increased B cell responses, or 
similar signs of hyperreactivity. We were surprised 
to find rather the opposite phenotype and a strongly 
reduced B cell compartment in these Eµ-VH-OBF-1 
mice. 
The analysis of Eµ-VH-OBF-1 mice of the mouse 
line #30 suggests that enforced expression of OBF-1 
in early B cell development can be deleterious for 
these cells. The block in B lymphopoiesis appeared 
at the preBI to preBII transition. At that stage in B 
cell development, the V to DJH and V-JL rearrange-
ments occur. Involvements of OBF-1 in the expres-
sion of the Ig light chain genes have been reported, 
and they could be one reason for the developmental 
block. In addition, overexpression of Spi-B in hu-
man hematopoietic progenitor cells can block T, B 
and NK cell development in vitro (Schotte et al., 
2003).  
B cells that have differentiated beyond the preBII 
cell stage do not express noticeable levels of trans-
genic OBF-1 protein, as judged by western blot 
analysis of total bone marrow and spleen extracts 
(Fig. 29). mRNA, however, can be detected by 
northern blot and RT-PCR/southern blot in the bone 
marrow and in the spleen of the Eµ-VH-OBF-1 mice 
of line #30 and, at lower levels, line #8 (Figures 28 
and 29). 
We plan to analyze the early B cells in this 
transgenic mouse model in greater detail to address 
the question whether the block of B cell develop-
ment and the lack of OBF-1 protein expression in B 
cells beyond the preBII cell stage are caused, as we 
hypothesize, by an increase of apoptosis of B cells 
that highly express OBF-1. We also plan to analyze 
sorted c-kit+ B220+ and CD25+ B220+ bone marrow 
B cells for expression of OBF-1, Spi-B and markers 
of apoptosis.  
As mentioned earlier, our analysis relies mostly 
on experiments conducted in this one mouse line 
(line #30), which shows the most severe and most 
obvious phenotype in B cell development. A reduc-
tion of mature B cells was also observed in mice 
from other mouse lines, but it was clearly less severe 
than in line #30. We need to analyze at least another 
line to study its transgene expression and phenotype 
more in detail in order to assure that what we ob-
serve in line #30 is not an artifact specific to this 
line, but directly due to transgenic OBF-1 expression 
in bone marrow B cells of these animals. Of course, 
the generation of transgenic animals ectopically 
overexpressing the transgene always creates an 
artifical situation that will easily lead to artifacts that 
do not reflect the natural in vivo function of the pro-
tein being studied. Therefore, one has to be cautious 
with the interpretation of the results. We specifically 
used this method to identify candidate target genes 
that can be verified in the wild type situation, and 
that also clearly depend on OBF-1, based on the 
comparison of OBF-1 deficient mice to wild type 
mice. Thus, the analysis of line #30 alone is already 
useful, but should be backed up by data from at least 
one additional transgenic line. We are currently plan-
ning to investigate line #543 more in detail and to 
deepen our analysis of ectopic OBF-1 expression in 
B cells.  
 
 
3.3 Summary 
 
There is growing evidence that OBF-1 has an im-
portant function in modulating BCR signaling 
strength, most likely by acting downstream of the 
BCR in the PLCγ2/PKC/Ca2+ pathway. Firstly, OBF-
1 deficient- B cells have a defect in BCR-triggered 
Ca2+ mobilization, which was restored in CD22-/- 
OBF-1-/- compound mutant mice (Samardzic et al., 
2002a). CD22 is a negative regulator of BCR signal-
ing, and CD22-deficient mice have a lowered activa-
tion threshold for BCR crosslinking and increased 
Ca2+ mobilization upon BCR stimulation (Nitschke 
et al., 1997).  
Additional evidence for this is offered by the 
work comprised in the present thesis. We show that 
OBF-1 transcriptionally activates the Spi-B 
transcription factor, which was shown previously to 
be involved in this pathway. It was assumed that this 
involvement of Spi-B (together with PU.1) is medi-
ated by an as yet unidentified protein X coupling 
Syk phosphorylation to the phosphorylation of 
downstream targets, such as PLCγ and BLNK 
(Garrett-Sinha et al., 1999). In this model, the level 
of Spi-B protein would directly control the transcrip-
tion of this factor X (see also Fig. 35).  
Second, we observed a transcriptional upregula-
tion of PLCγ2 in T cells overexpressing OBF-1. We 
plan to investigate PLCγ2 expression in OBF-1 defi-
cient B cells, especially of splenic follicular B cells. 
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If the lack of OBF-1 lead to reduced PLCγ2 expres-
sion, this would represent a second manner how 
OBF-1 activity could interfere with parts of the BCR 
signaling cascade essential for B cell maturation. 
Several downstream targets of the PLCγ/Ca2+/PKC 
pathway were also affected by the overexpression of 
OBF-1 in T cells, including FcγRIIβ, and, possibly, 
Myl4.  
A third line of evidence for the involvement of 
OBF-1 in BCR signaling was the finding that B cells 
lacking OBF-1 also show a reduced proliferation 
following anti-IgM stimulation in vitro (Sun et al., 
2003). In vivo, it has been recognized earlier that 
OBF-1 deficiency affects early B lymphopoiesis, 
leading to a reduction of transitional splenic B cells 
(Hess et al., 2001; Schubart et al., 2000), possibly 
caused by apoptosis during the negative selection of 
self-reactive B cells occurring at this stage (Carsetti 
et al., 1995; Sater et al., 1998). Therefore, OBF-1 
might well be directly involved in the selection of 
transitional B cells. Lack of OBF-1 has an impact on 
the Ig κ repertoire (Jankovic and Nussenzweig, 
2003), leading to a reduction of a subset of Ig κ 
genes (Casellas et al., 2002). On the other hand, we 
observe that constitutive overexpression of OBF-1 in 
B cells of Eµ-VH-OBF-1 transgenic mice results in a 
severe block of B cell development at the preBI to 
preBII transition in the bone marrow (Fig. 29), fur-
ther supporting the concept that a tight control of 
OBF-1 expression is critical for early B cell 
development. In addition, the reduced numbers of 
marginal zone B cells found in one specific OBF-1 
deficient mouse strain (Samardzic et al., 2002b) 
could be explained by a model in which OBF-1 is 
required for setting the normal threshold for imma-
ture B cell development and selection in the bone 
marrow. It is currently unclear whether this effect of 
OBF-1 deficiency is independent of Spi-B, whose 
expression levels were also reduced in the bone mar-
row of OBF-1 deficient mice (data not shown). It 
could be caused by direct binding of OBF-1/Oct-1 or 
OBF-1/Oct-2 complexes to specific octamer sites in 
some of the Ig κ promoters.   
While the modulation of BCR signaling strength 
could be one important physiological function of 
OBF-1, the crucial function of OBF-1 in the 
development of GCs in the spleen reflects a different 
mechanism, since OBF-1-/- CD22-/- double deficient 
mice were still unable to form GCs and to mount 
humoral immune responses, although their BCR 
activation threshold was similar to the WT situation 
(Samardzic et al., 2002a). Our data presented here 
indicate that the expression of Spi-B, controlled by 
the upregulation of OBF-1 protein in the GC B cells 
may be a key element in the GC formation that does 
not rely on an altered BCR signaling strength, but 
rather on the activation of one specific downstream 
pathway following BCR activation. 
In brief, we have generated transgenic mice 
overexpressing OBF-1 and have identified Spi-B as 
the most physiologically relevant in vivo target of 
OBF-1 to date. These findings greatly help to extend 
our understanding of how OBF-1 is involved in B 
cell activation and GC formation and place it di-
rectly upstream of Spi-B in a transcriptional cascade 
that appears to be intimately linked to B cell receptor 
signaling.  
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4 Materials and Methods 
 
 
Mouse strains and cell lines 
 
The lck-OBF-1 construct used to generate transgenic 
mice contains an N-terminally HA epitope-tagged 
human OBF-1 cDNA under the control of the mur-
ine proximal lck promoter (-3100 to +23 relative to 
the transcription start site).  
The Eµ-VH-OBF-1 construct used to generate the 
second line of transgenic mice contains the same N-
terminally HA epitope-tagged human OBF-1 cDNA, 
this time under the control of the murine VDJ enhan-
cer (Eµ) coupled to the VH promoter. Sequence data 
is available at 
http://www.fmi.ch/groups/matthias.p/Bartholdy.html. 
Both transgenic mouse lines were obtained and bred 
in B6CF1 x C57BL/6 background and were bred to a 
wild type partner of the same genetic background.  
OBF-1 deficient mice were in 129SV-C57BL/6 
background. All animal work and experiments were 
done in compliance with local and institutional 
regulations.  
For RNA expression analysis, mice were sacrificed, 
the organs were taken, rinsed in PBS and immedi-
ately homogenized in TRIZOL reagent (Life 
Technologies). Total RNA was prepared using TRI-
ZOL reagent and purified on RNeasy Miniprep col-
umns (Qiagen) according to the manufacturers' 
instructions.  
 
Cell lines: Abelson pro-B cell lines were derived 
from wild type and OBF-1-/- mice and were de-
scribed previously (Schubart et al. 1996b) 
 
 
PCR 
 
To determine the OBF-1 genotype, genomic DNA 
was isolated from tail biopsies and used as a tem-
plate for polymerase chain reaction (PCR). The PCR 
assay for the OBF-1 wild type and OBF-1 mutant 
loci was carried out with the following primer 
combinations, respectively: 
5’-GCT CCC TGA CCA TTG AC-3’,  
5’-TCC TGT CCC ATC CCC CTG TAA-3’ 
and 
5’-GGC TTA GAT AAC AAA GCG TGT GCT C-3’, 
5’-GCG TGC CCA TCT TGT TCA ATG G-3’. 
The size of the PCR products for the WT allele was 
560bp and for the mutant allele 830bp.  
 
Transgenic OBF-1-HA was detected using the 
following primer combinations:  
5’-GGT TGA GTG GTG GGG GTA GGG-3’ and  
5’-CAC ACG GAC GCC CTG GTA TGG-3’ (for 
genotyping),  
5’-CAC TCT CTC TGT GGA AGG CTT TG-3’ and  
5’-TTC TCA GCT CTA GAC GGC GTA GT-3’ (for 
QPCR).  
 
Spi-B was detected with the PCR primers  
5’-CAG TTC TCC TCC AAG CAC AAG-3’,  
5’-CCA GCC ATT CAT CTC GCA TAG-3’ (stan-
dard RT-PCR for all isoforms and splice variants, 
also used to generate a probe for Northern blotting),  
5’-CTC TGA ACC ACC ATG CTT GCT-3’,  
5’-TCC TTC TGG GTA CAA ACA GCT TAA-3’ 
(QPCR for form 1),  
5’-AGG GCG GCC CTG ACA T-3’,  
5’-TCC TTC TGG GTA CAA ACA GCT TAA-3’ 
(QPCR for form 2).  
To amplify Spi-B promoter 2 in chromatin immuno-
precipitations (ChIP) samples, the primers  
5’-GCG CCC AGC CTT CTC CTC CA-3’ and  
5’-AAA TGT CCC CCA CTC TCC CTG-3’ were 
used.  
 
To amplify the BLR-1 promoter in ChIP samples, 
the following primers were used:  
5’-TGT AGA GGA GGC TGG GAG TA-3’ and  
5’-CGA GAA GGT TTG TGC TGG TG-3’. 
 
GAPDH (QPCR):  
5’-ACC TGC CAA GTA TGA TGA CAT CA-3’,  
5’-GTA GCC CAA GAT GCC CTT CAG T-3’.  
 
β-actin (for Northern blot probe):  
5’-ATG GAT GAC GAT ATC GCT GCG CTG-3’, 
5’-CTA GAA GCA CTT GCG GTG CAC GAT-3’. 
 
Primers used to amplify parts of the Eµ-VH-OBF-1 
expression cassette in pBluescript II KS+: 
c T7 (primer in pBluescript II KS+):  
5’-TAA TAC GAC TCA CTA TAG GG-3’ 
d T3 (primer in pBluescript II KS+):  
5’-ATT AAC CCT CAC TAA AGG GA-3’ 
e pEV< (primer in pCDNA3):  
5’-CCC CAA ACT CAC CCT GAA GTT C-3’ 
f #12542 (primer in hOBF-1):  
5’-AAG GAC TGG CTT GGG ATA G-3’ 
g #30015 (primer in VDJ promoter): 
5’-CTG TCC AGC CCC ACC AAA CCG-3’ 
 
Quantitative real-time PCR (QPCR) was performed 
on an ABI PRISM 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA) using a 
SybrGreen-based kit from Applied Biosystems.  
 
 
Plasmids 
 
The expression cassettes used to generate lck-OBF-1 
and Eµ-VH-OBF-1 transgenic mice are shown in 
Section 2.2 and Section 2.3, respectively. The HA-
tagged hOBF-1 sequence was derived in both cases 
from two plasmids available in our lab: The N-termi-
nal part was obtained as a 0.7 kb BamHI-BbsI frag-
ment from the plasmid pCDNA OBF-1, while the C-
terminal part was obtained as a 1.3 kb BbsI-SfiI 
fragment from pEV OBF-1/9HA. The lck proximal 
promoter/enhancer region was obtained as a 3.3 kb 
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NotI-BamHI fragment from the plasmid p1017 
kindly provided by Roger Perlmutter. The VDJ 
enhancer (Eµ) was obtained as a 1 kb XbaI fragment 
from the plasmid 1-27 and the VH promoter was 
obtained as a 0.2 kb fragment from the plasmid S-
19. Both plasmids 1-27 and S-19 were kindly pro-
vided by Thomas Jenuwein. The cloning strategy is 
depicted in Figure 34.  
 
 
 
Cell culture and protein expression in eu-
karyotic cells 
 
Adherent cells were maintained in DMEM plus 10% 
fetal calf serum. All B cell lines were grown at 37ºC 
and 10% CO2 in RPMI supplemented with 10 % 
FCS (Life Technologies, Inc.), penicil-
lin/streptomycin and 50 mM β-mercaptoethanol 
(Fluka).  
HEK293T cells were transfected in 6-well-plates 
using FuGENE6 (Roche, Basel, Switzerland) 
according to the manufacturers instructions.  
 
 
Protein extract, western blotting and 
luciferase assay 
 
For western blotting, B and T cells were lysed by 
repeated cycles of freeze and thaw in 20 mM 
HEPES pH7.9, 20 % glycerol, 400 mM NaCl, 0.5 
mM EDTA, 0.25 mM EGTA, 0.025 % NP-40, 1 mM 
DTT, 0.5 mM NaF and ‘complete’ protease inhibitor 
cocktail (Roche). Protein concentrations were deter-
mined with Bradford reagent (BioRad) and 30 µg of 
protein for each sample was resolved by SDS-PAGE 
with subsequent transfer onto Immobilon membrane 
(Millipore). HA-tagged proteins were detected with 
the monoclonal antibody 12CA5, and endogenous 
OBF-1 was detected using a polyclonal antibody that 
was raised in rabbits against the C-terminal 154 
amino acids of murine OBF-1. Bands were visual-
ized with the ECL system (Amersham). 
To measure luciferase activity, reporter plasmids 
were cotransfected and cells were lysed in 0.1 M 
potassium phosphate buffer, pH7.8 containing 1 mM 
DTT by repeated cycles of freeze and thaw. The cell 
lysates were measured in a Bertold Luminometer 
according to standard protocols. The reporter plas-
mids P1-luc (D2393) and P2-luc (D2397) were kindly 
provided by D. Tenen and are described elsewhere 
(Chen et al. 1998). In brief, P1-luc consists of the 
170 bp Spi-B promoter 1 driving the firefly 
luciferase gene in the pXP2 expression vector. P2-luc 
is based on the same vector, but contains the 800 bp 
Spi-B promoter 2 instead of the Spi-B promoter 1. 
P2-S-luc and P2-M-luc are identical to P2-luc, but contain 
specific mutations in the octamer site (Figure 4b 
shows the exact mutations, which are identical to the 
mutations in the oligonucleotides P2-M and P2-S). For 
transient transfections, 600 ng of OBF-1 expression 
vector (Strubin et al. 1995) or empty expression vec-
tor and equimolar amounts of luciferase reporter 
vectors were used. Samples were filled up with 
empty vector to a total amount of 1200 ng DNA per 
transfection. 
 
 
Electrophoretic mobility shift assay (EMSA) 
 
In vitro translated proteins were prepared as de-
scribed previously (Sauter and Matthias 1998). 
Binding reactions contained equimolar amounts of 
proteins, 1 mM EDTA, 250 µg/ml BSA, 20 mM 
HEPES (pH 7.9), 50 mM KCl, 4% Ficoll, 6.25 x 105 
cpm/ml of 32P-labeled double-stranded oligonucleo-
tide probe, 25 µg/ml single stranded DNA, and ei-
Figure 34  Cloning strategy 
applied to obtain the Eµ-
VH-OBF-1 (upper figure) 
and lck-OBF-1 expression 
cassettes (lower figure) 
that were used to generate 
transgenic mice. The name 
of the plasmid from which 
the DNA fragments were 
derived are indicated in the
figure. The restriction sites 
that were used for cloning 
and the approximate size of 
the DNA fragments are also 
indicated.  
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ther 25 µg/ml poly(dI·dC) (Amersham Pharmacia 
Biotech). Protein-DNA complexes were resolved on 
a 4% (30:1) polyacrylamide:bisacrylamide, 0.25 x 
TBE gel at 200 V for 1 h, dried, and subjected to 
autoradiography. 
The following double-stranded synthetic 
oligonucleotides were used: 
P2 probe: 5’-CCC CCA GCG TCT GTG CAT GCA 
AAT CCC AGG GAG AGT GGG GG-3’ , 5’-CCC 
CCA CTC TCC CTG GGA TTT GCA TGC ACA 
GAC GCT GGG GG-3’ 
P2-S probe: 5’-CCC CCA GCG TCT GTG CAT GCT 
AAT CCC AGG GAG AGT GGG GG-3’ , 5’-CCC 
CCA CTC TCC CTG GGA TTA GCA TGC ACA 
GAC GCT GGG GG-3’ 
P2-M probe: 5’-CCC CCA GCG TCT GTG CCG 
GCA CCT CCC AGG GAG AGT GGG GG-3’ , 5’-
CCC CCA CTC TCC CTG GGA GGT GCC GGC 
ACA GAC GCT GGG GG-3’ 
 
 
Northern blotting 
 
RNA was prepared by Trizol (Life Technologies, 
Inc.) according to the manufacturer’s instructions. 15 
mg of total RNA was analyzed by Northern blotting 
using Hybond-XL membranes (Amersham Phar-
macia Biotech). OBF-1 was visualized with a radio-
labelled full length probe. Quantification of signal 
intensity was performed on a Molecular Dynamics 
PhosphorImager using Image Quant software. 
 
 
RNase protection assay 
 
RNase protection was performed as described earlier 
(Schubart et al. 1996b). In brief, a probe was in vitro 
transcribed from a vector containing the murine Spi-
B promoter and 5’ coding region (kindly provided by 
D. Tenen, described in (Chen et al. 1998)). The gel-
purified radiolabeled probe was afterwards hybrid-
ized with 20 mg of total RNA at 50 °C over night. 
After RNase digestion, RNA was resolved on a 5% 
polyacrylamide gel and autoradiographed. The pro-
tected part of the murine Spi-B RNA is shown in 
Figure 3A. In the same assay, a control probe of S16 
mRNA was used for normalization of loaded RNA 
quantity. Signal intensity was quantified on a 
Molecular Dynamics PhosphorImager using Image 
Quant software. 
 
 
Immunofluorescent staining and flow 
cytometry (FACS) analysis 
 
Single cell suspensions of freshly prepared thymo-
cytes were prepared, stained and analyzed according 
to standard procedures (Rolink et al. 1994). FACS 
analysis was performed on a FACSCalibur (BD 
Biosciences, San Jose, CA), and fluorescence data 
were collected on 30,000 events by gating on living 
cells and typical forward-side scatter appearance of 
lymphocytes. CellQuest software was used for 
collecting and analyzing data. Cell sorting was per-
formed on a MoFlo (DakoCytomation) with a purity 
of at least 94 %.  
The mAbs 7D4 (anti-CD25; biotinylated), 53-6.7 
(anti-CD8a; PE-labeled) and GL3 (anti-γδ-TCR; PE-
labeled) were purchased from Pharmingen (BD 
Biosciences), San Diego, CA.; RA3-6B2 (anti-B220; 
FITC labeled (IHC)), and GK1.5 (anti-CD4; FITC-
labeled), anti-CD122-FITC (#1905-02), and strepta-
vidin-RPE were purchased from Southern 
Biotechnology Associates (Birmingham, USA). 
Biotinylated peanut agglutinin (PNA-biotin, Vector 
Lab) was used for immunohistochemistry 
 
 
Immunohistochemistry and in situ 
hybridization 
 
Young adult mice were sacrificed, the thymi were 
taken, rinsed in PBS and fixed for 16 hours in 4% 
paraformaldehyde. After a series of washes in PBS, 
0.85% NaCl, 50% ethanol in PBS and 70% ethanol 
in PBS, the thymi were paraffin embedded according 
to standard procedures and 6 µm sections were pre-
pared for histochemistry.  
For in situ hybridization, a 450 bp probe from the 3’ 
UTR of the murine Spi-B cDNA and the correspond-
ing antisense probe were DIG-labeled with the DIG 
RNA labeling kit (Roche) according to the manufac-
turer’s instructions.  
 
 
Chromatin immunoprecipitation (ChIP) 
 
ChIP was performed as described previously 
(Masternak et al. 2003). In brief, 4 x 107 thymocytes 
(or 5 x 106 STI571-treated Abelson B cells) were 
harvested, suspended in 40 ml (4 ml) RPMI 1640 
and crosslinked for 10 minutes at room temperature 
with 4 ml (400 µl) 11% formaldehyde / 0.1 M NaCl / 
50 mM Hepes pH 7.9. Crosslinking was stopped by 
addition of 6.5 ml (650 µl) 1 M glycine pH 8 and 
incubation for 5 minutes at room temperature. Cells 
were washed with 50 ml (5 ml) cold PBS containing 
protease inhibitors (Complete, Roche, Basel, 
Switzerland), resuspended in 40 ml (4 ml) ice cold 
cell lysis buffer (5 mM Pipes, pH8.0 / 85 mM KCl / 
0.5% NP40) + Complete (Roche) and vortexed. Nu-
clei were spun down immediately for 7 minutes at 
2,500 rpm, then lysed for 10 minutes at room 
temperature in 2.2 ml Nuclei lysis buffer (50 mM 
Tris, pH8.0 / 10 mM EDTA / 1% SDS). Chromatin 
was sonicated with a Branson 250 sonicator: 3 X 20” 
pulses constant power output setting 7, precleared by 
centrifugation at 12000 rpm for 10 minutes at 4°C. 
Chromatin was transferred to fresh vials and stored 
at -80°C.  
To immunoprecipitate chromatin with specific 
antibodies, 10 µg (3 µg) of chromatin were diluted 
with immunoprecipitation (IP) buffer (20 mM Tris-
HCl, pH 8.0, 200 mM NaCl, 2 mM EDTA, 0.1% 
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sodium deoxycholate, 0.1% SDS and the protease 
inhibitor complex Complete) containing 50 g/ml 
salmon sperm DNA, 100 g/ml Escherichia coli 
tRNA and 1 mg/ml bovine serum albumin. 
Immunoprecipitation was performed with an anti-
HA antibody (12CA5) in case of the thymocytes and 
with the monoclonal OBF-1 antibody C-20 (SC-955 
X, Santa Cruz Biotechnology, CA) in case of the 
Abelson cell lines. Immune complexes were cap-
tured at room temperature with protein A-Sepharose 
beads. Beads were washed twice with IP buffer, 
twice with IP buffer containing 500 mM NaCl, twice 
with 20 mM Tris-HCl, pH 8.0, 0.25 M LiCl, 2 mM 
EDTA, 0.5% NP-40, 0.5% sodium deoxycholate and 
once in TE containing 0.1% NP-40. Immunoprecipi-
tated chromatin fragments were eluted with 100 mM 
Tris-HCl, pH 8.0, 1% SDS for 10 min at 65 °C, di-
luted twofold with 400 mM NaCl, 200 g/ml pro-
teinase K, digested for 1 h at 37 °C and incubated 
overnight at 65 °C to reverse the crosslinks. After 
extraction with phenol-chloroform and chloroform, 
DNA was precipitated with isopropanol in the pres-
ence of glycogen, washed in 80% ethanol and resus-
pended in TE. Immunoprecipitated DNA derived 
from 100 ng of input chromatin DNA and a stan-
dards containing 10 ng of total input chromatin DNA 
were analyzed by PCR. 
 
 
RNA preparation and hybridization to Affy-
metrix Microarrays MG-U74 and MG-
U74v2   
 
Sorted thymocytes were collected, or, alternatively, 
total thymi were isolated from mice, briefly rinsed 
with PBS and sonicated in Trizol. Total RNA from 
these sorted cells or thymi was immediately isolated 
with the Trizol method (Life Technologies, Inc.), 
followed by a purification using the RNeasy kit from 
Qiagen according to the manufacturer’s instructions. 
Microarray analysis was performed using 
MG_U74A version 2 GeneChips™ (Affymetrix). 10 
µg of total RNA was reverse transcribed using the 
SuperScript Choice system for cDNA synthesis (Life 
Technologies) according to the protocol 
recommended by Affymetrix. 
 
Data processing 
Chip analysis was performed using the Affymetrix 
Microarray Suite v5 and GeneSpring 5.1 (Silicon 
Genetics). Changes in gene expression were as-
sessed by looking for concordant changes between 
replicates using a signed Wilcoxon rank test. The 
“change” p-value threshold was < 0.003. Genes 
whose detection p-value was > 0.05 (absent) in all 
conditions were also discarded. Detailed information 
complying with MIAME standards can be found in 
electronic form on the web at the public 
ArrayExpress database at 
http://www.ebi.ac.uk/arrayexpress. 
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6 Appendix 
 
 
 
6.1 Genes differentially regulated similarly in all microarray 
experiments 
 
6.1.1  Genes upregulated in total thymocytes of lck-OBF-1 mice and 
upregulated in the subfraction of CD25+ CD4+ CD8+ thymocytes of lck-
OBF-1 mice 
 
Reference Name Gene 
Symbol 
Description Fold up-
regulation 
B or T cell surface molecules / Cell adhesion 
101917_at interleukin 2 receptor, alpha chain Il2ra activation marker; receptor component B, T cells 2.45
102337_s_at Fc receptor, IgG, low affinity IIb Fcgr2b IgG binding receptor 2.16
102695_at, 
102744_at 
T-cell receptor gamma, variable 2 Tcrg-V2 T cell receptor component of γδ-T cells 1.77
160553_at lymphocyte antigen 6 complex, 
locus D, ThB 
Ly6d cell surface antigen expressed by most CD4+CD8+ 
(DP) thymocytes at high levels; downregulated in 
mature CD4+ and CD8+ SP T cells. Interaction of 
TCR/coreceptor with the self-MHC-peptide 
contributes to the downregulation of ThB expression 
on developing thymocytes. 
1.99
160820_at immunoglobulin superfamily, 
member 8; PGRL 
Igsf8 Ig superfamily; most prominent CD81-associated 
cell surface protein on thymocytes as well as a 
number of T cell and B cell lines; probably 
modulates T cell motility 
2.3
103005_s_at CD44 antigen Cd44 hyaluronate binding protein; homing/cell adhesion; 
results indicate that CD44 expression is part of a 
genetic program controlled by the beta-catenin/Tcf-4 
signaling pathway and suggest a role for CD44 in 
the generation and turnover of epithelial cells 
2.8
 
Transcription factors / cofactors 
102994_at signal transducer and activator of 
transcription 4 
Stat4 IFN-γ activation site-binding protein expressed in 
early myeloid differentiation. Can be activated by 
specific cytokines, such as IL-12, IFN-α, and IL-2. 
Requirement for STAT4 and a role for IFN-g as an 
amplifying factor in IL-12 induction of the functional 
IL-18 receptor complex.   
1.57
160483_at transcription factor 4 Tcf4 antiapoptotic; target genes: c-myc and cyclin D1; in 
Wnt signaling pathway; binds beta-catenin. 
expressed in embryo, intestine… 
2.03
93417_at, 
93418_g_at 
myocyte enhancer factor 2B Mef2b MADS box TF; early embryo heart/skeletal muscle; 
myocyte differentiation 
6.73
93657_at Spi-B transcription factor (Spi-
1/PU.1 related) 
Spib Ets TF; T, B cells; immune response, GC formation, 
secondary Ig isotypes 
8.84
94821_at X-box binding protein 1 Xbp1 bZIP TF; essential for Ig secretion and plasma cell 
development; high XBP-1 mRNA levels are found in 
specialized secretory cells; stimulated by LPS 
1.78
97497_at Notch gene homolog 1 
(Drosophila) 
Notch1 Notch 1-deficient CLPs adopt a B cell fate in the 
thymus; antiapoptotic 
1.93
97974_at zinc finger protein, multitype 1 / 
FOG-1 
Zfpm1 GATA-1 cofactor; can repress GATA-3-dependent 
activation of the IL-5 promoter in T cells and inhibit 
GATA-3 dependent Th2 development in CD4+ T 
cells when overexpressed during primary activation 
of naive T cells.  FOG -/- mice die during mid-
embryonic development with severe anemia. Partial 
block of erythroid differentiation and lack of 
megakaryocytes in the absence of FOG.  
1.99
97853_at PC4 and SFRS1 interacting 
protein 2 (Psip2, LEDGF) 
Psip2 survival factor in stress reaction; transcriptional 
activator of heat shock and stress-related genes 
1.61
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Intracellular Signaling 
102851_s_at hemopoietic cell phosphatase Hcph protein Tyr phosphatase; myeloid; motheaten 1.54
95022_at A kinase (PRKA) anchor protein 
(gravin) 12 
Akap12 kinase (PRKA) anchor protein 1.86
99372_at endothelial differentiation, 
sphingolipid G-protein-coupled 
receptor, 5 
Edg5 endothelial differentiation, sphingolipid G-protein-
coupled receptor 
4.27
 
Calcium signaling 
103448_at S100 calcium binding protein A8 
(calgranulin A) 
S100a8 expression is negatively regulated by c-Fos/AP-1 2.28
103503_at phospholipase C, gamma 2 Plcg2 essential for specific functions of Fc epsilon R and 
Fc gamma R 
7.15
103935_at ATPase, Ca++ transporting, 
ubiquitous (SERCA3a) 
Atp2a3 calcium ion transport 1.77
160487_at myosin, light polypeptide 4, alkali; 
atrial, embryonic 
Myl4 calcium ion binding;  7.61
 
Proapoptotic Genes 
96338_at EGL nine homolog 2 (C. elegans) Egln2 putative regulator of growth and apoptosis 2.5
98498_at caspase 7 Casp7 1.43
97551_at huntingtin interacting protein 1 
related 
Hip1r proapoptotic; Overexpression resulted in rapid 
caspase 3-dependent cell death; component of the 
endocytic machinery; neurons 
2.37
 
Other Genes 
94061_at cysteine-rich protein 1 (intestinal) Crip1 LIM domain; mainly expressed in intestine, thymus, 
spleen, and lung. Transgenic mice overexpressing 
Crip1 had only about 50% of WT WBC count - 
proportionately fewer lymphocytes and more 
monocytes, eosinophils, neutrophils. FACS: CRIP tg 
have more CD4+/CD8+ thymic lymphocytes. 
1.78
161666_f_at growth arrest and DNA-damage-
inducible 45 beta 
Gadd45b essential for promoting TNF-alpha-mediated cell 
survival. However, neither TNF-a signalling nor cell 
survival is affected in mice lacking gadd45b 
1.37
160084_at ornithine decarboxylase, structural Odc degraded by the 26 S proteasome via a ubiquitin-
independent pathway; degradation is greatly 
accelerated by association with the polyamine-
induced regulatory protein antizyme 1 (AZ1) 
1.56
102336_at RW1 protein Rw1-
pending 
integral to membrane 2.14
 
As Yet Uncharacterized Genes 
102383_at RIKEN cDNA 5730593F17 gene 5730593F1
7Rik 
C/EBP-induced protein (ortholog of human and rat) 1.43
104294_at RIKEN cDNA 5430411K16 gene 5430411K1
6Rik 
DKFZP564B116 protein Homolog; Putative ortholog 
of inhibitor of BTK (IBTK) 
1.62
160122_at RIKEN cDNA 2410004D18 gene 2410004D1
8Rik 
asparaginase 2 superfamily 2.27
160684_at RIKEN cDNA 8430410A17 gene 8430410A1
7Rik 
DC12 protein Putative Ortholog 1.2
96158_at cDNA sequence BC017133 BC017133  1.61
96221_at expressed sequence AI429613 AI429613 CIKS / ACT1 homolog (NFkappaB-activating 
protein, connection to IkappaB-kinase) 
2.37
99366_at RIKEN cDNA E030024M05 gene E030024M
05Rik 
 1.88
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6.1.2  Genes downregulated in total thymocytes of lck-OBF-1 mice and 
downregulated in the subfraction of CD25+ CD4+ CD8+ thymocytes of 
lck-OBF-1 mice 
 
  
Reference Name Gene 
Symbol 
Description Fold down-
regulation 
B or T cell surface molecules / Cell adhesion 
101311_at T-cell receptor beta, variable 13 Tcrb-V13  -1.53
102237_at CD28 antigen Cd28  -1.79
104121_at junction plakoglobin Jup  -1.11
104606_at CD52 antigen / B7 Cd52  -1.66
92203_s_at CD6 antigen Cd6 binds activated leukocyte cell adhesion molecule 
(ALCAM, CD166), a member of the immunoglobulin 
(Ig) superfamily (IgSF) 
-2.17
92204_at CD6 antigen Cd6  
94726_at T-cell receptor beta, variable 13 Tcrb-V13  -1.76
94764_at integrin alpha L Itgal  -1.69
98323_at chemokine (C-C motif) receptor 9 Ccr9  -1.87
99053_at intercellular adhesion molecule 2 Icam2  -1.55
102940_at lymphotoxin B Ltb  -2.28
  
Transcription factors / cofactors 
160617_at Kruppel-like factor 13 Klf13  -1.44
99602_at TGFB inducible early growth 
response 1 
Tieg1  -1.31
  
Intracellular Signaling 
100511_at RIKEN cDNA 6330406L22 gene 6330406L2
2Rik 
 -1.4
103279_at SH2 domain protein 1A Sh2d1a  -1.56
160545_at cyclin D3 Ccnd3  -1.57
92185_at RIKEN cDNA A630084M22 gene A630084M
22Rik 
 -1.5
  
Calcium Signaling 
103596_at diacylglycerol kinase, alpha Dgka  -1.5
  
Thymocyte-specific genes 
102203_at placental protein 11 related Pp11r /  
Tcl-30 
 -1.99
92471_i_at schlafen 2 Slfn2  -1.81
93637_at CD5 antigen Cd5  -1.76
  
Other Genes 
94835_f_at tubulin, beta 2 Tubb2  -2.15
92642_at carbonic anhydrase 2 Car2  -1.77
93652_i_at vesicle-associated membrane 
protein 1 
Vamp1  -1.63
93861_f_at Mouse endogenous murine 
leukemia virus modified polytropic 
provirus DNA, complete 
  -1.62
96172_at immune associated nucleotide 1 Ian1  -1.69
102850_at tyrosine kinase, non-receptor, 2 Tnk2  -1.66
104598_at dual specificity phosphatase 1 Dusp1  -1.76
97384_at glia maturation factor, gamma Gmfg  -1.62
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As Yet Uncharacterized Genes 
160379_at erythrocyte protein band 4.1 Epb4.1  -1.76
93195_at malignant fibrous histiocytoma 
amplified sequence 1 
Mfhas1  -1.85
94428_at ilvB (bacterial acetolactate 
synthase)-like 
Ilvbl  -1.61
96640_at RIKEN cDNA 3110001A13 gene 3110001A1
3Rik 
 -1.46
97967_at Mus musculus 11 days embryo head cDNA, RIKEN full-length enriched library, clone:6230425C21 
product:hypothetical protein, full insert sequence. 
-2.12
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7 Abbreviations 
 
 
AFCs antibody-forming cells 
APCs antigen presenting cells 
APC allophycocyanin 
BCR B cell receptor 
bHLH (basic) helix-loop-helix 
bp base pairs 
CDR complementarity determining 
region 
ChIP chromatin immunoprecipitation 
CLP common lymphoid progenitor 
CSR class switch recombination 
CTD C-terminal domain 
DC dendritic cell 
DETC dendritic epidermal T cell 
DIG digoxigenin 
DMEM Dulbecco’s modified Eagle 
medium 
DN double negative 
DNP-KLH dinitrophenyl-keyhole limpet 
hemocyanin 
DP double positive 
DSB (DNA) double strand break 
EICE Ets-IRF composite elements 
ELISA enzyme-linked immunosorbent 
serologic assay 
ER endoplasmatic reticulum 
EST expressed sequence tag 
FACS fluorescence activated cell 
sorting 
FCS fetal calf serum 
FDC follicular dendritic cell 
FITC fluorescein (mistakenly 
abbreviated by its commonly-
used reactive isothiocyanate 
form) 
FR framework region 
GC germinal center 
GFP green fluorescent protein 
GTFs general transcription factors 
HA hemagglutinin 
HAT histone acetyl transferase 
HDAC histone deacetylase 
HSC hemotopoietic stem cell 
IDC interdigitating cell 
IFN-γ interferon-γ 
 
 
 
 
Ig Immunoglobulin 
iIEL intestinal intraepithelial 
lymphocytes 
IP immunoprecipitation 
ITAM immunoreceptor tyrosine-based 
activation motif 
kb 1000 base pairs 
KCs keratinocytes 
KGF keratinocyte growth factor 
LCR locus control region 
LPS lipopolysaccharide 
Lt lymphotoxin 
MAR matrix attachment region 
M-CSF macrophage colony-stimulating 
factor 
MHC Major histocompatibility 
complex 
MIAME minimum information about a 
microarray experiment 
MZ marginal zone 
NK cell natural killer cell 
nt nucleotides 
PALS periarteriolar lymphoid sheath 
PBS phosphate buffered saline 
PC plasma cell 
PCR polymerase chain reaction 
PIC pre-initiation complex 
PE phycoerythrin 
PMA phorbol 12-myristate 13-acetate 
(also known as TPA) 
PNA peanut agglutinin 
Pol RNA polymerase 
QPCR quantitative PCR 
RPA RNase protection assay 
rpm revolutions per minute 
RT-PCR reverse transcription PCR 
RSS recombination signal sequence 
SC stem cell 
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate 
polyacrylamide gel 
electrophoresis 
SHM somatic hypermutation 
SP single positive 
TCR T cell receptor 
TD T cell dependent 
TdT terminal deoxynucleotidyl 
transferase 
tg transgenic 
TGF transforming growth factor 
TI T cell independent 
TNF tumor necrosis factor 
UPR unfolded protein response 
UTR untranslated region 
WT wild type 
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